WO1994027980A1 - Substituted oxazolyl compounds for the treatment of inflammation - Google Patents

Substituted oxazolyl compounds for the treatment of inflammation Download PDF

Info

Publication number
WO1994027980A1
WO1994027980A1 PCT/US1994/005395 US9405395W WO9427980A1 WO 1994027980 A1 WO1994027980 A1 WO 1994027980A1 US 9405395 W US9405395 W US 9405395W WO 9427980 A1 WO9427980 A1 WO 9427980A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzenesulfonamide
benzyl
oxazol
methylsulfonylphenyl
fluorophenyl
Prior art date
Application number
PCT/US1994/005395
Other languages
French (fr)
Inventor
Bryan H. Norman
Len F. Lee
Jaime L. Masferrer
John J. Talley
Original Assignee
G.D. Searle & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22064709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1994027980(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by G.D. Searle & Co. filed Critical G.D. Searle & Co.
Priority to AT94917983T priority Critical patent/ATE221054T1/en
Priority to DE69431056T priority patent/DE69431056T2/en
Priority to EP94917983A priority patent/EP0699192B1/en
Priority to DK94917983T priority patent/DK0699192T3/en
Priority to CA002161769A priority patent/CA2161769A1/en
Priority to JP7500726A priority patent/JPH08510736A/en
Priority to US08/535,227 priority patent/US5719163A/en
Priority to AU69495/94A priority patent/AU6949594A/en
Publication of WO1994027980A1 publication Critical patent/WO1994027980A1/en
Priority to US09/203,451 priority patent/US6090834A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Definitions

  • This invention is in the field of anti- inflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating inflammation and inflammation-associated disorders, such as arthritis.
  • NSAIDs common non-steroidal antiinflammatory drugs
  • An alternative to NSAIDs is the use of corticosteroids, which have even more drastic side effects, especially when long term therapy is involved.
  • Cyclooxygenase II is inducible by cytokines or endotoxins and such induction is inhibited by glucocortoids (J. Masferrer, et al, Proc. Natl . Acad. Sci , USA, 89, 3917 (1992)).
  • the 6-methoxy-2-napthylacetic acid metabolite of nabumetone has been found by E. Meade et al to selectively inhibit the COX II enzyme (J " . Biol . Chem. , 268, 6610 (1993)).
  • Futaki et al [Prostaglandins, 47, 1 (1994)) have reported that N- (2-cyclohexyloxy-4- nitrophenyDmethanesulfonamide inhibits the COX II enzyme.
  • the novel oxazoles disclosed herein are such safe and also effective antiinflammatory agents furthering such efforts.
  • the invention compounds are found to show usefulness in vivo as antiinflammatory agents with minimal side effects.
  • the substituted oxazolyl compounds disclosed herein preferably selectively inhibit cyclooxygenase II over cyclooxygenase I
  • 2,3-Diaryl-5-halo thiophenes are described in U.S. Patent No. 4,590,205 as analgesic or antiinflammatory agents. More particularly, 2,3- diaryl-5-bromo thiophenes are described in U.S. Patent No. 4,820,827 as having antiinflammatory and prostaglandin synthetase inhibitory activity for use in the treatment of inflammation and dysmenorrhea.
  • Copending application Serial No. PCT/US94/ 66 describes 4,5-substitutedphenylthiophenes as having antiinflammatory activity.
  • U. S. Patent No. 4,489,084, to F. Haviv and F.Kerdesky describes diphenyloxazolyl hydrazinoalkyl nitrile compounds for use as antiinflammatory agents.
  • U.S. Patent No. 4,143,047, to R. Harrison describes oxazole compounds as reactants to make 2-acylamino oxazole derivatives having anti-allergy activity.
  • N. Meanwell et al J. Med. Chem . , 35, 3498 (1992)] describe bis(substitutedphenyl)oxazoles as having ADP-induced platelet aggregation inhibition activity.
  • a class of substituted oxazolyl compounds useful in treating inflammation-related disorders is defined by Formula I:
  • R is selected from hydrido, alkyl, hydroxyalkyl, haloalkyl, alkenyl, hydroxyalkenyl, alkynyl, hydroxyalkynyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, heteroaryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position with halo
  • Compounds of Formula I would be useful for, but not limited to, the treatment of inflammation in a subject, and for treatment of other inflammation-associated disorders, such as, as an analgesic in the treatment of pain and headaches, or as an antipyretic for the treatment of fever.
  • compounds of Formula I would be useful to treat arthritis, including but not limited to rheumatoid arthritis, spondyloarthopathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis.
  • Such compounds of Formula I would be useful in the treatment of asthma, bronchitis, menstrual cramps, tendinitis, bursitis, and skin related conditions such as psoriasis, eczema, burns and dermatitis.
  • Compounds of Formula I also would be useful to treat gastrointestinal conditions such as inflammatory bowel syndrome, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis and for the prevention of colorectal cancer.
  • Compounds of Formula I would be useful in treating inflammation in such diseases as vascular diseases, migraine headaches, periarteritis nodosa, thyroidi is, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, myasthenia gravis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, conjunctivitis, swelling occurring after injury, myocardial ischemia, and the like.
  • the compounds are useful as anti-inflammatory agents, such as for the treatment of arthritis, with the additional benefit of having significantly less harmful side effects.
  • the compounds have a cyclooxygenase
  • the compounds have a cyclooxygenase I IC 50 of greater than about 0.5 ⁇ M, and more preferably of greater than 5 ⁇ M. Such preferred selectivity may indicate an ability to reduce the incidence of common NSAID-induced side effects.
  • a preferred class of compounds consists of those compounds of Formula I wherein R is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower alkenyl, lower hydroxyalkenyl, lower alkynyl, lower hydroxyalkynyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower ary
  • a class of compounds of particular interest consists of those compounds of Formula I wherein R is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, 1-propenyl, 2-propenyl, 1- butenyl, 2-butenyl, 3-butenyl, hydroxyethenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2- butynyl
  • a family of specific compounds of particular interest within Formula I consists of compounds and pharmaceutically-acceptable salts thereof as follows:
  • R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl
  • R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower
  • cycloalkyl is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2, 3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2,3-dihydrobenzofuryl, wherein R! is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically-acceptable salt or prodrug thereof.
  • a class of compounds of particular interest consists of those compounds of the first subclass wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptyl
  • a family of specific compounds of particular interest within the first subclass consists of compounds and pharmaceutically-acceptable salts thereof as follows:
  • R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl
  • a more preferred class of compounds of the second subclass consists of those compounds of wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl
  • R 1 is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically- acceptable salt or prodrug thereof.
  • a class of compounds of particular interest consists of those compounds of the second subclass wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptyl
  • a family of specific compounds of particular interest within the second subclass consists of compounds and pharmaceutically-acceptable salts thereof as follows:
  • alkyl is used, either alone or within other terms such as “haloalkyl”, “alkoxyalkyl” and
  • hydroxyalkyl embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl” radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl and the like.
  • alkenyl is used, it embraces linear or branched carbon carbon double bond- containing radicals having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkenyl radicals are "lower alkenyl” radicals having two to about six carbon atoms. Suitable “lower alkenyl” may be a straight or branched one such as vinyl, allyl, isopropenyl, 1- or 2-propenyl, 1-, 2- or 3-butenyl, pentenyl or the like.
  • alkynyl embraces linear or branched radicals having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms, and containing a carbon-carbon triple bond.
  • the more preferred "lower alkynyl” are radicals having two to ten carbons. Examples of such radicals include ethynyl, 1- or 2- propynyl, 1-, 2- or 3-butynyl and the like and isomers thereof.
  • hydroido denotes a single hydrogen atom (H) .
  • This hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical or two hydrido radicals may be attached to a carbon atom to form a methylene (-CH2-) radical.
  • halo means halogens such as fluorine, chlorine, bromine or iodine.
  • haloalkyl embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals.
  • a monohaloalkyl radical for one example, may have either a bromo, chloro or a fluoro atom within the radical.
  • Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals.
  • hydroxyalkyl embraces linear or branched alkyl radicals having one to about twelve carbon atoms any one of which may be substituted with one or more hydroxyl radicals.
  • hydroxyalkenyl embraces linear or branched alkenyl radicals having two to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals.
  • hydroxyalkynyl embraces linear or branched alkynyl radicals having two to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals.
  • alkoxy and “alkoxyalkyl” embrace linear or branched oxy-containing radicals each having alkyl portions of one to about twelve carbon atoms, such as methoxy radical.
  • alkoxyalkyl also embraces alkyl radicals having two or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals.
  • the "alkoxy” or “alkoxyalkyl” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy or haloalkoxyalkyl radicals.
  • aryl embraces aromatic radicals such as phenyl, naphthyl and biphenyl. Preferred aryl radicals are those consisting of one, two, or three benzene rings.
  • heteroaryl embraces radicals having an unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl [e.g., 4H-l,2,4-triazolyl, 1H-1, 2, 3-triazolyl, 2H-1,2,3- triazolyl, etc.] tetrazolyl [e.g.
  • unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g., tetrazolo [1, 5-b]pyridazinyl, etc.], etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group containing a sulfur atom, for example, thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example,
  • benzoxazolyl, benzoxadiazolyl, etc.] unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g., 1,2,4- thiadiazolyl, 1,3,4- thiadiazolyl, 1,2,5-thiadiazolyl, etc.] etc.; unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., benzothiazolyl, benzothiadiazolyl, etc.] and the like.
  • aralkyl embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenethyl, and diphenethyl.
  • benzyl and phenylmethy1 are interchangeable.
  • aryloxy embrace oxy-containing aryl radicals attached through an oxygen atom to other radicals. More preferred aryloxy radicals are "lower aryloxy" radicals having a phenyl radical. An example of such radicals is phenoxy.
  • aryloxyalkyl embraces alkyl radicals having one or more aryloxy radicals attached to the alkyl radical, that is, to form monoaryloxyalkyl and diaryloxyalkyl radicals.
  • the "aryloxy” or “aryloxyalkyl” radicals may be further substituted to provide haloaryloxyalkyl radicals alkylaryloxy radicals, and the like. Examples of such radicals include chlorophenoxy and methylphenoxy.
  • aralkyloxy embrace oxy-containing aralkyl radicals attached through an oxygen atom to other radicals.
  • aralkyloxyalkyl embraces alkyl radicals having one or more aralkyloxy radicals attached to the alkyl radical, that is, to form monoaralkyloxyalkyl and diaralkyloxyalkyl radicals.
  • the "aralkyloxy” or “aralkyloxyalkyl” radicals may be further substituted on the aryl ring portion of the radical.
  • heteroaryloxyalkyl embraces alkyl radicals having one or more heteroaryloxy radicals attached to the alkyl radical, that is, to form monoheteroaryloxyalkyl and diheteroaryloxyalkyl radicals.
  • heteroaryloxy radicals may be further substituted on the heteroaryl ring portion of the radical.
  • arylthio embraces radicals containing an aryl radical, as described above, attached to a divalent sulfur atom, such as a phenylthio radical.
  • arylthioalkyl embraces alkyl radicals substituted with one or more arylthio radicals, as described above.
  • cycloalkyl embraces radicals having three to ten carbon atoms, such as cyclopropyl cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • cycloalkylalkyl embraces alkyl radicals substituted with cycloalkyl radicals having three to ten carbon atoms, such as cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl and cycloheptylmethy1.
  • cycloalkenyl embraces unsaturated radicals having three to ten carbon atoms, such as cylopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and cycloheptenyl.
  • alkylsulfonyl whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals -S ⁇ 2 ⁇ - "Alkylsulfonyl" embraces alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above.
  • the "alkylsulfonyl” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals.
  • sulfamyl denotes a sulfonyl radical substituted with an amine radical, forming a sulfonamide (-SO2NH2).
  • carboxy or “carboxyl”, whether used alone or with other terms, such as “carboxyalkyl”, denotes -CO2H.
  • carboxyalkyl and “alkanoyl” embrace radicals having a carboxy radical as defined above, attached to an alkyl radical, which may be substituted or unsubstituted.
  • radicals examples include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, trifluoroacetyl or the like, in which the preferable one is formyl, acetyl, propionyl or trifluoroacetyl.
  • alkoxycarbonyl ester radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl.
  • alkoxycarbonylalkyl embraces alkyl radicals having one or more alkoxycarbonyl radicals attached to the alkyl radical.
  • aminocarbonylalkyl embraces alkyl radicals having one or more aminocarbonyl radicals attached to the alkyl radical.
  • alkylaminocarbonylalkyl embraces alkyl radicals having aminocarbonyl radicals substituted with one or two alkyl radicals. Examples of such include N- alkylaminocarbonylalkyl and N,N-dialkylaminocarbonylalkyl radicals such as N-methylaminocarbonylmethyl and N,N- dimethylaminocarbonylmethyl.
  • the present invention comprises a pharmaceutical composition for the treatment of inflammation and inflammation-associated disorders, such as arthritis, comprising a therapeutically-effective amount of a compound of Formula I in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.
  • the present invention also comprises a therapeutic method of treating inflammation or inflammation-associated disorders in a subject, the method comprising administering to a subject having such inflammation or disorder a therapeutically-effective amount of a compound of Formula I.
  • isomeric forms including and the pharmaceutically-acceptable salts thereof.
  • pharmaceutically-acceptable salts embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable.
  • Suitable pharmaceutically-acceptable acid addition salts of compounds of Formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid.
  • organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propanoic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicyclic, salicyclic, p- hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic) , methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, algenic, ⁇ -
  • Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N- methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of Formula I by reacting, for example, the appropriate acid or base with the compound of Formula I.
  • the compounds of the present invention may contain prodrugs of compounds of the current invention.
  • prodrug embraces compounds which are metabolized in vivo into compounds of the invention.
  • the compounds of the present invention may contain asymmetric carbon atoms, and, therefore, the instant invention may also include the individual diastereomers and enantiomers, which may be prepared or isolated by methods known to those skilled in the art.
  • any resulting racemate can be resolved into the optical antipodes by known methods, for example, by separation of the diastereomeric salts thereof, with an optically active acid, and liberating the optically active amine compound by treatment with a base.
  • Racemic compounds of the present invention can thus be resolved into their optical antipodes e.g., by fractional crystallization of d- or 1- (tartrates, mandelates, or camphorsulfonate) salts.
  • Synthetic Scheme I shows the four step procedure which can be used to prepare the substituted ketone compounds 4 from the substituted benzaldehyde 1 and acid 2, where R 2 is alkyl.
  • step one benzaldehyde 1 and substituted acetic acid 2 are first heated in acetic anhydride and triethylamine via a Perkin condensation.
  • step two hydrolysis produces the corresponding 2,3-disubstituted acrylic acids 3.
  • step three the acrylic acids 3 are reacted with diphenylphosphorylazide (DPPA) and triethylamine in toluene at 0°C and then warmed to room temperature to form acylazides.
  • DPPA diphenylphosphorylazide
  • step four the crude acylazides are heated to form an isocyanate via a Curtius rearrangement.
  • the isocyanate is trapped as the N-t-butyloxycarbonyl enamine derivative via the addition of tert-butanol.
  • Acidic hydrolysis such as by using concentrated HCl, provides the substituted ketone 4 intermediates.
  • Synthetic Scheme II shows an alternative approach which can be used to prepare substituted ketone intermediates 7, isomers of 4 where R 2 is alkyl, via the use of Friedel-Crafts acylation.
  • An acylating agent 5, such as an acid chloride is treated with aluminum chloride in an inert solvent, such as methylene chloride, chloroform, nitrobenzene, dichlorobenzene or chlorobenzene, and reacted with alkylthiobenzene 6 to form ketone 7.
  • TBSC1 is tert-butyl-dimethylsilyl chloride
  • MCPBA is m-chloroperoxybenzoic acid.
  • Scheme III shows the five step synthesis, as described in U.S. Patent No. 3,647,858, which can be used to prepare the 5- (4-alkylsulfonylphenyl) oxazoles 12 of Formula I from ketone 4 (prepared in Scheme I) .
  • Preparation of the silyl enol ether 8 is followed by oxidation, such as with m- chloroperbenzoic acid, to give the appropriate silylated benzoin 9.
  • Desilylation of this silylated benzoin 9 is achieved using aqueous acid, such as trifluoroacetic acid, to give the desired benzoin 10.
  • Scheme IV shows the five step synthesis, similar to that described above in Scheme III, which can be used to prepare the 4- (4-alkylsulfonylphenyl) oxazoles 17 of Formula I from ketone 7 (prepared in Scheme II) .
  • Preparation of the ⁇ ilyl enol ether 13 is followed by oxidation, such as with m- chloroperbenzoic acid, to give the appropriate silylated benzoin 14.
  • Desilylation of this silylated benzoin 14 is achieved using aqueous acid, such as trifluoroacetic acid to give the desired benzoin 15.
  • Scheme V shows the four step synthesis which can be used to prepare oxazoles 20 from ketones 4 (prepared in Synthetic Scheme I) .
  • ketones 4 are readily brominated via the addition of bromine in acetic acid to form the 2-bromoethanone intermediates.
  • step two reaction of the bromoethanone with aqueous acetone yields the benzoin 18.
  • step three reaction of the benzoin 18 with the appropriate acid chloride in the presence of base , such as pyridine, gives the benzoin esters 19.
  • step four benzoin esters 19 are converted to the oxazoles 20 upon treatment with ammonium acetate in acetic acid at reflux .
  • Scheme VI shows the four step synthesis which can be used to prepare oxazoles 23 from ketones 7 (prepared in Synthetic Scheme II) .
  • ketones 7 are readily brominated via the addition of bromine in acetic acid to form the 2- bromoethanone intermediates.
  • reaction of the bromoethanone with aqueous acetone yields the benzoin 21.
  • reaction of the benzoin 21 with the appropriate acid chloride in the presence of base, such as pyridine gives the benzoin esters 22.
  • step four benzoin esters 22 are converted to the oxazoles 23 upon treatment with ammonium acetate in acetic acid at reflux.
  • Synthetic Scheme VIII shows the three step procedure used to prepare sulfonamide antiinflammatory agents 25 from their corresponding methyl sulfones 24.
  • a THF solution of the methyl sulfones 24 at -78°C is treated with an alkyllithium reagent, e.g., methyllithium, n- butyllithium, etc.
  • an organoborane e.g., triethylborane, tributylborane, etc.
  • an aqueous solution of sodium acetate and hydroxyamine-O- sulfonic acid is added to provide the corresponding sulfonamide antiinflammatory agents 25 of this invention.
  • Step 1 Preparation of 1- (4-fluorophenyl) -2- hydroxy-2-(methylsulfonyl)ohenyl)ethanone
  • Step 2 Preparation of 4- (4-fluorophenyl) -2- (2- phenylethyl)-5- (4-(methylsulfonyl)phenyl) oxazole.
  • Methyl 3- [5- (4- fluorophenyl) -4- [4- ( methy lsulf onyl) pheny l]oxazol-2-yl] propanate was prepared in a manner analogous to Example 1.
  • Step 2 Preparation of 5- (4-Fluorophenyl) -4- f4- (methylsulfinvDphenyll -2-phenyloxazole.
  • the reaction was poured into a solution of aqueous sodium metabisulfite.
  • the aqueous solution was extracted using ethyl acetate and the organic layer was washed with saturated sodium metabisulfite, saturated sodium bicarbonate and brine.
  • the resulting clear solution was dried over sodium sulfate and concentrated in vacuo to give a white solid which was purified by flash chromatography on a silica gel column using 50% ethyl acetate/hexane as the eluent.
  • the aqueous solution was extracted using ethyl acetate and the organic layer was washed with saturated sodium metabisulfite, saturated sodium bicarbonate and brine. The resulting clear solution was dried over sodium sulfate and concentrated m vacuo to give a white solid which was purified by flash chromatography on a silica gel column using 50% ethyl acetate/hexane as the eluent.
  • Step 2 Preparation of 2-benzyloxymethyl-4- (4- fluorophenyl) -5- [4- (methylsulfonyl) henyl1 oxazole.
  • Step 1 Preparation of 1- (cyclohexyl) -2-hydroxy-2- T4- (methylthiophenyl) ethanone
  • a 250 mL round bottomed flask was equipped with a mechanical stirrer and reflux condenser and charged with 30 mL of absolute ethanol, 3 , 4-dimethyl- 5- (2-hydroxyethyl) thiazolium iodide (2.00 g, 7.0 mmol), 4-methylthiobenzaldehyde (10.66 g, 70.0 mmol), and freshly distilled cyclohexanecarboxaldehyde (7.68 g, 70.1 mmol) .
  • the solution was stirred vigorously, treated with triethylamine (4.27 g, 42.2 mmol) and heated to reflux for 24 hours.
  • Step 3 Preparation of 2- (phenyl) -4- (cyclohexyl) -5- T4- (methvthio)phenyl1 oxazole
  • Step 4 Preparation of 2-phenyl-4- (cyclohexyl) -5- T4- (methylsulfonyl) henyl1oxazole
  • the reaction was poured into a solution of aqueous sodium metabisulfite.
  • the aqueous solution was extracted using ethyl acetate and the organic layer was washed with saturated sodium metabisulfite, saturated sodium bicarbonate and brine.
  • the resulting clear solution was dried over sodium sulfate and concentrated in vacuo to give a white solid which was purified by flash chromatography on a silica gel column using 50% ethyl acetate/hexane as the eluent.
  • Step 1 Preparation of 2- (4-fluoroohenvl) -3- (4-methylthiophenyl)propenoic acid
  • Acetic anhydride 500 mL
  • 4- (methylthio)benzaldehyde 100.2 g, 0.66 mol
  • 4- fluorophenylacetic acid 101.6 g, 0.66 mol
  • triethylamine 68.1 g, 0.67 mol
  • the diaryl acrylic acid (226.5 g, 0.78 mol) was placed in a 2 L round bottom flask with anhydrous toluene (800 mL) and triethylamine (81.2 g, 0.80 mol) . After cooling to 0°C, diphenylphosphoryl azide (217.4 g, 0.79 mol) was added, the solution was stirred at 0°C for 20 minutes and at room temperature for 2.50 hours. The reaction was poured into water, extracted with ether, dried over magnesium sulfate, and concentrated in vacuo to remove the ether. The remaining toluene solution was heated to reflux and a vigorous evolution of gas occurred.
  • the crude bromoketone was dissolved in dichloromethane and washed with IN NaHS0 3 , dried over anhydrous MgS0 4 , filtered and concentrated in vacuo to give 68.8 g of 1- (4-fluorophenyl) -2-(4-methylthiophenyl) -2-bromoethanone as a yellow solid which was used directly without further purification.
  • the crude bromoketone was dissolved in 300 mL acetone and 150 mL of water and heated to reflux for 2.5 hours. The solution was concentrated in.
  • Step 4 Preparation of ethyl 2-T4- (4-fluorophenyl) -5- r4-methylthio)phenyl1oxazol-2-yllacetate
  • the crude solid was purified by flash chromatography using a silica gel column and 20% ethyl acetate/hexane as the eluent to give a white solid which was recrystallized from 50% ethyl acetate/isooctane to give 5.55 g (80%) of a white solid whose structure was assigned as ethyl 2- [4- (4-fluorophenyl) -5- [4- methylthio)phenyl]oxazol-2-yl]acetate and was judged suitable for taking onto the next step.
  • Step 5 Preparation of ethyl 2- T4- (4-fluorophenyl) -5- r4-methy1sulfonyl)phenyl1oxazol-2-y11 -1- benzyl-acetate
  • the carrageenan foot edema test was performed with materials, reagents and procedures essentially as described by Winter, et al., (Proc. Soc. EXP. Biol. Med.. HI, 544 (1962)) .
  • Male Sprague-Dawley rats were selected in each group so that the average body weight was as close as possible. Rats were fasted with free access to water for over sixteen hours prior to the test. The rats were dosed orally (1 mL) with compounds suspended in vehicle containing 0.5% methylcellulose and 0.025% surfactant, or with vehicle alone.
  • the analgesia test using rat carrageenan was performed with materials, reagents and procedures essentially as described by Hargreaves, et al., (Pain, 32, 77 (1988)). Male Sprague-Dawley rats were treated as previously described for the Carrageenan Foot Pad Edema test. Three hours after the injection of the carrageenan, the rats were placed in a special plexiglass container with a transparent floor having a high intensity lamp as a radiant heat source, positionable under the floor. After an initial twenty minute period, thermal stimulation was begun on either the injected foot or on the contralateral uninjected foot. A photoelectric cell turned off the lamp and timer when light was interrupted by paw withdrawal. The time until the rat withdraws its foot was then measured. The withdrawal latency in seconds was determined for the control and drug-treated groups, and percent inhibition of the hyperalgesic foot withdrawal determined. Results are shown in Table I.
  • the compounds of this invention exhibited inhibition in vitro of COX II.
  • the COX II inhibition activity of the compounds of this invention illustrated in the Examples was determined by the following methods.
  • Recombinant baculoviruses were isolated by transfecting 4 ⁇ g of baculovirus transfer vector DNA into SF9 insect cells (2xl0e8) along with 200 ng of linearized baculovirus plasmid DNA by the calcium phosphate method. See M.D. Summers and G.E. Smith, A Manual of Methods for Baculovirus Vectors and Insect Cell Cul ture Procedures, Texas Agric. Exp. Station Bull. 1555 (1987). Recombinant viruses were purified by three rounds of plaque purification and high titer (10E7 - 10E8 pfu/ml) stocks of virus were prepared.
  • SF9 insect cells were infected in 10 liter fermentors (0.5 x 10 ⁇ /ml) with the recombinant baculovirus stock such that the multiplicity of infection was 0.1. After 72 hours the cells were centrifuged and the cell pellet homogenized in Tris/Sucrose (50 mM: 25%, pH 8.0) containing 1% 3- [ (3-cholamidopropyl) dimethylammonio] -1-propanesulfonate (CHAPS) . The homogenate was centrifuged at 10,000xG for 30 minutes, and the resultant supernatant was stored at -80°C before being assayed for COX activity.
  • Tris/Sucrose 50 mM: 25%, pH 8.0
  • CHAPS 3- [ (3-cholamidopropyl) dimethylammonio] -1-propanesulfonate
  • COX activity was assayed. as PGE 2 formed/ ⁇ g protein/time using an ELISA to detect the prostaglandin released.
  • CHAPS-solubilized insect cell membranes containing the appropriate COX enzyme were incubated in a potassium phosphate buffer (50 mM, pH 8.0) containing epinephrine, phenol, and heme with the addition of arachidonic acid (10 ⁇ M) .
  • Compounds were pre-incubated with the enzyme for 10-20 minutes prior to the addition of arachidonic acid. Any reaction between the arachidonic acid and the enzyme was stopped after ten minutes at 37°C/room temperature by transferring 40 ⁇ l of reaction mix into 160 ⁇ l ELISA buffer and 25 ⁇ M indomethacin.
  • the PGE2 formed was measured by standard ELISA technology (Cayman Chemical) . Results are shown in Table II.
  • compositions comprising one or more compounds of Formula I in association with one or more non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients.
  • carrier non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants
  • the compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • the compounds and composition may, for example, be administered intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically.
  • the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid.
  • the pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules.
  • the active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier.
  • the amount of therapeutically active compound that is administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound employed, and thus may vary widely.
  • the pharmaceutical compositions may contain active ingredient in the range of about 0.1 to 1000 mg, preferably in the range of about 0.5 to 500 mg and most preferably between about 1 and 100 mg.
  • a daily dose of about 0.01 to 100 mg/kg body weight, preferably between about 0.1 and about 50 mg/kg body weight and most preferably from about 1 to 20 mg/kg body weight, may be appropriate.
  • the daily dose can be administered in one to four doses per day.
  • the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration.
  • the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for con ⁇ venient administration.
  • Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.
  • Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration.
  • the compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers.
  • Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
  • the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more immunomodulators, antiviral agents or other antiinfective agents.
  • the compounds of the invention can be administered in combination with antihistamines or with other such agents known heretofore to be effective in combination with antiinflammatory agents.
  • the therapeutic agents can be formulated as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition.
  • the examples herein can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

Abstract

A class of substituted oxazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by formula (I) wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R1 is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo, and wherein R2 is alkyl; or a pharmaceutically-acceptable salt thereof; provided R1 is not phenyl when R2 is methyl and R is isopropyl or tert-butyl.

Description

SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION
FIELD OF THE INVENTION
This invention is in the field of anti- inflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating inflammation and inflammation-associated disorders, such as arthritis.
BACKGROUND OF THE INVENTION
Prostaglandins play a major role in the inflammation process and the inhibition of prostaglandin production, especially production of PGG2, PGH2 and PGE2, has been a common target of antiinflammatory drug discovery. However, common non-steroidal antiinflammatory drugs (NSAIDs) that are active in reducing the prostaglandin-induced pain and swelling associated with the inflammation process are also active in affecting other prostaglandin-regulated processes not associated with the inflammation process. Thus, use of high doses of most common NSAIDs can produce severe side effects, including life threatening ulcers, that limit their therapeutic potential. An alternative to NSAIDs is the use of corticosteroids, which have even more drastic side effects, especially when long term therapy is involved.
Previous NSAIDs have been found to prevent the production of prostaglandins by inhibiting enzymes in the human arachidonic acid/prostaglandin pathway, including the enzyme cyclooxygenase (COX) . Recently, the sequence of another heretofore unknown enzyme in the human arachidonic acid/prostaglandin pathway has been reported by T. Hla and K. Nielson, Proc. Natl . Acad . Sci , USA, 89, 7384 (1992) and named "cyclooxygenase II (COX II) " or "prostaglandin G/H synthase II". The discovery of an inducible enzyme associated with inflammation provides a viable target of inhibition which more effectively reduces inflammation and produces fewer and less drastic side effects. Cyclooxygenase II is inducible by cytokines or endotoxins and such induction is inhibited by glucocortoids (J. Masferrer, et al, Proc. Natl . Acad. Sci , USA, 89, 3917 (1992)). The 6-methoxy-2-napthylacetic acid metabolite of nabumetone has been found by E. Meade et al to selectively inhibit the COX II enzyme (J". Biol . Chem. , 268, 6610 (1993)). In addition, Futaki et al [Prostaglandins, 47, 1 (1994)) have reported that N- (2-cyclohexyloxy-4- nitrophenyDmethanesulfonamide inhibits the COX II enzyme.
The references below that disclose antiinflammatory activity, show continuing efforts to find a safe and effective antiinflammatory agent. The novel oxazoles disclosed herein are such safe and also effective antiinflammatory agents furthering such efforts. The invention compounds are found to show usefulness in vivo as antiinflammatory agents with minimal side effects. The substituted oxazolyl compounds disclosed herein preferably selectively inhibit cyclooxygenase II over cyclooxygenase I
2,3-Diaryl-5-halo thiophenes are described in U.S. Patent No. 4,590,205 as analgesic or antiinflammatory agents. More particularly, 2,3- diaryl-5-bromo thiophenes are described in U.S. Patent No. 4,820,827 as having antiinflammatory and prostaglandin synthetase inhibitory activity for use in the treatment of inflammation and dysmenorrhea. Copending application Serial No. PCT/US94/ 66 describes 4,5-substitutedphenylthiophenes as having antiinflammatory activity.
Pyrazole derivatives having antiinflammatory activity are described in U.S. Patent No. 5, 134,142, to Matsuo et al. U.S. Patent No. 3,578,671, to K. Brown, describes antiinflammatory 4, 5-diphenyloxazoles substituted in the 2-position by a saturated or unsaturated aliphatic acid. U.S. Patent No. 4,051,250, to J. Dahm et al, describes oxazole, imidazole and thiazole compounds, including 2- mercapto-4- (4-methylmercaptophenyl) -5- (4- chlorophenyl)oxazole, as having antiphlogistic, analgesic and antipyretic activity. Other related diphenyloxazole disclosures include U.S. Patent No. 4,001,228, to G. Mattalia, for antiaggregating activity and U.S. Patent No. 3,895,024, to R. Hafeli, for intermediates in the production of antiinflammatory agents. U. S. Patent No. 4,489,084, to F. Haviv and F.Kerdesky, describes diphenyloxazolyl hydrazinoalkyl nitrile compounds for use as antiinflammatory agents. U.S. Patent No. 4,143,047, to R. Harrison, describes oxazole compounds as reactants to make 2-acylamino oxazole derivatives having anti-allergy activity.
U.S. Patent No. 4,791,124, to Lutomski et al, describes the pesticide activity of substituted bis (4-halophenyl)oxazoles. U.S. Patent No.
4,775,687, to Meguro et al describes the possible use of 4,5-phenyl oxazoles as starting materials for antidiabetic compounds. WO publication No. 517,591, published December 9, 1992, describes bis(halophenyl)oxazole derivatives as starting materials for the preparation of antiinflammatory agents.
N. Meanwell et al [J. Med. Chem . , 35, 3498 (1992)] describe bis(substitutedphenyl)oxazoles as having ADP-induced platelet aggregation inhibition activity. U.S. Patent No. 4,812,470, to N. Rogers et al, describes phenyl substituted oxazoles as having antibacterial activity.
U.S. Patent No. 3.901,908, to K. Fitzi and R. Pfister, describes 2-alkyl and 2-cycloalkyl-4, 5- phenyloxazoles as intermediates in the synthesis of imidazoles having analgesic and antipyretic activity. Specifically, 2-tert-butyl-4- (4- methylsulfonylphenyl) -5-phenyloxazole is described.
U.S. Patent No. 4,632,930, to Carini et al, describes antihypertensive alkyl and aryl substituted imidazole, thiazole and oxazole derivatives.
Specifically, 5-phenyl-4- (4-methylsulfonylphenyl) - α,α-bis (trifluorome hyl) thiazole-2-methanol is described.
R. Cremylin et al describe the synthesis of heterocyclic sulfonyl derivatives and specifically, 4 ' , 4"- (2-methyl-4, 5-oxazoldiyl) -bis- benzenesulfonamide (J". Heterocycl . Chem . , 22, 1211 (1985) ) .
T. van Es and O.G.Backeberg [J. Chem. Soc. , 1363 (1963)] describe the synthesis of 2-methyl-4, 5- substitutedphenyloxazoles, and specifically, 4- [5- (4- chloropheny1) -2-methyl- -oxazoly1]benzenesulfonamide. DESCRIPTION OF THE INVENTION
A class of substituted oxazolyl compounds useful in treating inflammation-related disorders is defined by Formula I:
Figure imgf000007_0001
wherein R is selected from hydrido, alkyl, hydroxyalkyl, haloalkyl, alkenyl, hydroxyalkenyl, alkynyl, hydroxyalkynyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, heteroaryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, alkoxycarbony1, alkoxycarbonylalkyl, carboxy, carboxyalkyl, arylthioalkyl, aminocarbonylalkyl, N-alkyla inocarbonylalkyl and N,N-dialkylaminocarbonylalkyl; wherein R^ is selected from cycloalkyl, cycloalkenyl, aryl and heteroaryl, wherein R1 is optionally substituted at a substitutable position by alkyl, alkoxy and halo; and wherein R^ is selected from alkyl, haloalkyl and amino; or a pharmaceutically-acceptable salt thereof; provided R is not methyl when R^ is amino; and further provided that R^ is not phenyl when R^ is methyl and R is isopropyl or tert-butyl.
The phrase "further provided", as used in the above description, is intended to mean that the denoted proviso is not to be considered conjunctive with the other provisos.
Compounds of Formula I would be useful for, but not limited to, the treatment of inflammation in a subject, and for treatment of other inflammation-associated disorders, such as, as an analgesic in the treatment of pain and headaches, or as an antipyretic for the treatment of fever. For example, compounds of Formula I would be useful to treat arthritis, including but not limited to rheumatoid arthritis, spondyloarthopathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis. Such compounds of Formula I would be useful in the treatment of asthma, bronchitis, menstrual cramps, tendinitis, bursitis, and skin related conditions such as psoriasis, eczema, burns and dermatitis. Compounds of Formula I also would be useful to treat gastrointestinal conditions such as inflammatory bowel syndrome, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis and for the prevention of colorectal cancer. Compounds of Formula I would be useful in treating inflammation in such diseases as vascular diseases, migraine headaches, periarteritis nodosa, thyroidi is, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, myasthenia gravis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, hypersensitivity, conjunctivitis, swelling occurring after injury, myocardial ischemia, and the like. The compounds are useful as anti-inflammatory agents, such as for the treatment of arthritis, with the additional benefit of having significantly less harmful side effects.
Preferably, the compounds have a cyclooxygenase
II IC50 of less than about 0.1 μM, and also have a selectivity ratio of cyclooxygenase II inhibition over cyclooxygenase I inhibition of at least 50, and more preferably of at least 100. Even more preferably, the compounds have a cyclooxygenase I IC50 of greater than about 0.5 μM, and more preferably of greater than 5 μM. Such preferred selectivity may indicate an ability to reduce the incidence of common NSAID-induced side effects.
A preferred class of compounds consists of those compounds of Formula I wherein R is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower alkenyl, lower hydroxyalkenyl, lower alkynyl, lower hydroxyalkynyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower aralkoxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, carboxy, lower alkoxycarbonyl, lower alkoxycarbonylalkyl, lower carboxyalkyl, lower arylthioalkyl, lower aminocarbonylalkyl, lower N- alkylaminocarbonylalkyl and lower N,N- dialkylaminocarbonylalkyl; wherein R^- is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl and heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, 3,4- methylenedioxyphenyl, indolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2,3-dihydrobenzofuryl, wherein R! is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; and wherein R^ is selected from lower alkyl, lower haloalkyl and amino.
A class of compounds of particular interest consists of those compounds of Formula I wherein R is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, 1-propenyl, 2-propenyl, 1- butenyl, 2-butenyl, 3-butenyl, hydroxyethenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2- butynyl, 3-butynyl, hydroxyethynyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n- propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl, optionally substituted at a "substitutable position by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert- butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethyl and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position on the phenyl radical with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position on the phenyl radical with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbony1, methoxycarbonylmethy1, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, carboxy, acetyl, propanoic, butanoic, pentanoic, hexanoic, phenylthiomethyl, aminocarbonylmethyl, N-methylaminocarbonylmethy1 and N,N-dimethylaminocarbonylmethy1; wherein R1 is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, cyclopentenyl, cycloheptenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3- dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3- dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; and wherein R2 is selected from methyl, ethyl, trifluoromethyl, difluoromethyl, fluoromethyl and amino.
A family of specific compounds of particular interest within Formula I consists of compounds and pharmaceutically-acceptable salts thereof as follows:
4- [2-benzyl-5- (phenyl)oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (2-fluorophenyl)oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (3-fluorophenyl)oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (4-fluorophenyl)oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (2, 4-difluorophenyl)oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (2, 5-difluorophenyl)oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (2, 6-difluorophenyl)oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (3 , 4-difluorophenyl)oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3 , 5-difluorophenyl)oxazol-4- yl] enzenesulfonamide; 4- [2-benzyl-5- (2-chlorophenyl)oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (3-chlorophenyl)oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (4-chlorophenyl)oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (2,4-dichlorophenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (2,5-dichlorophenyl)oxazol-4- yl]benzenesulfonamide;
4-[2-benzyl-5- (2,6-dichlorophenyl)oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (3,4-dichlorophenyl)oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (3,5-dichlorophenyl)oxazol-4- yl]benzenesulfonamide;
4-[2-benzyl-5- (2-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5- (3-methoxyphenyl)oxazol-4- yl]benzenesulfonamide;
4-[2-benzyl-5-(4-methoxyphenyl)oxazol-4- yl] enzenesulfonamide;
4-[2-benzyl-5- (2,4-dime hoxyphenyl)oxazol-4- yl]benzenesulfonamide;
4-[2-benzyl-5- (2,5-dimethoxyphenyl)oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (2,6-dimethoxyphenyl)oxazol-4- y1]benzenesulfonamide; 4-[2-benzyl-5- (3,4-dimethoxyphenyl)oxazol-4- yl]benzenesulfonamide;
4-[2-benzyl-5-(3,5-dimethoxyphenyl)oxazol-4- yl]benzenesulfonamide;
4-[2-benzyl-5-(2-methylphenyl)oxazol-4- y1]benzenesulfonamide;
4-[2-benzyl-5- (3-methylphenyl)oxazol-4- yl]benzenesulfonamide;
4-[2-benzyl-5- (4-methylphenyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5-(2,4-dimethylphenyl)oxazol-4- yl]benzenesulfonamide; 4- 2-benzyl-5- (2,5-dimethylphenyl)oxazol-4- yl]benzenesulfonamide; 4- 2-benzyl-5- (2,6-dimethylphenyl)oxazol-4- yl]benzenesulfonamide; 4- 2-benzyl-5- (3,4-dimethylphenyl)oxazol-4- yl]benzenesulfonamide; 4- 2-benzyl-5- (3,5-dimethylphenyl)oxazol-4- yl]benzenesulfonamide; 4- 2-benzyl-5- (2-chloro-4-methylphenyl)oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5-(3-chloro-4-methylphenyl)oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (3-chloro-2-methylphenyl)oxazol-4- yl]benzenesulfonamide; 4- 2-benzyl-5- (2-chloro-6-methylphenyl)oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5-(4-chloro-2-methylphenyl)oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5- (4-chloro-3-methylphenyl)oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (2-chloro-4-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 2-benzyl-5-(3-chloro-4-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 2-benzyl-5-(3-chloro-2-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (2-chloro-6-methoxyphenyl)oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5- ( -chloro-2-methoxyphenyl)oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5-(4-chloro-3-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 4- 2-benzyl-5- (3,5-dichloro-4-methoxyphenyl)oxazol-
4-y1] enzenesulfonamide; 4- 2-benzyl-5-(2-fluoro-4-methylphenyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5- (3-fluoro-4-methylphenyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5- (3-fluoro-2-methylphenyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5- (2-fluoro-6-methylphenyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5-(4-fluoro-2-methylphenyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5- (4-fluoro-3-methylphenyl)oxazol-4- yl]benzenesulfonamide;
4-[2-benzyl-5- (2-fluoro-4-methoxyphenyl)oxazol-4- yl] enzenesulfonamide; 4-[2-benzyl-5- (3-fluoro-4-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5- (3-fluoro-2-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5-(2-fluoro-6-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5- (4-fluoro-2-methoxyphenyl)oxazol-4- yl]benzenesulfonamide;
4-[2-benzyl-5-(2-thienyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5- (5-chloro-2-thienyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5- (cyclohexyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5- (1-cyclohexenyl)oxazol-4- yl]benzenesulfonamide; 4-[2-benzyl-5- (2-cyclohexenyl)oxazol-4- yl]benzenesulfonamide;
4-[2-benzyl-5- (3-cyclohexenyl)oxazol-4- yl]benzenesulfonamide; 2-benzyl-4-(4-methylsulfonylphenyl) -5-phenyloxazole; 2-benzyl-4- (4-methylsulfonylphenyl)-5- (2- fluorophenyl)oxazole;
2-benzyl-4- (4-methylsulfonylphenyl)-5- (3- fluorophenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2, 4- difluorophenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2, 5- difluorophenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2, 6- difluorophenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3 , 4- difluorophenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3 , 5- difluorophenyl) oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (2- chlorophenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3- chlorophenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4- chlorophenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2, 4- dichlorophenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2, 5- dichlorophenyl) oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (2, 6- dichlorophenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3 , 4- dichlorophenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3 , 5- dichlorophenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2- methoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3- methoxyphenyl)oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (4- methoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2,4- dimethoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2, 5- dimethoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2, 6- dimethoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3,4- dimethoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3 , 5- dimethoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3- methylphenyl)oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (4- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2, 4- dimethylphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2,5- dimethylphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2, 6- dimethylphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3,4- dimethylphenyl)oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (3, 5- dimethylphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2-chloro-4- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-chloro-4- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-chloro-2- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2-chloro-6- methylphenyl)oxazole;
2-benzyl-4- ( -methylsulfonylphenyl) -5- (4-chloro-2- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-chloro-3- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2-chloro-4- methoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-chloro-4- methoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-chloro-2- methoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2-chloro-6- methoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-chloro-2- methoxyphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-chloro-3- methoxyphenyl)oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (3, 5-dichloro-
4-methoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2-fluoro-4- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-fluoro-4- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-fluoro-2- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2-fluoro-6- methylphenyl)oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-fluoro-2- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-fluoro-3- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2-fluoro-4- methoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-fluoro-4- methoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-fluoro-2- methoxyphenyl)oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (2-fluoro-6- methoxyphenyl)oxazole; 2-benzyl-4- (4-me hylsulfonylphenyl) -5- (4-fluoro-2- methoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2- thienyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (5-chloro-2- thienyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl)-5-
(cyclohexyl)oxazole-; 2-benzyl-4- (4-methylsulfonylphenyl)-5- (1- cyclohexenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl)-5- (2- cyclohexenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3- cyclohexenyl)oxazole;
2- (ethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (trifluoromethyl)-4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (difluoromethyl)-4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (hydroxyme hyl) -4-(4-methylsulfonylphenyl) -5- phenyloxazole; 2- (carboxy)-4- (4-methylsulfonylphenyl)-5- phenyloxazole;
2- (methoxycarbonyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (ethoxycarbonyl)-4-(4-methylsulfonylphenyl) -5- phenyloxazole; 2-(propyl)-4-(4-methylsulfonylphenyl)-5- phenyloxazole; 2- (benzyl)-4- (4-methylsulfonylphenyl)-5- phenyloxazole; 2- (phenylthiomethyl)-4-(4-methylsulfonylphenyl) -5- phenyloxazole;
2-(phenoxymethyl)-4- (4-methylsulfonylphenyl)-5- phenyloxazole; 2- ( (4-chlorophenoxy)methyl)-4-(4- methylsulfonylphenyl) -5-phenyloxazole; 2- ( (3-chlorophenoxy)methyl) -4-(4- methylsulfonylphenyl)-5-phenyloxazole; 2- ( (2-chlorophenoxy)methyl) -4- (4- methylεulfonylphenyl) -5-phenyloxazole; 2- ( (4-fluorophenoxy)methyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- ( (3-fluorophenoxy)methyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- ( (2-fluorophenoxy)methyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- ( (4-carboxyphenoxy)methyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- ( (3-carboxyphenoxy)methyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- ( (2-carboxyphenoxy)methyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- (2-phenethyl) -4- (4-methylsulfonylphenyl) -5- pheny1oxazo1e; 2 - (3-phenpropy1) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (carboxymethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole;
2- (ethoxycarbonylmethyl) -4- (4-methylsulfonylphenyl)
5-phenyloxazole; 2- (methoxycarbonylmethy1) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- (2-carboxyethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (2-methoxycarbonylethyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- (2-ethoxycarbonylethyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole;
2- (3-carboxypropyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (3-methoxycarbonylpropyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- (3-ethoxycarbonylpropyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- (2-quiniolyloxymethyl) -4- (4-methylsulfonylphenyl) -
5-phenyloxazole; 4- [2- (ethyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- [2- (trifluoromethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- [2- (difluoromethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (hydroxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (carboxy) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (methoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (ethoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- [2- (propyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (benzyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (phenylthiomethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [ 2 - (phenoxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- ( (4-chlorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- [2- ( (3-chlorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- ( (2-chlorophenoxy)methyl) -5-phenyloxazol-4- y1]benzenesulfonamide; 4- [2- ( (4-fluorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4-[2- ( (3-fluorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- ( (2-fluorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- [2- ( (4-carboxyphenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- ( (3-carboxyphenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- ( (2-carboxyphenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (2-phenylethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- (3-phenylpropyl) -5-phenyloxazol-4- yl]benzenesuIfonamide;
4- 2- (carboxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- (ethoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- (methoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- (2-carboxyethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (2-methoxycarbonylethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- (2-ethoxycarbonylethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (3-carboxypropyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (3-methoxycarbonylpropyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- (3-ethoxycarbonylpropyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- (2-quiniolyloxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2-benzy1-4-phenyloxazol-5-yl]benzenesulfonamide; 4- 2-benzyl-4- (2-fluorophenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (3-fluorophenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (4-fluorophenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (2, 4-difluorophenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (2,5-difluorophenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (2, 6-difluorophenyl)oxazol-5- yl]benzenesulfonamide; - 2-benzyl-4- (3, 4-difluorophenyl)oxazol-5- yl]benzenesulfonamide; - 2-benzyl-4- (3 , 5-difluorophenyl)oxazol-5- yl]benzenesulfonamide; - 2-benzyl-4- (2-chlorophenyl)oxazol-5- yl]benzenesulfonamide; - 2-benzyl-4- (3-chlorophenyl)oxazol-5- yl]benzenesulfonamide; - 2-benzyl-4- (4-chloropheny1)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (2 ,4-dichlorophenyl)oxazol-5- yl]benzenesulfonamide; - 2-benzyl-4- (2, 5-dichlorophenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (2, 6-dichlorophenyl)oxazol-5- yl]benzenesulfonamide; - 2-benzyl-4- (3 , 4-dichlorophenyl)oxazol-5- yl]benzenesulfonamide; - 2-benzyl-4- (3 , 5-dichlorophenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (2-methoxyphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzy1-4- (3-methoxyphenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (4-methoxyphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (2,4-dimethoxyphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (2,5-dimethoxyphenyl)oxazol-5- yl]benzenesulfonamide;
4- -benzyl-4- (2, 6-dimethoxyphenyl) oxazol-5- yl]benzenesulfonamide; 4- 2-benzyl-4- (3 , 4-dimethoxyphenyl) oxa"zol-5- yl]benzenesulfonamide; 2-benzyl-4- (3 , 5-dimethoxyphenyl) oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (2-methylphenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (3-methylphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (4-methylphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzy1-4- (2 , 4-dimethylphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (2, 5-dimethylphenyl)oxazol-5- yl] enzenesulfonamide; 2-benzyl-4- (2, 6-dimethylphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (3 ,4-dimethylphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (3 , 5-dimethylphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (2-chloro-4-methylphenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (3-chloro-4-methylphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzy1-4- (3-chloro-2-methylphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (2-chloro-6-methylphenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (4-chloro-2-methylphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (4-chloro-3-me hylphenyl)oxazol-5- yl] enzenesulfonamide;
4- 2-benzyl-4- (2-chloro-4-methoxyphenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (3-chloro-4-methoxyphenyl)oxazol-5- yl]benzenesulfonamide; [2-benzy1-4- (3-chloro-2-methoxyphenyl)oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (2-chloro-6-methoxyphenyl)oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (4-chloro-2-methoxyphenyl)oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (4-chloro-3-methoxyphenyl)oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (3 , 5-dichloro-4-methoxyphenyl)oxazol-
5-y1]benzenesulfonamide;
4- [2-benzyl-4- (2-fluoro-4-methylphenyl)oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (3-fluoro-4-methylphenyl)oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (3-fluoro-2-methylphenyl)oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (2-fluoro-6-methylphenyl)oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (4-fluoro-2-methylphenyl)oxazol-5- yl]benzenesulfonamide;
4- [2-benzy1-4- (4-fluoro-3-methylphenyl)oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (2-fluoro-4-methoxyphenyl)oxazol-5- yl]benzenesulfonamide; 4- [2-benzy1-4- (3-fluoro-4-methoxyphenyl)oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (3-fluoro-2-methoxyphenyl)oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (2-fluoro-6-methoxyphenyl)oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (4-fluoro-2-methoxyphenyl)oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (2-thienyl)oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (5-chloro-2-thienyl)oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (cyclohexyl)oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (1-cyclohexenyl)oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (2-cyclohexenyl)oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (3-cyclohexenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-5- (4-methylsulfonylphenyl) -4-phenyloxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2- fluorophenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3- fluorophenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2, 4- difluorophenyl) oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (2, 5- difluorophenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2, 6- difluorophenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3 , 4- difluorophenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3,5- difluorophenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2- chlorophenyl)oxazol-4-yl]benzenesulfonamide; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3- chlorophenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4- chlorophenyl)oxazol-4-yl]benzenesulfonamide; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2, 4- dichlorophenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2, 5- dichlorophenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2, 6- dichlorophenyl)oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (3,4- dichlorophenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3 , 5- dichlorophenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2,4- dimethoxyphenyl) oxazole,•
2-benzyl-5- (4-methylsulfonylphenyl) -4- (2, 5- dimethoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2, 6- dimethoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3,4- dimethoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3,5- dimethoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2- methylphenyl)oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (3- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2, 4- dimethylphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2,5- dimethylphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2, 6- dimethylphenyl)oxazole;
2-benzyl-5- (4-me hylsulfonylphenyl) -4- (3 , 4- dimethylphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3, 5- dimethylphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2-chloro-4- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-chloro-4- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-chloro-2- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2-chloro-6- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4-chloro-2- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4-chloro-3- methylphenyl)oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (2-chloro-4- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-chloro-4- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-chloro-2- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2-chloro-6- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4-chloro-2- methoxyphenyl)oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (4-chloro-3- methoxyphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3, 5-dichloro-
4-methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2-fluoro-4- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-fluoro-4- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-fluoro-2- methylphenyl)oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (2-fluoro-6- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4-fluoro-2- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4-fluoro-3- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2-fluoro-4- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-fluoro-4- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-fluoro-2- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2-fluoro-6- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4-fluoro-2- methoxyphenyl)oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (2- thienyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (5-chloro-2- thienyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4-
(cyclohexyl)oxazole-; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (1- cyclohexenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2- cyclohexenyl)oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (3- cyclohexenyl)oxazole; 2- (ethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2- (trifluoromethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2- (difluoromethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2- (hydroxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole;
2- (carboxy) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2- (methoxycarbonyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2- (ethoxycarbonyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2- propyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole;
2- benzyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole;
2- phenylthiomethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole;
2- phenoxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; (4-chlorophenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole;
2- (3-chlorophenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole;
2- (2-chlorophenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; (4-fluorophenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole;
2- (3-fluorophenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; (2-fluorophenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; (4-carboxyphenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; (3-carboxyphenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; 2- (2-carboxyphenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole;
2- 2-phenethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 3-phenpropyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; carboxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole;
2- ethoxycarbonylmethyl) -5- (4-methylsulfonylphenyl)
4-phenyloxazole; methoxycarbonylmethy1) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; 2-carboxyethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2-methoxycarbonylethy1) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; 2-ethoxycarbonylethyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; 3-carboxypropyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 3-methoxycarbonylpropyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; 3-ethoxycarbonylpropyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; 2-quiniolyloxymethyl) -5- (4-methylsulfonylphenyl) -
4-phenyloxazole;
4- 2- (ethyl) -4-phenyloxazol-5-yl]benzenesulfonamide; 4- 2- (trifluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 2- (difluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- 2- (hydroxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 2- (carboxy) -4-phenyloxazol-5- yl]benzenesulfonamide; 2- (methoxycarbonyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- 2- (ethoxycarbonyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 2- (propyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 2- (benzyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 2- (phenylthiomethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- 2- (phenoxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 2- ( (4-chlorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4-[2- ( (3-chlorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (2-chlorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (4-fluorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (3-fluorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (2-fluorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- [2- ( (4-carboxyphenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (3-carboxyphenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (2-carboxyphenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4-[2- (2-phenethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (3-phenpropy1) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- [2- (carboxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2 - (ethoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (methoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (2-carboxyethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (2-methoxycarbonylethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- [2- (2-ethoxycarbonylethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (3-carboxypropyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (3-methoxycarbonylpropyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (3-ethoxycarbonylpropyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (2-quiniolyloxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 5- (4-fluorophenyl) -2-methyl-4- [4-
(methylsulfonyl)phenyl]oxazole,• 3- [5- (4-fluorophenyl) -4- [4- (methylsulfonyl)phenyl] oxazol-2-yl]propanoic acid; methyl 3- [5- (4-fluorophenyl) -4- [4- (methylsulfonyl) phenyl]oxazol-2-yl]propanate;
4- (4-fluorophenyl) -2- (2-ρhenylethyl) -5- (4-
(methylsulfonyl)phenyl)oxazole; 4- (4-fluorophenyl) -2-methyl-5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenyloxazole; 2-benzyl-4- (4-fluorophenyl) -5- (4-
(methylsulfonyl)phenyl)oxazole; 4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2- (3- phenylpropyl)oxazole;
4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2 - propyloxazole; 2- (tert-butyl) -4- (4-fluorophenyl) -5-[4- methylsulfonylphenyl]oxazole; 4- (4-fluorophenyl) -2- [ (4-methoxyphenyl)methyl] -5- [4- methylsulfonylphenyl] oxazole 4- (4-fluorophenyl) -2- [ (3-methoxyphenyl)methyl] -5- [4- methylsulfonylphenyl]oxazole; 2- (diphenylmethy1) -4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl]oxazole; 2- [4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl]oxazol-2-yl]acetic acid; ethyl 2- [4- (4-fluorophenyl) -5-[4- methylsulfonylphenyl]oxazol-2-yl] acetate; 3- [4- (4-fluorophenyl) -5- [ -methylsulfonylphenyl] oxazol-2-yl]propanoic acid; methyl 3- [4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl]oxazol-2-yl]propanate; 4- [4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl]oxazol-2-yl]butanoic acid; methyl 4- [4- (4-fluorophenyl) -5- [4-methylsulfonyl phenyl]oxazol-2-yl]butanate;
3- [4- (4-fluorophenyl) -5- [4-methylsulfonyl phenyl]oxazol-2-yl]propanamide; ethyl 2- [4- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl]oxazol-2-yl] -2-benzyl-acetate; 4- (4-fluorophenyl) -2- (cyclohexylethyl) -5- [4- (methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2- (3-fluorophenoxymethyl) -5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2- (3-chlorophenoxymethyl) -5- [4- (methylsulfonyl)phenyl]oxazole;
4- (4-fluorophenyl) -2- (pyridyloxymethyl) -5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenoxymethyloxazole; 4- (4-fluorophenyl) -2- (2-hydroxyethyl) -5- [4- (methylsulfonyl)phenyl]oxazole; 4- ( -fluorophenyl) -2- (hydroxymethyl) -5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (cyclohexyl) -2-phenyl-5-[4- (methylsulfonyl)phenyl]oxazole;
4- (4-fluorophenyl) -2-benzyloxymethyl-5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2-cyclohexyl-5- [4-
(methylsulfonyl)phenyl]oxazole; and 5- (4-fluorophenyl) -2-phenyl-4- [4-
(methylsulfonyl)phenyl]oxazole.
Within Formula I there is a subclass of compounds of high interest wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R^ is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo, and wherein R^ is methyl; or a pharmaceutically-acceptable salt thereof; provided R! is not phenyl when R is isopropyl or tert-butyl.
A more preferred class of compounds of the first subclass wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and wherein R! is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2, 3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2,3-dihydrobenzofuryl, wherein R! is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically-acceptable salt or prodrug thereof.
A class of compounds of particular interest consists of those compounds of the first subclass wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethy1 and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, pentanoic, hexanoic and aminocarbonylmethyl; and wherein R^ is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2- cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2, 3-dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert- butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo.
A family of specific compounds of particular interest within the first subclass consists of compounds and pharmaceutically-acceptable salts thereof as follows:
5- (4-fluorophenyl) -2-methyl-4- [4- (methylsulfonyl) phenyl]oxazole;
3- [5- (4-fluorophenyl) -4- [4- (methylsulfonyl)phenyl] -2- oxazol-2-yl]propanoic acid; methyl 3- [5- (4-fluorophenyl) -4- [4- (methylsulfonyl) phenyl] -2-oxazol-2-yl]propanate; 4- (4-fluorophenyl) -2- (2-phenylethyl) -5- (4- (methylsulfonyl)phenyl)oxazole; 4- (4-fluorophenyl) -2-methyl-5- [4- methylsulfonylphenyl]oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenyloxazole; 2-benzyl-4- (4-fluorophenyl) -5- (4- (methylsulfonyl)phenyl) oxazole;
4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2- (3- phenylpropyl)oxazole; 4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2- propyloxazole; 2- (tert-butyl) -4- (4-fluorophenyl) -5-[4- methylsulfonylphenyl]oxazole; 4- (4-fluorophenyl) -2- [ (4-methoxyphenyl)methyl] -5- [4- methylsulfonylphenyl]oxazole 4- (4-fluorophenyl) -2- [ (3-methoxyphenyl)methyl] -5- [4- methylsulfonylphenyl]oxazole;
2- (diphenylmethy1) -4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl]oxazole; 2- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] oxazol-2-yl]acetic acid; ethyl 2-[4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl]oxazol-2-yl]acetate; 3- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] oxazol-2-yl]propanoic acid; methyl 3- [4- (4-fluorophenyl) -5- [4-methylsulfonyl phenyl]oxazol-2-yl]propanate;
4- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] oxazol-2-yl]butanoic acid; methyl 4- [4- (4-fluorophenyl) -5- (4-methylsulfonyl phenyl)oxazol-2-yl]butanate; 3-[4- (4-fluorophenyl) -5-[4-methylsulfonylphenyl] oxazol-2-yl]propanamide; ethyl 2- [4- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl]oxazol-2-yl] -2-benzyl-acetate; 4- (4-fluorophenyl) -2- (cyclohexylethyl) -5- [4- (methylsulfonyl)phenyl]oxazole;
4- (4-fluorophenyl) -2- (3-fluorophenoxymethyl) -5- [4- (methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2- (3-chlorophenoxymethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2 - (pyridyloxymethyl) -5- [4- (methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenoxymethyloxazole; 4- (4-fluorophenyl) -2- (2-hydroxyethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (hydroxymethyl) -5- [4- (methylsulfonyl)phenyl] oxazole; 4- (cyclohexyl) -2-phenyl-5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2-benzyloxymethyl-5- [4- (methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2-cyclohexyl-5- [4-
(methylsulfonyl)phenyl] oxazole; and 5- (4-fluorophenyl) -2-phenyl-4- [4-
(methylsulfonyl)phenyl]oxazole.
Within Formula I there is a second subclass of compounds of high interest wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R^ is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo; and wherein R2 is amino; or a pharmaceutically-acceptable salt or . prodrug thereof; provided R is not methyl.
A more preferred class of compounds of the second subclass consists of those compounds of wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and wherein R! is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3- dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3- dihydrobenzofuryl, wherein R1 is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically- acceptable salt or prodrug thereof.
A class of compounds of particular interest consists of those compounds of the second subclass wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethy1, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethy1 and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, pentanoic, hexanoic and aminocarbonylmethyl; and wherein R^ is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2- cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2, 3-dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert- butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo.
A family of specific compounds of particular interest within the second subclass consists of compounds and pharmaceutically-acceptable salts thereof as follows:
4- [2-benzyl-5- (phenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-fluorophenyl)oxazol-4- y1]benzenesulfonamide;
4- [2-benzyl-5- (3 , 4-difluorophenyl)oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (4-chlorophenyl)oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (3 , 4-dichlorophenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-methoxyphenyl)oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3 ,4-dimethoxyphenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-methylphenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3 ,4-dimethylphenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3-chloro-4-methylphenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-chloro-3-methylphenyl)oxazol-4- yl]benzenesulfonamide; - 2-benzyl-5- (3-chloro-4-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (4-chloro-3-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; - 2-benzyl-5- (3 , 5-dichloro-4-methoxyphenyl)oxazol-
4-y1]benzenesulfonamide; - 2-benzyl-5- (3-fluoro-4-methylphenyl)oxazol-4- yl]benzenesulfonamide; - 2-benzyl-5- (4-fluoro-3-methylphenyl)oxazol-4- yl]benzenesulfonamide; - 2-benzyl-5- (3-fluoro-4-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (2-thienyl)oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (5-chloro-2-thienyl)oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (cyclohexyl)oxazol-4- yl]benzenesulfonamide; - 2-benzyl-5- (1-cyclohexenyl)oxazol-4- yl]benzenesulfonamide;
4- 2- (ethyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- 2 - (trifluoromethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2 - (difluoromethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (hydroxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- (carboxy) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2 - (methoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- (ethoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- (n-propyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- (benzyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- (phenoxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- ( (4-chlorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- ( (4-fluorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- ( (4-carboxyphenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
2- (2-phenylethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
2- (3-phenylpropyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (carboxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- (ethoxycarbonylmethyl) -5-phenyloxazol-4- y1]benzenesulfonamide;
4- 2- (methoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- (2-quiniolyloxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-4-phenyloxazol-5-yl]benzenesulfonamide; 4- 2-benzyl-4- (3 ,4-difluorophenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (4-chlorophenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (3 , 4-dichlorophenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (4-methoxyphenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (3 , 4-dimethoxyphenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (4-methylphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (3 , 4-dimethylphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzy1-4- (3-chloro-4-methylphenyl)oxazol-5- yl]benzenesulfonamide; 4-[2-benzyl-4- (4-chloro-3-methylphenyl)oxazol-5- yl]benzenesulfonamide; 4-[2-benzyl-4- (3-chloro-4-methoxyphenyl)oxazol-5- yl]benzenesulfonamide; 4-[2-benzyl-4-(4-chloro-3-methoxyphenyl)oxazol-5- yl]benzenesulfonamide; 4-[2-benzyl-4- (3,5-dichloro-4-methoxyphenyl)oxazol-
5-y1]benzenesulfonamide; 4-[2-benzyl-4- (3-fluoro-4-methylphenyl)oxazol-5- yl]benzenesulfonamide;
4-[2-benzyl-4- (4-fluoro-3-methylphenyl)oxazol-5- yl]benzenesulfonamide; 4-[2-benzyl-4- (3-fluoro-4-methoxyphenyl)oxazol-5- yl]benzenesulfonamide; 4-[2-benzyl-4- (2-thienyl)oxazol-5- yl]benzenesulfonamide; 4-[2-benzyl-4-(5-chloro-2-thienyl)oxazol-5- yl]benzenesulfonamide; 4-[2-benzyl-4-(cyclohexyl)oxazol-5- yl]benzenesulfonamide;
4-[2-benzyl-4- (1-cyclohexenyl)oxazol-5- yl]benzenesulfonamide; 4-[2-(ethyl) -4-phenyloxazol-5-yl]benzenesulfonamide; 4-[2- (trifluoromethyl)-4-phenyloxazol-5- yl]benzenesulfonamide;
4-[2-(difluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4-[2-(hydroxymethyl)-4-phenyloxazol-5- yl]benzenesulfonamide; 4-[2- (carboxy)-4-phenyloxazol-5- yl] enzenesulfonamide; 4-[2- (methoxycarbonyl)-4-phenyloxazol-5- yl]benzenesulfonamide; 4-[2-(ethoxycarbony1) -4-phenyloxazol-5- yl]benzenesulfonamide;
4-[2- (propyl)-4-phenyloxazol-5- yl]benzenesulfonamide; 4- [ 2 - (benzyl ) -4 -phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (phenoxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (4-chlorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (4-fluorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (4-carboxyphenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- [2- (2-phenethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (3-phenpropyl) -4-phenyloxazol-5- y1]benzenesulfonamide; 4- [2- (carboxymethyl) -4-phenyloxazol-5- y1]benzenesulfonamide; 4- [2- (ethoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (methoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- [2- (2-quiniolyloxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [5- (4-fluorophenyl) -2-methyl-oxazol-4- yl]benzenesulfonamide; [5- (4-fluorophenyl) -4- (4-aminosulfonylphenyl) -2- oxazol-2-yl]propanoic acid; methyl 3- [5- (4-fluorophenyl) -4- (4- aminosulfonylphenyl)oxazol-2-yl]propanate; 4- [4- (4-fluorophenyl) -2- (2-phenylethyl) -oxazol-5- yl]benzenesulfonamide;
4- [4- (4-fluorophenyl) -2-methyloxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2-phenyloxazol-5- yl]benzenesulfonamide; 4-[2-benzyl-4- (4-fluorophenyl)oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (3-phenylpropyl)oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2-propyloxazol-5- yl]benzenesulfonamide; 4- [2- (tert-butyl) -4- (4-fluorophenyl)oxazol-5- yl]benzenesulfonamide;
4- [4- (4-fluorophenyl) -2- (4-methoxyphenyl) methyloxazol-5-yl]benzenesulfonamide 4- [4- (4-fluorophenyl) -2- (3-methoxyphenyl) methyloxazol-5-yl]benzenesulfonamide; 4- [2-diphenylmethyl-4- (4-fluorophenyl)oxazol-5- yl]benzenesulfonamide; 2- [4- (4-fluorophenyl) -5- [4- aminosulfonylphenyl]oxazol-2-yl]acetic acid; ethyl 2- [4- (4-fluorophenyl) -5- [4-aminosulfonylphenyl] oxazol-2-yl]acetate;
3- [4- (4-fluorophenyl) -5- [4- aminosulfonylphenyl]oxazol-2-yl]propanoic acid; methyl 3- [4- (4-fluorophenyl) -5- [4- aminosulfonylphenyl]oxazol-2-yl]propanate; 4- [4- (4-fluorophenyl) -5- [4- aminosulfonylphenyl]oxazol-2-yl]butanoic acid; methyl 4- [4- (4-fluorophenyl) -5- [4-aminosulfonyl phenyl]oxazol-2-yl]butanate; 3- [4- (4-fluorophenyl) -5- [4-aminosulfonyl phenyl]oxazol-2-yl]propanamide; ethyl 2- [4- (4-fluorophenyl) -5- [4-aminosulfonyl phenyl]oxazol-2-yl] -2-benzyl-acetate; 4- [4- (4-fluorophenyl) -2- (cyclohexylethyl) oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (3-fluorophenoxymethyl) oxazol-5-yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (3-chlorophenoxymethyl) oxazol-5-yl] enzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (pyridyloxymethyl)oxazol-5- yl]benzenesulfonamide;
4- [4- (4-fluorophenyl) -2-phenoxymethyloxazol-5- yl]benzenesulfonamide; 4-[4- (4-fluorophenyl) -2- (2-hydroxyethyl)oxazol-5- yl]benzenesulfonamide; 4-[4- (4-fluorophenyl) -2- (hydroxymethyl)oxazol-5- yl]benzenesulfonamide; 4-[4- (cyclohexyl) -2-phenyloxazol-5- yl]benzenesulfonamide; 4-[4-(4-fluorophenyl)-2-benzyloxymethyloxazol-5- yl]benzenesulfonamide; 4-[4-(4-fluorophenyl) -2-cyclohexyloxazol-5- yl]benzenesulfonamide; and
4-[5- (4-fluorophenyl) -2-phenyloxazol-4- yl]benzenesulfonamide.
Where the term "alkyl" is used, either alone or within other terms such as "haloalkyl", "alkoxyalkyl" and
"hydroxyalkyl", embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl and the like. Where the term "alkenyl" is used, it embraces linear or branched carbon carbon double bond- containing radicals having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkenyl radicals are "lower alkenyl" radicals having two to about six carbon atoms. Suitable "lower alkenyl" may be a straight or branched one such as vinyl, allyl, isopropenyl, 1- or 2-propenyl, 1-, 2- or 3-butenyl, pentenyl or the like. The term "alkynyl" embraces linear or branched radicals having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms, and containing a carbon-carbon triple bond. The more preferred "lower alkynyl" are radicals having two to ten carbons. Examples of such radicals include ethynyl, 1- or 2- propynyl, 1-, 2- or 3-butynyl and the like and isomers thereof. The term "hydrido" denotes a single hydrogen atom (H) . This hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical or two hydrido radicals may be attached to a carbon atom to form a methylene (-CH2-) radical. The term "halo" means halogens such as fluorine, chlorine, bromine or iodine. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either a bromo, chloro or a fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. The term
"hydroxyalkyl" embraces linear or branched alkyl radicals having one to about twelve carbon atoms any one of which may be substituted with one or more hydroxyl radicals. The term "hydroxyalkenyl" embraces linear or branched alkenyl radicals having two to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. The term "hydroxyalkynyl" embraces linear or branched alkynyl radicals having two to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about twelve carbon atoms, such as methoxy radical. The term "alkoxyalkyl" also embraces alkyl radicals having two or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The "alkoxy" or "alkoxyalkyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy or haloalkoxyalkyl radicals. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl and biphenyl. Preferred aryl radicals are those consisting of one, two, or three benzene rings. The term "heteroaryl" embraces radicals having an unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl [e.g., 4H-l,2,4-triazolyl, 1H-1, 2, 3-triazolyl, 2H-1,2,3- triazolyl, etc.] tetrazolyl [e.g. lH-tetrazolyl, 2H- tetrazolyl, etc.], etc.; unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g., tetrazolo [1, 5-b]pyridazinyl, etc.], etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group containing a sulfur atom, for example, thienyl, etc.; unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g., 1, 2, 4-oxadiazolyl, 1,3 , 4-oxadiazolyl, 1,2, 5-oxadiazolyl, etc.] etc.; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. benzoxazolyl, benzoxadiazolyl, etc.]; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g., 1,2,4- thiadiazolyl, 1,3,4- thiadiazolyl, 1,2,5-thiadiazolyl, etc.] etc.; unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., benzothiazolyl, benzothiadiazolyl, etc.] and the like. The term "aralkyl" embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenethyl, and diphenethyl. The terms benzyl and phenylmethy1 are interchangeable. The term "aryloxy" embrace oxy-containing aryl radicals attached through an oxygen atom to other radicals. More preferred aryloxy radicals are "lower aryloxy" radicals having a phenyl radical. An example of such radicals is phenoxy. The term "aryloxyalkyl" embraces alkyl radicals having one or more aryloxy radicals attached to the alkyl radical, that is, to form monoaryloxyalkyl and diaryloxyalkyl radicals. The "aryloxy" or "aryloxyalkyl" radicals may be further substituted to provide haloaryloxyalkyl radicals alkylaryloxy radicals, and the like. Examples of such radicals include chlorophenoxy and methylphenoxy. The term "aralkyloxy" embrace oxy-containing aralkyl radicals attached through an oxygen atom to other radicals. The term "aralkyloxyalkyl" embraces alkyl radicals having one or more aralkyloxy radicals attached to the alkyl radical, that is, to form monoaralkyloxyalkyl and diaralkyloxyalkyl radicals. The "aralkyloxy" or "aralkyloxyalkyl" radicals may be further substituted on the aryl ring portion of the radical. The term "heteroaryloxyalkyl" embraces alkyl radicals having one or more heteroaryloxy radicals attached to the alkyl radical, that is, to form monoheteroaryloxyalkyl and diheteroaryloxyalkyl radicals. The "heteroaryloxy" radicals may be further substituted on the heteroaryl ring portion of the radical. The term "arylthio" embraces radicals containing an aryl radical, as described above, attached to a divalent sulfur atom, such as a phenylthio radical. The term "arylthioalkyl" embraces alkyl radicals substituted with one or more arylthio radicals, as described above. The term "cycloalkyl" embraces radicals having three to ten carbon atoms, such as cyclopropyl cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. The term "cycloalkylalkyl" embraces alkyl radicals substituted with cycloalkyl radicals having three to ten carbon atoms, such as cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl and cycloheptylmethy1. The term "cycloalkenyl" embraces unsaturated radicals having three to ten carbon atoms, such as cylopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and cycloheptenyl. The term "sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals -Sθ2~- "Alkylsulfonyl" embraces alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. The "alkylsulfonyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals. The terms "sulfamyl", "aminosulfonyl" and "sulfonamidyl" denote a sulfonyl radical substituted with an amine radical, forming a sulfonamide (-SO2NH2). The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes -CO2H. The terms "carboxyalkyl" and "alkanoyl" embrace radicals having a carboxy radical as defined above, attached to an alkyl radical, which may be substituted or unsubstituted. Examples of such radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, trifluoroacetyl or the like, in which the preferable one is formyl, acetyl, propionyl or trifluoroacetyl. The term "alkoxycarbonyl" means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a "carbonyl" (-C=0) radical. Examples of such "alkoxycarbonyl" ester radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl. The term "alkoxycarbonylalkyl" embraces alkyl radicals having one or more alkoxycarbonyl radicals attached to the alkyl radical. The term
"aminocarbonylalkyl" embraces alkyl radicals having one or more aminocarbonyl radicals attached to the alkyl radical. The term "alkylaminocarbonylalkyl" embraces alkyl radicals having aminocarbonyl radicals substituted with one or two alkyl radicals. Examples of such include N- alkylaminocarbonylalkyl and N,N-dialkylaminocarbonylalkyl radicals such as N-methylaminocarbonylmethyl and N,N- dimethylaminocarbonylmethyl.
The present invention comprises a pharmaceutical composition for the treatment of inflammation and inflammation-associated disorders, such as arthritis, comprising a therapeutically-effective amount of a compound of Formula I in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.
The present invention also comprises a therapeutic method of treating inflammation or inflammation-associated disorders in a subject, the method comprising administering to a subject having such inflammation or disorder a therapeutically-effective amount of a compound of Formula I.
Also included in the family of compounds of Formula I are isomeric forms including and the pharmaceutically-acceptable salts thereof. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propanoic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicyclic, salicyclic, p- hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic) , methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, algenic, β- hydroxybutyric, salicyclic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N- methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of Formula I by reacting, for example, the appropriate acid or base with the compound of Formula I.
The compounds of the present invention may contain prodrugs of compounds of the current invention. The term "prodrug" embraces compounds which are metabolized in vivo into compounds of the invention.
The compounds of the present invention may contain asymmetric carbon atoms, and, therefore, the instant invention may also include the individual diastereomers and enantiomers, which may be prepared or isolated by methods known to those skilled in the art.
In other words, any resulting racemate can be resolved into the optical antipodes by known methods, for example, by separation of the diastereomeric salts thereof, with an optically active acid, and liberating the optically active amine compound by treatment with a base. Racemic compounds of the present invention can thus be resolved into their optical antipodes e.g., by fractional crystallization of d- or 1- (tartrates, mandelates, or camphorsulfonate) salts.
Additional methods for resolving optical isomers, known to those skilled in the art may be used, for example, those discussed by J. Jagues et al in Enantiomers. Racemates, and Resolutions, John Wiley and Sons, New York (1981) . Compounds of the present invention also are meant to include, where possible, hydrated species.
GENERAL SYNTHETIC PROCEDURES
The compounds of the invention can be synthesized according to the following procedures of Schemes I-VIII, wherein the R-R2 substituents are as defined for Formula I, above, except where further noted.
Scheme I
Figure imgf000055_0001
1 . DPPA, Et3N,
Ph-CH3 , 0°C - Δ
2 . t-BuOH , HC1 ,
RT- Δ
Figure imgf000055_0002
Synthetic Scheme I shows the four step procedure which can be used to prepare the substituted ketone compounds 4 from the substituted benzaldehyde 1 and acid 2, where R2 is alkyl. In step one, benzaldehyde 1 and substituted acetic acid 2 are first heated in acetic anhydride and triethylamine via a Perkin condensation. In step two, hydrolysis produces the corresponding 2,3-disubstituted acrylic acids 3. In step three, the acrylic acids 3 are reacted with diphenylphosphorylazide (DPPA) and triethylamine in toluene at 0°C and then warmed to room temperature to form acylazides. In step four, the crude acylazides are heated to form an isocyanate via a Curtius rearrangement. The isocyanate is trapped as the N-t-butyloxycarbonyl enamine derivative via the addition of tert-butanol. Acidic hydrolysis, such as by using concentrated HCl, provides the substituted ketone 4 intermediates.
Scheme II
Figure imgf000056_0001
Synthetic Scheme II shows an alternative approach which can be used to prepare substituted ketone intermediates 7, isomers of 4 where R2 is alkyl, via the use of Friedel-Crafts acylation. An acylating agent 5, such as an acid chloride, is treated with aluminum chloride in an inert solvent, such as methylene chloride, chloroform, nitrobenzene, dichlorobenzene or chlorobenzene, and reacted with alkylthiobenzene 6 to form ketone 7.
Other synthetic approaches are possible to form the desired ketones. These alternatives include reacting appropriate Grignard or lithium reagents with substituted acetic acids or corresponding esters. Scheme III
Figure imgf000057_0001
MCPBA
Figure imgf000057_0002
RCOC1 Base
Figure imgf000057_0003
TBSC1 is tert-butyl-dimethylsilyl chloride MCPBA is m-chloroperoxybenzoic acid.
Scheme III shows the five step synthesis, as described in U.S. Patent No. 3,647,858, which can be used to prepare the 5- (4-alkylsulfonylphenyl) oxazoles 12 of Formula I from ketone 4 (prepared in Scheme I) . Preparation of the silyl enol ether 8 is followed by oxidation, such as with m- chloroperbenzoic acid, to give the appropriate silylated benzoin 9. Desilylation of this silylated benzoin 9 is achieved using aqueous acid, such as trifluoroacetic acid, to give the desired benzoin 10. Reaction of the benzoin 10 with the appropriate acid chloride in the presence of base, such as pyridine, gives the benzoin esters 11 which may be converted to the antiinflammatory oxazoles 12 of the present invention upon treatment with ammonium acetate in acetic acid at reflux.
Scheme IV
Figure imgf000058_0001
MCPBA
Figure imgf000058_0002
14
RCOC1 Base
Figure imgf000058_0003
17
16
Scheme IV shows the five step synthesis, similar to that described above in Scheme III, which can be used to prepare the 4- (4-alkylsulfonylphenyl) oxazoles 17 of Formula I from ketone 7 (prepared in Scheme II) . Preparation of the εilyl enol ether 13 is followed by oxidation, such as with m- chloroperbenzoic acid, to give the appropriate silylated benzoin 14. Desilylation of this silylated benzoin 14 is achieved using aqueous acid, such as trifluoroacetic acid to give the desired benzoin 15. Reaction of the benzoin 15 with the appropriate acid chloride in the presence of base, such as pyridine, gives the benzoin esters 16 which may be converted to the antiinflammatory oxazoles 17 of the present invention upon treatment with ammonium acetate in acetic acid at reflux.
Scheme V
Figure imgf000059_0001
18
Figure imgf000059_0002
19
20
Scheme V shows the four step synthesis which can be used to prepare oxazoles 20 from ketones 4 (prepared in Synthetic Scheme I) . In step one, ketones 4 are readily brominated via the addition of bromine in acetic acid to form the 2-bromoethanone intermediates. In step two, reaction of the bromoethanone with aqueous acetone yields the benzoin 18. In step three, reaction of the benzoin 18 with the appropriate acid chloride in the presence of base , such as pyridine, gives the benzoin esters 19.
In step four, benzoin esters 19 are converted to the oxazoles 20 upon treatment with ammonium acetate in acetic acid at reflux .
Scheme VI
Figure imgf000060_0001
21
Figure imgf000060_0002
23 22
Similarly, Scheme VI shows the four step synthesis which can be used to prepare oxazoles 23 from ketones 7 (prepared in Synthetic Scheme II) . In step one, ketones 7 are readily brominated via the addition of bromine in acetic acid to form the 2- bromoethanone intermediates. In step two, reaction of the bromoethanone with aqueous acetone yields the benzoin 21. In step three, reaction of the benzoin 21 with the appropriate acid chloride in the presence of base, such as pyridine, gives the benzoin esters 22. In step four, benzoin esters 22 are converted to the oxazoles 23 upon treatment with ammonium acetate in acetic acid at reflux. Scheme VII
Figure imgf000061_0001
20
12
Figure imgf000061_0002
23
17
An alternative synthesis of the alkylsulfonylphenyloxazoles 12 and 17 is accomplished as shown in Synthetic Scheme VII from oxazoles 20 and 23 (prepared in Schemes V and VI) . Oxazoles 20 and 23, where R2 is an alkyl radical, are oxidized, such as with MCPBA (2 equivalents) in methylene chloride to form the antiinflammatory alkylsulfonyl oxazoles 12 and 17. Other suitable oxidizing agents include Oxone®, hydrogen peroxide, periodate, peracetic acid and the like.
Scheme VIII
Figure imgf000062_0001
Synthetic Scheme VIII shows the three step procedure used to prepare sulfonamide antiinflammatory agents 25 from their corresponding methyl sulfones 24. In step one, a THF solution of the methyl sulfones 24 at -78°C is treated with an alkyllithium reagent, e.g., methyllithium, n- butyllithium, etc. In step two, the anions generated in step one are treated with an organoborane, e.g., triethylborane, tributylborane, etc., at -78°C then allowed to warm to ambient temperature prior to stirring at reflux. In step three, an aqueous solution of sodium acetate and hydroxyamine-O- sulfonic acid is added to provide the corresponding sulfonamide antiinflammatory agents 25 of this invention.
The following examples contain detailed descriptions of the methods of preparation of compounds of Formula I. These detailed descriptions fall within the scope, and serve to exemplify, the above described General Synthetic Procedures which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All parts are by weight and temperatures are in Degrees centigrade unless otherwise indicated. EXAMPLE 1
Figure imgf000063_0001
4- (4-Fluorophenyl) -2- (2-phenylethyl) -5- (4- (methyls lfonyl)phenyl)oxazole
Step 1: Preparation of 1- (4-fluorophenyl) -2- hydroxy-2-(methylsulfonyl)ohenyl)ethanone
A suspension of 2.03 g sodium hydride in 125 mL tetrahydrofuran (THF) was stirred at O'C under a nitrogen atmosphere as a solution containing 20.0 g of l-(4-fluorophenyl) -2-[4-
(methylthio)phenyl]ethanone, as prepared in U.S. Patent No. 3,647,858, in 100 mL of THF was added dropwise over 30 minutes. The reaction was allowed to warm to 25'C for 18 hours. A solution containing 12.7 g (84.5 mmol) of tert-butyl-dimethylsilyl chloride (DBSCL) in 20 mL THF was added over 5 minutes and the resulting solution stirred at 25°C for 18 hours. The reaction was quenched by pouring into aqueous sodium bicarbonate. The mixture was extracted with ethyl acetate and the combined organic extracts dried over sodium sulfate. Concentration in vacuo provides a yellow oil, which solidified on standing to give 27.9 g of the silyl enol ether. NMR spectra was consistent with the assigned structure. The silyl enol ether was used without .further purification.
A solution containing 27.9 g of the silyl enol ether in 500 mL methylene chloride (CH2C12) was cooled to O'C under a nitrogen atmosphere while being stirred mechanically. 77.lg of m-chloroperoxybenzoic acid (technical grade, 50-60%) was added and the reaction was stirred at O'C for 2 hours and allowed to warm to 25 'C over 1 hour. The reaction mixture was washed with an aqueous solution of sodium metabisulfite, followed by aqueous sodium bicarbonate. The organic solution was dried over sodium sulfate and concentrated in vacuo to give 24.5 g of 1- (4-fluorophenyl) -2-tert-butyldimethylsilyloxy- 2- [4- (methylsulfonyl)phenyl] ethanone. NMR spectra were consistent with the assigned structure. This material was used without further purification.
The benzoin silyl ether was dissolved in
100 mL of 90% aqueous trifluoroacetic acid and stirred at 25'C for 18 hours. The reaction was quenched by slowly pouring into saturated aqueous sodium bicarbonate solution. The product was extracted with ethyl acetate and the combined organic extracts were dried over sodium sulfate. Concentration in vacuo provided an oily solid, which was recrystallized from 50% ethyl acetate/isooctane to give 15.5 g of a crystalline white solid (mp 122- 123 *C) whose structure was assigned as l-(4- fluorophenyl) -2-hydroxy-2-
(methylsulfonyl)phenyl) ethanone on the basis of its spectral properties.
The isomeric benzoin, 2- (4-fluorophenyl) -2- hydroxy-1- (4- (methylsulfonyl)phenyl) ethanone, was prepared analogously from 2- (4-fluorophenyl) -1- [4- (methylthio)phenyl ethanone.
Step 2: Preparation of 4- (4-fluorophenyl) -2- (2- phenylethyl)-5- (4-(methylsulfonyl)phenyl) oxazole.
A solution containing 5.00 g of l-(4- fluorophenyl) -2-hydroxy-2- (4- (methylsulfonyl)phenyl)ethanone in 100 mL methylene chloride (CH2CI2) was stirred at 25*C as 6.60 mL of pyridine was added, followed by 3.61 mL of hydrocinnamoyl chloride.
The reaction was stirred at 25'C for 48 hours, after which the organic solution was washed with IN HCl, dried over sodium sulfate and concentrated in vacuo to give an oily solid. This material was recrystallized from 50% ethyl acetate/isooctane to give 4.40 g of a beige crystalline solid (mp 152-153.5'O . NMR spectra were consistent with the assigned structure of l-(4- fluorophenyl) -2- [4- (methylsulfonyl)phenyl]-2- [ 2 - phenyDpropionyloxy ethanone. This material was dissolved in 100 mL of glacial acetic acid and 7.70 g of ammonium acetate was added. The reaction was heated to reflux with stirring for 1.5 hours, after which it was cooled to room temperature and poured into 100 mL of water. The product was extracted with ethyl acetate and the combined organic extracts washed with aqueous sodium bicarbonate, dried over sodium sulfate and concentrated in vacuo to give an oily solid which was recrystallized from 50% ethyl acetate/isooctane to give 3.55 g of 4- (4- fluorophenyl) -2- (2-phenylethyl)-5-(4-(methylsulfonyl) phenyl)oxazole as a white crystalline solid (mp 117- 118 *C) . NMR spectra was consistent with the assigned structure.
EXAMPLE 2
Figure imgf000066_0001
4 - ( 4 -Fluorophenyl ) -2 -methyl -5 - [4- ( me thy lsulf onyl ) phenyl ] oxazole
4- (4 -Fluorophenyl) -2 -methyl -5- [4- (methylsulfonyl) phenyl] oxazole was prepared in an analogous manner from 2- (4-f luorophenyl) -1- [4- (methylthio) phenyl] ethanone. Melting point: 158- 159'C.
EXAMPLE 3
Figure imgf000066_0002
4- ( 4 -Fluorophenyl ) -5- [4- ( methylsulfonyl ) phenyl] -2 -phenyloxazole
4- (4 -Fluorophenyl) -5- [4- (methylsulfonyl) phenyl] -2 -phenyloxazole was prepared in a manner analogous to Example 1. Melting point: 204-205 "C. EXAMPLE 4
Figure imgf000067_0001
2-Be zyl-4-( 4 -fluorophenyl ) -5- ( 4- ( methyl sulfonyl ) phenyloxazole
2-Benzyl-4- (4-f luorophenyl) -5- (4-
( me thy lsulf onyl) phenyloxazole was prepared in a manner analogous to Example 1. The m/z 408 (M+H) + was consistent with the assigned structure.
EXAMPLE 5
Figure imgf000067_0002
4- (4 -Fluorophenyl ) -5- [4-methylsulf onylphenyl] 2- ( 3 -pheny lpropyl ) oxazole
4- (4 -Fluorophenyl) -5- [4-methylsulf onyl phenyl] -2- (3 -pheny lpropyl) oxazole was prepared in a manner analogous to Example 1. The m/z 436 (M+H)+ was consistent with the assigned structure. EXAMPLE 6
Figure imgf000068_0001
4- ( 4 -Fluorophenyl ) -5- [ -methylsulf onylphenyl ]
2 -propyloxazole
4- (4 -Fluorophenyl) -5- [4-methylsulf onyl phenyl] -2 -propyloxazole was prepared in a manner analogous to Example 1. The m/z 360 (M+H)+ was consistent with the assigned structure.
EXAMPLE 7
Figure imgf000068_0002
2- (Tert-butyl) -4- ( 4-f luorophenyl ) -5- [4- ( me thy ls lf onyl ) phenyl ] oxazole
2- (Tert-butyl) -4- (4-f luorophenyl) -5- [4- (methylsulfonyl) phenyl] oxazole was prepared in a manner analogous to Example 1. Melting point: 130- 131'C. EXAMPLE 8
Figure imgf000069_0001
4- (4-Fluorophenyl) -2- (4-methoxyphenyl)methyl 5- [4-methylsulfonylphenyl]oxazole
4- (4-Fluorophenyl)-2- (4-methoxyphenyl)methy1- 5-[4-methylsulfonylphenyl]oxazole was prepared in a manner analogous to Example 1. Melting point: 123- 124*C.
EXAMPLE 9
Figure imgf000069_0002
4 - ( 4 -Fluorophenyl ) -2- ( 3 -methoxyphenyl ) methyl- 5- [4 -methylsulf onylphenyl ] oxazole
4- (4 -Fluorophenyl) -2- ( 3 -methoxyphenyl ) me thy 1-
5- [4-methylsulf onylphenyl] oxazole was prepared in a manner analogous to Example 1. The m/z 437 (M+H)+ was consistent with the assigned structure. EXAMPLE 10
Figure imgf000070_0001
2 -Diphenylmethyl-4- ( 4 -fluorophenyl ) -
5 - [ 4 -methylsulf onylphenyl ] oxazole
2 -Dipheny lmethy 1-4- (4-f luorophenyl) -5- [4- methy lsulf onylphenyl] oxazole was prepared in a manner analogous to Example 1. Melting point: 155-156'C.
EXAMPLE 11
Figure imgf000070_0002
Ethyl 2- [4- (4-f luorophenyl) -5- (4- me thy lsulf onylphenyl ) oxazol-2-yl ] acetate
Ethyl 2- [4- (4-f luorophenyl) -5- (4- methylsulfonylphenyl)oxazol-2-yl] acetate was prepared in a manner analogous to Example 1. Melting point: 123-124'C. EXAMPLE 12
Figure imgf000071_0001
Methyl 3- [4- ( 4-f luorophenyl ) -5- [4- methylsu If onylphenyl] oxazol -2 -yl] propanate
Methyl 3- [4- (4-f luorophenyl ) -5- [4- methylsulf onylphenyl] oxazol-2-yl]propanate was prepared in a manner analogous to Example 1. The m/.
404 (M+H)+ was consistent with the assigned structure.
EXAMPLE 13
Figure imgf000071_0002
Methyl 4- [4- ( 4-f luorophenyl ) -5- [4- methylsu If onylphenyl ] oxazol -2 -yl ] but ana te
Methyl 4- [4- (4- fluorophenyl) -5-[4- methylsulfonylphenyl]oxazol-2-yl]butanateι was prepared in a manner analogous to Example 1. Melting point: 89-91'C. EXAMPLE 14
Figure imgf000072_0001
5- ( 4 -Fluorophenyl ) -2 -methyl -4- [4- ( methyl sulfonyl) phenyl] oxazole
5- (4 -Fluorophenyl) -2-methyl-4- [4- (methylsulfonyl) phenyl] oxazole was prepared in a manner analogous to Example 1. The m/z 332 (M+H)+ was consistent with the assigned structure.
EXAMPLE 15
Figure imgf000072_0002
Methyl 3- [5- ( 4-f luorophenyl ) -4- [4- ( me th lsulf onyl ) phenyl] oxazol -2 -yl] ropanate
Methyl 3- [5- (4- fluorophenyl) -4- [4- ( methy lsulf onyl) pheny l]oxazol-2-yl] propanate was prepared in a manner analogous to Example 1. The m/z 404 (M+H)+ was consistent with the assigned structure.
EXAMPLE 16
Figure imgf000073_0001
2- [4- (4-Fluorophenyl) -5- [4 (methylsulfonyl) henyl] oxazol-2-yl] acetic acid
2- [4- (4-Fluorophenyl) -5- [4- (methylsulfonyl) phenyl]oxazol-2-yl]acetic acid was prepared from Example 11 via alkaline hydrolysis using 1 N sodium hydroxide in methanol and appropriate reaction conditions. Melting point: 118-120'C.
EXAMPLE 17
Figure imgf000074_0001
3- [4- (4 -Fluorophenyl ) -5- [4-
( me thy lsulf onyl ) phenyl] oxazol-2yl] ropanoic acid
3- [4- (4 -Fluorophenyl) -5- [4- (methylsulfonyl] phenyl] oxazol-2-yl] ropanoic acid was prepared from Example 12 in a manner analogous to Example 17. Melting point: 197-198°C. The m/z 390 (M+H) + was consistent with the assigned structure.
EXAMPLE 18
Figure imgf000074_0002
4- [4- (4 -Fluorophenyl) -5- [4-
(methylsulfonyl ) phenyl] oxazol-2-yl]butanoic acid 4-[4- (4-Fluorophenyl) -5-[4- (methylsulfonyl; phenyl]oxazol-2-yl]butanoic acid was prepared from Example 13 in a manner analogous to Example 17. Melting point: 140-141°C. The /z 404 (M+H)+ was consistent with the assigned structure.
EXAMPLE 19
Figure imgf000075_0001
3- [5- (4-Fluorophenyl) -4- [4-
(me hylsulfonyl)phenyl] - oxazol-2-yl]propanoic acid
3-[5-(4-Fluorophenyl) -4-[4- (methylsulfonyl) phenyl]oxazol-2-yl]propanoic acid was prepared from Example 15 in a manner analogous to Example 17. The m/z 390 (M+H)+ was consistent with the assigned structure. EXAMPLE 20
Figure imgf000076_0001
4- (4-Fluorophenyl) -2- ( 3-hydroxypropyl ) -5- [4
(methylsulfonyl )phenyl] oxazole
A solution containing 100 mg (0.239 mmol) of 3- [4- (4-fluorophenyl) -5- [4- (methylsulfonyl) henyl]oxazol-2-yl]propanoic acid, methyl ester in 10 mL of tetrahydrofuran was cooled to 0°C with stirring under a nitrogen atmosphere as 0.53 mL of diisobutylalummum hydride (IM in toluene, 0.523 mmol) was added dropwise over 5 minutes. The reaction was allowed to warm to 25°C and poured into 100 mL of a saturated solution of sodium potassium tartarate. Ethyl acetate (100 mL) was added and the mixture was stirred until the layers separated (approx. 1 hour) . The organic layer was separated and dried over sodium sulfate. Concentration in vacuo gave an oily solid, which was recrystallized from 50 % ethyl acetate-isooctane to give 75 mg of a white crystalline solid (mp 123-124°C) which was characterized on the basis of its spectral characteristics: ÷'-H-NMR (CDCI3, 300 MHz) 3 2.10 (m, 2H) , 2.56 (bs, IH) , 3.01 (t, 2H, J=7.0 Hz), 3.07 (s, 3H) , 3.80 (t, 2H, J=5.9 Hz), 7.09 (t, 2H, J=8.5 Hz), 7.57 (dd, 2H, J=8.5 and 5.5 Hz), 7.73 (d, 2H, J=8.5 Hz) and 7.89 (d, 2H, J=8.5 Hz) . 19F-NMR (CDC13, 280 MHz) 3 -111.97. LRMS m/z 376 (M + H)+. HRMS calc. for C19H18NO4FS: 376.1019. Observed: 376.1026. Analysis calc. for Cι9Hι8N0 FS-C: 60.79, H: 4.83, N: 3.73. Observed-C: 60.53, H: 4.85, N: 3.66.
EXAMPLE 21
Figure imgf000078_0001
3- [4- (4 -Fluorophenyl) -5- (4- ( me thy lsulf onyl ) phenyl ) oxazol -2 -yl ] ropanamide
3- [4- (4-f luorophenyl) -5- (4- (methylsulfonyl) phenyl) oxazol -2 -yl] propanamide was prepared by treating methyl 3- [4- (4-f luorophenyl) -5- ( 4- ( methy lsul f onyl) henyl) oxazol -2 -yl] propanoic acid, (Example 12) with excess ammonia in methanol for 5 days. Melting point: 193-195 *C.
EXAMPLE 22
Figure imgf000078_0002
5- (4 -Fluorophenyl ) -2 -phenyl -4- [4- (methylsulfonyl ) phenyl ] oxazole Steo 1: Preparation of 5- (Fluorophenyl) -4- [4- (methylthio)phenyll -2-phenyloxazole
A solution containing 560 mg (2.03 mmol) of 2- (4-fluorophenyl) -2-hydroxy-l- [4- (methylthio)phenyl] ethanone in 50 mL of methylene chloride was stirred at 25°C as 0.82 mL (10.15 mmol) of pyridine was added, followed by 0.28 mL (2.44 mmol) of benzoyl chloride. The reaction was stirred at 25°C for 2 days, after which it was washed with IN HCl, dried over sodium sulfate and concentrated m vacuo to give a crude oil which was characterized as the benzoin ester on the basis of its spectral characteristics: ^-H-NMR (CDCI3, 300 MHz) d 2.53 (s, 3H) , 7.08 (s, IH) , 7.12 (t, 2H, J=8.7 Hz), 7.27 (d, 2H, J=8.7 Hz), 7.49 (t, 2H, J=7.7 Hz), 7.60 (m, 3H) , 7.94 (d, 2H, J=8.7 Hz) and 8.14 (d, 2H, J=8.7 Hz) . This material was dissolved in 50 mL of glacial acetic acid and 1.56 g (20.3 mmol) of ammonium acetate was added. The reaction was heated at reflux for 2 hours, cooled to 25°C and poured into 100 mL of water. The aqueous solution was extracted with ethyl acetate and the combined organic extracts were washed with water and sodium bicarbonate solution, dried over sodium sulfate and concentrated in vacuo. The crude solid was purified by flash chromatography using a silica gel column and 50% ethyl acetate/hexane as the eluent to give a white solid which was recrystallized from 50% ethyl acetate/isooctane to give 450 mg (61%) of a white crystalline solid (mp 118-119°C) whose structure was assigned as 5- (4-fluorophenyl) -4-[4- (methylthio) phenyl] -2-phenyl oxazole on the basis of its spectral characteristics: iH-NMR (CDCI3, 300 MHz) 9 2.52 (s, 3H) , 7.10 (t, 2H, J=8.8 Hz), 7.28 (d, 2H, J=8.5 Hz), 7.47 (m, 3H) , 7.62 (m, 4H) and 8.13 (m, 2H) . 19F-NMR (CDCI3, 280 MHz) d -111.96. LRMS m/z 361 (M)+. HRMS Calc'd. for C22H16NOFS: 361.0937. Observed: 361.0970. Analysis Calc'd. for C22H3.6NOFS: C, 71.51; H, 6.55; N, 3.79. Observed: C, 72.85; H, 4.52; N, 3.84'.
Step 2: Preparation of 5- (4-Fluorophenyl) -4- f4- (methylsulfinvDphenyll -2-phenyloxazole.
A solution containing 64 mg (0.173 mmol) of 5- (4-fluorophenyl) -4- [4- (methylthio)phenyl] -2- phenyloxazole in 10 mL of methylene chloride was stirred at -78°C as 60 mg (0.173 mmol based on 50% purity) of m-chloroperoxybenzoic acid was added all at once. The reaction was stirred at -78°C for 1 hour. Thin-layer chromatography (TLC) (silica, 50% hexane- ethyl acetate) indicated that the reaction mixture consisted of mostly sulfoxide, with a minor amount of sulfide and sulfone. The reaction was poured into a solution of aqueous sodium metabisulfite. The aqueous solution was extracted using ethyl acetate and the organic layer was washed with saturated sodium metabisulfite, saturated sodium bicarbonate and brine. The resulting clear solution was dried over sodium sulfate and concentrated in vacuo to give a white solid which was purified by flash chromatography on a silica gel column using 50% ethyl acetate/hexane as the eluent. Recrystallization from 50% ethyl acetate/isooctane gave 48 mg (74%) of a white crystalline solid (mp 164-165°C) whose structure was assigned as 5- (4-fluorophenyl) -4- [4- (methylsulfinyl) henyl] -2-phenyl oxazole on the basis of its spectral characteristics: ^-H-NMR (CDCI3, 300 MHz) θ 2.80 (s, 3H) , 7.16 (t, 2H, J=8.5 Hz), 7.54 (m, 3H) , 7.66-7.75 (m, 4H) , 7.93 (d, 2H, J=8.5 Hz) and 8.19 (m, 2H) . LRMS m/z 377 (M)+. HRMS Calc'd. for C22H16NO2FS: 377.0886. Observed: 377.0868. Analysis Calc'd. for C22Hi6N02FS: C70.01; H, 4.27; N, 3.71. Observed: C, 68.18; H, 4.19; N, 3.58. Step 3: Preparation of 5- (4-Fluorophenyl) -4-f4- (methylsulfonyl)phenyll-2-phenyloxazole.
A solution containing 64 mg (0.173 mmol) of 5- (4-fluorophenyl) -4-[4-(methylthio)phenyl] -2 - phenyloxazole in 10 mL of methylene chloride was stirred at -78 °C as 120 mg (0.346 mmol based on 50% purity) of m-chloroperoxybenzoic acid was added all at once. The reaction was stirred at -78 °C for 1 hour and TLC (silica, 50% hexane-ethyl acetate) indicated that the reaction mixture consisted of mostly sulfone. The reaction was poured into a solution of aqueous sodium metabisulfite. The aqueous solution was extracted using ethyl acetate and the organic layer was washed with saturated sodium metabisulfite, saturated sodium bicarbonate and brine. The resulting clear solution was dried over sodium sulfate and concentrated m vacuo to give a white solid which was purified by flash chromatography on a silica gel column using 50% ethyl acetate/hexane as the eluent. Recrystallization from 50% dichloromethane/isooctane gave 62 mg (91%) of a white crystalline solid (mp 175- 176°C) whose structure was assigned as 5- (4- fluorophenyl) -4-[4- (methylsulfonyl)phenyl]-2-phenyl oxazole on the basis of its spectral characteristics: XH-NMR (CDCI3, 300 MHz) 33.13 (s, 3H) , 7.19 (t, 2H, J=8.6 Hz), 7.55 (m, 3H) , 7.69 (m, 2H) , 8.00 (m, 2H) , 8.17 (m, 2H) . LRMS m/z 393 (M)+. HRMS Calc'd. for C22H16NO3FS: 393.0835. Observed: 393.0865. EXAMPLE 23
Figure imgf000082_0001
4- (4-Fluorophenyl) -2-cyclohexyl-5- [4- (methylsulfonyl)phenyl]oxazole
4- (4-Fluorophenyl) -2-cyclohexyl-5-[4- (methylsulfonyl)phenyl]oxazole was prepared in a manner analogous to Example 1. Melting point: 127- 128°C.
EXAMPLE 24
Figure imgf000082_0002
4- (4-Fluorophenyl) -2-benzyloxymethyl-5- [4' (methylsulfonyl)phenyl]oxazole
Step 1: Preparation of the benzoin ester
A solution containing 2.07 g (6.71 mmol) of 1-(4-fluorophenyl)-2-hydroxy-2-[4- (methylsulfonylphenyl)ethanone in 100 mL of methylene chloride was stirred at 25°C as 2.71 mL (33.55 mmol) of pyridine was added, followed by the addition 'of 1.27 mL (8.05 mmol) of benzyloxyacetyl chloride. The reaction was stirred at 25°C for 48 hours, after which the resulting yellow solution was washed with IN HCl, dried over sodium sulfate and concentrated in vacuo. The oily yellow solid was purified via flash chromatography on a silica gel column using 20 % ethyl acetate/hexane as the eluent. This provided 2.22 g (73 %) of a white foam, which was characterized as the benzoin ester on the basis of its NMR spectra: 1H-NMR (CDC13, 300 MHz) 3 3.03 (s, 3H) , 4.23 (d, IH, J=17.0 Hz), 4.33 (d, IH, J=17.0 Hz) , 4.67 (s, 2H) , 6.95 (s, IH) , 7.13 (t, 2H, J=8.5 Hz), 7.35 (m, 5H) , 7.66 (d, 2H, J=8.1 Hz) and 7.98 (m, 4H) . 19F-NMR (CDCI3, 280 MHz) 3 -102.5.
Step 2: Preparation of 2-benzyloxymethyl-4- (4- fluorophenyl) -5- [4- (methylsulfonyl) henyl1 oxazole.
A solution containing 2.22 g (4.86 mmol) of the benzoin ester and 3.74 g (48.6 mmol) of ammonium acetate in 100 mL of acetic acid was heated to 80°C for 2 hours. The reaction was cooled to 25°C and poured into water. The product was extracted into ethyl acetate and the combined organic extracts washed with an aqueous solution of sodium bicarbonate. The solution was dried over sodium sulfate and concentrated m. vacuo to give a yellow oil. This crude material was purified by flash chromatography on a silica gel column using 25 % ethyl acetate/hexane as the eluent to give 1.92 g (90%) of a clear oil, which was characterized as 2-benzyloxymethyl-4- (4- fluorophenyl) -5- [4- (methylsulfonyl)phenyl]oxazole on the basis of its spectral properties: 1H-NMR (CDCI3, 300 MHz) 9 3.07 (s, 3H) , 4.70 (s, 2H) , 4.72 (s, 2H) , 7.11 (t, 2H, J=8.8 Hz) , 7.22-7.40 (m, 5H) , 7.58 (m, 2H) , 7.76 (d, 2H, J=8.8 Hz) and 7.91 (d, 2H, J=8.8 Hz) . 19F-NMR (CDCI3, 280 MHz) d -111.88.
EXAMPLE 25
Figure imgf000084_0001
2-Phenyl-4- ( cyclohexyl) -5- [4- (methylsulfonyl) phenyl] oxazole
Step 1: Preparation of 1- (cyclohexyl) -2-hydroxy-2- T4- (methylthiophenyl) ethanone
A 250 mL round bottomed flask was equipped with a mechanical stirrer and reflux condenser and charged with 30 mL of absolute ethanol, 3 , 4-dimethyl- 5- (2-hydroxyethyl) thiazolium iodide (2.00 g, 7.0 mmol), 4-methylthiobenzaldehyde (10.66 g, 70.0 mmol), and freshly distilled cyclohexanecarboxaldehyde (7.68 g, 70.1 mmol) . The solution was stirred vigorously, treated with triethylamine (4.27 g, 42.2 mmol) and heated to reflux for 24 hours. The solution was treated with additional portions of 3, 4-dimethyl-5- (2- hydroxyethyl)thiazolium iodide (2.05 g, 7.01 mmol), triethylamine (4.84 g, 48.0 mmol), and cyclohexanecarboxaldehyde (7.01 g, 62.5 mmol), and heated to reflux for an additional 42 hours. The solution was concentrated in vacuo, the residue dissolved in chloroform, washed with 3 N HCl, saturated aqueous sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to afford 18.75 g, (>100%) of a yellow oil that solidified upon standing. The crude solid was purified by trituration with ether providing the desired compound in pure form 15.80 g, (86%, mp 110-111.5°C) which was characterized as 1- (cyclohexyl) -2-hydroxy-2- [4- (methylthiophenyl) ethanone on the basis of its NMR spectra. ^H-NMR (CDCI3, 300 MHz) θ 1.00-1.47 (m, 6H) , 1.60-1.95 (m, 4H) , 2.45 (m, IH) , 2.52 (s, 3H) , 4.38(d, J=3.9 Hz, IH) , 7.55 (d, J=3.9 Hz, IH) , 7.25 (m, 4H) . HRMS Calc'd. for C15H20NO2S: 264.1184. Observed: 264.1207.
Step 2 : Preparation of benzoin ester
A solution containing 162 mg (0.62 mmol) of 1- (cyclohexyl) -2-hydroxy-2- [4- (methylthiophenyl) ethanone in 10 mL of methylene chloride was stirred at 25°C as 251 μL (31 mmol) of pyridine was added, followed by the addition of 86 μL (1.24 mmol) of benzoyl chloride. The reaction was stirred at 25°C for 48 hours, after which the resulting yellow solution was washed with IN HCl, dried over sodium sulfate and concentrated in vacuo. The crude solid was purified via flash chromatography on a silica gel column using 10 % ethyl acetate/hexane as the eluent. This provided 131 mg (57 %) of a white foam, which was characterized as the benzoin ester on the basis of its NMR spectra: iH-NMR (CDCI3, 300 MHz) d 1.03-1.48 (m, 6H) , 1.56-1.88 (m, 3H) , 2.03-2.14 (m, IH) , 2.48 (s, 3H) , 2.53 (m, IH) , 6.28 (s, IH) , 7.20-7.70 (m, 5H) , 8.05-8.17 (m, 4H) .
Step 3: Preparation of 2- (phenyl) -4- (cyclohexyl) -5- T4- (methvthio)phenyl1 oxazole
A solution containing 131 mg (0.355 mmol) of the benzoin ester and 273 mg (35 mmol) of ammonium acetate in 10 mL of acetic acid was heated to 80°C for 2 hours. The reaction was cooled to 25°C and poured into water. The product was extracted into ethyl acetate and the combined organic extracts washed with an aqueous solution of sodium bicarbonate. The solution was dried over sodium sulfate and concentrated in vacuo to give the crude oxazole. This crude material was purified crystallization from a mixture of dichloromethane and isooctane to give 89 mg, (72%, mp 151-151.5°C) of material, which was characterized as 2- (phenyl) -4- (cyclohexyl) -5- [4-
(methythio)phenyl]oxazole on the basis of its spectral properties: iH-NMR (CDCI3, 300 MHz) 3 1.30-1.45 (m, 3H) , 1.70-1.94 (m, 7H) , 2.54 (s, 3H) , 2.80-2.90 (m, IH) , 7.34 (d, J=8.5Hz, 2H) , 7.42 (m, 3H) , 7.55 (d, J=8.5Hz, 2H) , 8.08 (d, J=7.7Hz, 2H) . HRMS Calc'd. for C22H23NOS (M+H): 350.1579. Observed: 350.1597. The material from this experiment was used directly in the next step without further purification.
Step 4: Preparation of 2-phenyl-4- (cyclohexyl) -5- T4- (methylsulfonyl) henyl1oxazole
A solution of 38 mg (0.11 mmol) of 2-phenyl-4- (cyclohexyl) -5- [4- (methythio)phenyl]oxazole in 4 mL of methylene chloride was stirred at -78°C as 75 mg (0.22 mmol based on 50% purity) of m-chloroperoxybenzoic acid was added all at once. The reaction was stirred at -78°C for 1 hour. Thin-layer chromatography (TLC) (silica, 50% hexane/ethyl acetate) indicated the reaction mixture consisted of mostly sulfone. The reaction was poured into a solution of aqueous sodium metabisulfite. The aqueous solution was extracted using ethyl acetate and the organic layer was washed, with saturated sodium metabisulfite, saturated sodium bicarbonate and brine. The resulting clear solution was dried over sodium sulfate and concentrated in vacuo to give a white solid which was purified by crystallization from 50% dichloromethane/isooctane gave 26 mg (62%) of pure product, whose structure was assigned as 2-phenyl-4- (cyclohexyl)-5-[4- (methylsulfonyl)phenyl]oxazole on the basis of its spectral characteristics: mp 231°C. 1H-NMR (CDCI3, 300 MHz) 31.34-1.43 ( , 3H) , 1.72-1.95 (m, 7H) , 2.84 (m, IH) , 3.10 (s, 3H) , 7.47 (m, 3H) , 7.82 (d, J=8Hz, 2H) , 8.03 (d, J=8Hz, 2H) , 8.10 (m, 2H) . . LRMS m/z 382 (M)+. HRMS Calc'd. for C22H23NO3S: 382.1477. Observed: 382.1436. Analysis Calc'd. for C22H23NO3S: C, 69.27; H, 6.08; N, 3.67. Observed: C, 68.99; H, 6.07; N, 3.63.
EXAMPLE 26
Figure imgf000087_0001
4- (4-Fluorophenyl) -2- (3-hydroxymethyl) -5- [4- (methylsulfonyl)phenyl]oxazole
To a solution containing 5.0 g (11.4 mmol) of 2-benzyloxymethyl-4-(4-fluorophenyl) -5-[4- (methylsulfonyl)phenyl]oxazole (prepared in Example 24) in 20 mL of 50 % THF-methanol, was added 100 mg of 10% Pd on charcoal in a Fisher-Porter bottle. The reaction vessel was evacuated and then charged with hydrogen at 50 psi for 24 hours. The Pd on carbon was removed by filtration through diatomaceous earth and the filtrate concentrated in vacuo to give 3.8 g- (97 %) of a white crystalline solid (mp 156-157°C) (recrystallized from 50% ethyl acetate/isooctane) whose structure was assigned as 4- (4-fluorophenyl) -2- hydroxymethyl-5- [4- (methylsulfonyl)phenyl]oxazole on the basis of its spectral characteristics: 1H-NMR (CDC13, 300 MHz) 3 3.07 (s, 3H) , 3.21 (bs, IH) , 4.81 (s, 2H) , 7.10 (t, 2H, J=8.5 Hz), 7.56 (m, 2H) , 7.72 (d, 2H, J=8.8 Hz) and 7.90 (d, 2H, J=8.8 Hz) . 19F-NMR (CDCI3, 280 MHz) 3 -111.5. LRMS m/z 348 (M + H)+. HRMS Calc'd. for C17H14NO4FS: 348.0706. Observed: 348.0681. Analysis Calc'd. for C17H14NO4FS: C:, 58.78; H, 4.06; N, 4.03. Observed: C, 58.67; H, 4.02; N, 4.01.
EXAMPLE 27
Figure imgf000088_0001
4 - ( 4 -Fluorophenyl ) -2 - ( 2 -hydroxyethyl ) - 5 - [ 4 (methyl sulfonyl ) phenyl ] oxazole
4- ( -Fluorophenyl ) -2- (2 -hydroxyethyl ) -5- [ 4- (methylsulfonyl) phenyl] oxazole was prepared in a manner consistent with that described in Example 20. The m/z 362 (M+H) + was consistent with the assigned structure . EXAMPLE 28
Figure imgf000089_0001
4- (4-Fluorophenyl) -5- [4-
(methylsulfonyl) henyl] - 2-phenoxymethyloxazole
A solution containing 1.69 g (4.87 mmol) of 4- (4-fluorophenyl) -2-hydroxymethyl-5- [4-
(methylsulfonyl)phenyl]oxazole (Example 26) in 100 mL of methylene chloride was stirred at 25°C as 1.36 L (9.74 mmol) of triethylamine was added dropwise, followed by the addition of 560 uL (7.30 mmol) of methanesulfonyl chloride. The reaction was stirred for 20 minutes, after which the organic solution was washed with IN HCl, dried over sodium sulfate and concentrated in vacuo to give methyl [4- (4- fluorophenyl) -5- [4- (methylsulfonyl)phenyl]oxazol-2- yl]methanesulfonate as a yellow oil which was characterized as the expected mesylate by its NMR spectrum: iH-NMR (CDC13, 400 MHz) 3 3.08 (s, 3H) , 3.17 (s, 3H) , 5.37 (s, 2H) , 7.12 (t, 2H, J=8.8 Hz), 7.58 (m, 2H) , 7.78 (d, 2H, J=8.8 Hz) and 7.94 (d, 2H, J=8.8 Hz) . This material was used without further purification. A solution containing 544 mg (1.28 mmol) of methyl [4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl]oxazol-2-yl]methanesulfonate in 20 mL of DMF was stirred at 25°C as 353 mg (2.56 mmol) of potassium carbonate and 240 mg (2.56 mmol) of phenol were added. The reaction was stirred for 2 days at 25°C and poured into 100 mL of water. To this mixture was added 100 mL of ethyl acetate and the layers separated. The organic layer was washed with water, dried over sodium sulfate and concentrated in vacuo to give a crude beige solid which was purified by flash chromatography on a silica gel column using 25% ethyl acetate/hexane as the eluent to give 475 mg (88%) of a white solid which was recrystallized from 50% ethyl acetate/isooctane to give a white crystalline solid (mp 168-169°C) whose structure was assigned as 4- (4-fluorophenyl) -5- [4- (methylsulfonyl) - phenyl] -2-phenoxymethyloxazole on the basis of its spectral characteristics: 1H-NMR (CDCI3, 300 MHz) 3 3.07 (s, 3H) , 5.23 (s, 2H) , 6.98 (m, 5H) , 7.33 (t, 2H, J=8.2 Hz), 7.60 (m, 2H) , 7.77 (d, 2H, J=8.5 Hz) and 7.92 (d, 2H, J=8.5 Hz) . 19F-NMR (CDCI3, 280 MHz) 3 -111.9. Analysis calc. for C23H18NO4FS- C: 65.24, H: 4.28, 3.31. Observed- C: 65.10, H: 4.29, N: 3.28.
EXAMPLE 29
Figure imgf000090_0001
4 - ( 4 -F luorophenyl ) -2 - ( pyridyloxymethyl ) - 5 - [ 4
( methyl sul f onyl ) phenyl ] oxa zo le
4- ( 4 -Fluorophenyl ) -2- (pyridyloxymethyl ) -5- [ 4- (methylsulfonyl ) phenyl ] oxazole was prepared in a manner consistent with Example 28. Melting point: 276-278°C.
EXAMPLE 30
Figure imgf000091_0001
4- (4-Fluorophenyl) -2- (3-chlorophenoxymethyl) -5- [4- (methylsulfonyl)phenyl]oxazole
A solution containing 612 mg (1.44 mmol) of methyl [4- (4-fluorophenyl)-5-[4-
(methylsulfonyl)phenyl]oxazol-2-yl]methanesulfonate (as prepared in Example 28) in 20 mL of DMF was stirred at 25°C as 397 mg (2.88 mmol) of potassium carbonate and 0.3 mL (2.88 mmol) of 3-chlorophenol were added. The reaction was stirred for 2 days at 25°C and poured into 100 mL of water. To this mixture was added 100 mL of ethyl acetate and the layers separated. The organic layer was washed with water, dried over sodium sulfate and concentrated in vacuo to give the crude solid which was purified by flash chromatography on a silica gel column using 50% ethyl acetate/hexane as the eluent to give 528 mg (80%) of a white solid which was recrystallized from 50% dichloromethane/isooctane to give a white crystalline solid (mp 112-114°C) whose structure was assigned as 4- (4-fluorophenyl) -5-[4- (methylsulfonyl)phenyl]-2- (3- chlorophenoxy)me hyloxazole on the basis of its spectral characteristics: 1H-NMR (CDCI3, 300 MHz) 3 3.08 (s, 3H) , 5.22 (s, 2H) , 7.08 (m, 2H) , 7.13 (m, 3H) , 7.26 (m, IH) , 7.59 (dd, 2H, J=8.8, 5.4 Hz), 7.62 (dd, 2H, J=8.8, 5.4 Hz), 7.78 (d, 2H, J=8.8 Hz), 7.93 (d, 2H, J=8.8 Hz). 19F-NMR (CDCI3, 280 MHz) 3 -111.8. Analysis Calc'd. for C23H17NO4FSCI: C, 60.33; H, 3.74; N, 3.06. Observed: C, 60.19; H, 3.80; N,
3.03
EXAMPLE 31
Figure imgf000092_0001
4- (4-Fluorophenyl ) - 2 - (4-fluorophenoxymethyl) -5- [4- (methylsulfonyl)phenyl]oxazole
A solution containing 585 mg (1.37 mmol) of methyl [4- (4-fluorophenyl) -5-[4- (methylsulfonyl)phenyl]oxazol-2-yl]methanesulfonate (as prepared in Example 28) in 15 mL of DMF was stirred at 25°C as 380 mg (2.74 mmol) of potassium carbonate and 308 mg (2.74 mmol) of 4-fluorophenol are added. The reaction was stirred for 2 days at 25°C and poured into 100 mL of water. To this mixture was added 100 mL of ethyl acetate and the layers separated. The organic layer was washed with water, dried over sodium sulfate and concentrated in vacuo to give the crude solid which was purified by flash chromatography on a silica gel column using 50% ethyl acetate/hexane as the eluent to give 528 mg (80%) of a white solid which was recrystallized from 50% dichloromethane/isooctane to give a white crystalline solid (mp 133-134°C) whose structure was assigned as 4- (4-fluorophenyl) -5-[4- (methylsulfonyl) -phenyl] -2- [ (4-fluorophenoxy)methyl]oxazole on the basis of its spectral characteristics: ^-NMR (CDCI3, 300 MHz) 3 3.08 (s, 3H) , 5.19 (s, 2H) , 7.00 (m, 4H) , 7.13 (m, 2H) , 7.58 (dd, 2H, J=8.8, 5.2 Hz), 7.61 (dd, 2H,
J=8.8, 5.2 Hz), 7.77 (d, 2H, J=8.7 Hz), 7.93 (d, 2H, J=8.7 Hz). 19F-NMR (CDCI3, 280 MHz) 3 -111.8, -122.5. Analysis Calc'd. for C23H17NO4F2S: C, 62.58; H, 3.88; N, 3.17. Observed: C, 62.44; H, 4.04; N, 3.11.
EXAMPLE 32
Figure imgf000093_0001
4- (4 -Fluorophenyl) -2- (cyclohexyl ethyl ) -5- [4-
( methyl sulfonyl) henyl] oxazole
A solution containing 2.02 g (7.24 mmol) of 1- (4-f luorophenyl) -2-hydroxy-2- [4- (methylthiophenyl) ethanone in 100 mL of methylene chloride was stirred at 25°C as 1.76 mL (21.72 mmol) of pyridine was added, followed by the addition of 1.52 g (8.69 mmol) of 2-cyclohexylpropionyl chloride. The reaction was stirred at 25°C for 48 hours, after which the resulting yellow solution was washed with IN HC1, dried over sodium sulfate and concentrated in vacuo. The crude solid was purified via flash chromatography on a silica gel column using 10 % ethyl acetate/hexane as the eluent. This provided 2.87 g
(96 %) of a white foam, which was characterized as the benzoin ester on the basis of its NMR spectra: 1H-NMR (CDCI3, 300 MHz) 3 0.80-0.96 (m, 2H) , 1.10-1.25 (m, 4H) , 1.45-1.78 (m, 7H) , 2.40 (m, 2H) , 2.43 (s, 3H) , 6.75 (s, IH) , 7.05 (m, 2H) , 7.23 (d, 2H, J=8 Hz), 7.35 (d, 2H, J=8 Hz) and 7.95 (m, 2H) . 19F-NMR (CDCI3, 280 MHz) 3 -104.4.
A solution containing 2.87 g (6.92 mmol) of the benzoin ester and 5.3 g (69 mmol) of ammonium acetate in 100 mL of acetic acid was heated to 80°C for 2 hours. The reaction was cooled to 25°C and poured into water. The product was extracted into ethyl acetate and the combined organic extracts washed with an aqueous solution of sodium bicarbonate. The solution was dried over sodium sulfate and concentrated in vacuo to give the crude oxazole. This crude material was purified by flash chromatography on a silica gel column using 25% ethyl acetate/hexane as the eluent to give 1.87 g (68%) of a clear oil, which was characterized as 2-(2-cyclohexylethyl)-4-(4- fluorophenyl)-5-[4- (methythio)phenyl]oxazole on the basis of its spectral properties: 1H-NMR (CDCI3, 400 MHz) 3 0.90-1.02 (m, 2H) , 1.10-1.40 (m, 4H) , 1.62-1.82 (m, 7H) , 2.49 (s, 3H) , 2.84 (t, J=8.0 Hz, 2H) , 7.03 (d, J=8.7Hz, IH) , 7.06 (d, J=8.7Hz, IH) , 7.22 (d, J=8.6Hz, 2H) , 7.45 (d, J=8.6Hz, 2H) , 7.58 (d, J=5.4Hz, IH) , 7.61 (d, J=5.4Hz, IH) . The material from this experiment was used directly in the next step without further purification. A solution of 1.87g (4.73 mmol) of 2-12- cyclohexylethyl) -4- (4-fluorophenyl) -5-[4- (methythio)phenyl]oxazole in 100 mL of methylene chloride was stirred at -78°C as 3.26 g (9.46 mmol based on 50% purity) of m-chloroperoxybenzoic acid was added all at once. The reaction was stirred at -78°C for 1 hour and TLC (silica, 50% hexane/ethyl acetate) indicated that the reaction mixture consisted of mostly sulfone. The reaction was poured into a solution of aqueous sodium metabisulfite. The aqueous solution was extracted using ethyl acetate and the organic layer was washed with saturated sodium metabisulfite, saturated sodium bicarbonate and brine. The resulting clear solution was dried over sodium sulfate and concentrated in vacuo to give a white solid which was purified by flash chromatography on a silica gel column using 50% ethyl acetate/hexane as the eluent. Recrystallization from 50% ethyl acetate/isooctane gave 1.76 g (87%) of a low melting semi-solid whose structure was assigned as 2- (2- cyclohexylethyl)-4- (4-fluorophenyl) -5-[4- (methylsulfonyl)phenyl]oxazole on the basis of its spectral characteristics: 1H-NMR (CDCI3, 300 MHz) 3 0.90-1.06 (m, 2H) , 1.11-1.40 (m, 7H) , 2.87 (apparent t, J=8.lHz, 2H) , 3.07 (s, 3H) , 7.10 (t, J=8.7Hz, 2H) , 7.59 (m, 2H) , 7.74 (d, J=8.7Hz, 2H) , 7.90 (d, J=8.7Hz, 2H) . 19F-NMR (CDC13, 280 MHz) 3 -112.49. LRMS m/z 427 (M)+. HRMS Calc'd. for C24H26NO3FS: 421.1617. Observed: 421.1611. Analysis Calc'd. for C24H26NO3FS: C, 67.43; H, 6.13; N, 3.28. Observed: C, 67.27; H, 6.15; N, 3.24. EXAMPLE 33
Figure imgf000096_0001
Ethyl 2 - [ 4 - ( 4 -f luorophenyl ) -5 - [ 4 - ( me thy lsulf onyl ) phenyl ] oxazol -2 -yl ] -2 -benzyl - acetate
Step 1: Preparation of 2- (4-fluoroohenvl) -3- (4-methylthiophenyl)propenoic acid
Acetic anhydride (500 mL) , 4- (methylthio)benzaldehyde (100.2 g, 0.66 mol), 4- fluorophenylacetic acid (101.6 g, 0.66 mol), and triethylamine (68.1 g, 0.67 mol) were placed in a 3 L round bottom flask and heated to reflux for 1.75 hours. The reaction was cooled to 110°C, and water (500 mL) was added cautiously through an addition funnel. This caused the solution to reflux vigorously and the temperature to rise to 135°C. A yellow precipitate formed, and after cooling to room temperature, was collected by filtration, washed with water, and recrystallized from ethyl acetate/isooctane to provide the diarylacrylic acid as yellow needles (135.2 g,
71%) : mp 172-176°C. ^H NMR (acetone d6) 300 MHz 7.84 (s, IH) , 7.03-7.28 (m, 10H) , 2.46 (s, 3H) . 19F NMR (acetone d6) -116.11 (m) . Mass spectrum M+ 288. Step 2 : Preparation of 1- (4-fluorophenyl) -2- (4-methylthiophenyl) ethanone
The diaryl acrylic acid (226.5 g, 0.78 mol) was placed in a 2 L round bottom flask with anhydrous toluene (800 mL) and triethylamine (81.2 g, 0.80 mol) . After cooling to 0°C, diphenylphosphoryl azide (217.4 g, 0.79 mol) was added, the solution was stirred at 0°C for 20 minutes and at room temperature for 2.50 hours. The reaction was poured into water, extracted with ether, dried over magnesium sulfate, and concentrated in vacuo to remove the ether. The remaining toluene solution was heated to reflux and a vigorous evolution of gas occurred. After 1.25 hours, tert-butyl alcohol (80 mL, 0.84 mol) was added to the reaction. After an additional 20 minutes, concentrated hydrochloric acid (41 mL) was added slowly causing the reaction to foam. The reaction was heated at 90°C overnight (14 hours) and a white precipitate formed after cooling. The precipitate was isolated by filtration, washed with cold ether, and air dried to yield the desired intermediate (182.7 g, 89%) : mp 134.5-138°C. XH NMR (acetone d6) 300 MHz 8.16 (m, 2H) , 7.24 (m, 6H) , 4.34 (s, 2H) , 2.46 (s, 3H) . 19F NMR (acetone d6) -107.88 (m) .
Step 3 : Preparation of 1- (4-fluoroohenvl) -2-
(4-methylthiophenyl) -2-hydroxy-ethanone
A 1 L three necked round bottomed flask equipped with reflux condenser, magnetic stir bar, thermometer adapter, and constant pressure addition funnel was charged with the intermediate from Step 2, (55.5 g, 0.21 mol), acetic acid (250 mL) and 33% HBr in acetic acid (120 mL) . The solution was stirred and treated with bromine (11.1 mL, 0.21 mol) from the addition funnel at such a rate that the bromine color was discharged rapidly, ca . 15 minutes. After an additional 10 minutes at room temperature, the solution was filtered through a Buchner funnel and the filtrate concentrated in vacuo to give an orange solid. The crude bromoketone was dissolved in dichloromethane and washed with IN NaHS03, dried over anhydrous MgS04, filtered and concentrated in vacuo to give 68.8 g of 1- (4-fluorophenyl) -2-(4-methylthiophenyl) -2-bromoethanone as a yellow solid which was used directly without further purification. The crude bromoketone was dissolved in 300 mL acetone and 150 mL of water and heated to reflux for 2.5 hours. The solution was concentrated in. vacuo and the residue taken up in dichloromethane, washed with saturated aqueous sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, filtered and reconcentrated in vacuo to give a light yellow solid that was crystallized .from a mixture of dichloromethane and isooctane to provide 37.8 g (65%) of pure 1- (4-fluorophenyl)-2- (4- methylthiophenyl) -2-hydroxy-ethanone: mp 90-92 °C.
Step 4: Preparation of ethyl 2-T4- (4-fluorophenyl) -5- r4-methylthio)phenyl1oxazol-2-yllacetate
A solution containing 8.00 g (29 mmol) of 1- (4-fluorophenyl)-2-hydroxy-2-[4-
(methylthiophenyl)ethanone in 100 mL of methylene chloride was stirred at 25°C as 7.0 mL (31 mmol) of pyridine was added, followed by the addition of 4.5 mL (35 mmol) of ethyl malonyl chloride. The reaction was stirred at 25°C for 48 hours, after which the resulting yellow solution was washed with IN HCl, dried over sodium sulfate and concentrated in vacuo. The crude solid was purified via flash chromatography on a silica gel column using 10% ethyl acetate/hexane as the eluent. This provided 7.31 g (64%) of a white foam, which was used directly without further purification. The product from above (7.31 g, 18.7 mmol) and 7.2 g of ammonium acetate (93.5 mmol, 5 equivalents) in 50 mL of glacial acetic were heated to reflux for 2 hours. The reaction mixture was cooled to 25°C and poured into 100 mL of water. The aqueous solution was extracted with ethyl acetate and the combined organic extracts were washed with water and sodium bicarbonate solution, dried over sodium sulfate and concentrated in vacuo. The crude solid was purified by flash chromatography using a silica gel column and 20% ethyl acetate/hexane as the eluent to give a white solid which was recrystallized from 50% ethyl acetate/isooctane to give 5.55 g (80%) of a white solid whose structure was assigned as ethyl 2- [4- (4-fluorophenyl) -5- [4- methylthio)phenyl]oxazol-2-yl]acetate and was judged suitable for taking onto the next step.
Step 5: Preparation of ethyl 2- T4- (4-fluorophenyl) -5- r4-methy1sulfonyl)phenyl1oxazol-2-y11 -1- benzyl-acetate
A solution of 755 mg (2.03 mmol) of ethyl 2- [4- (4-fluorophenyl) -5- [4-methylthio)phenyl]oxazol-2- yl]acetate (from Step 4) was dissolved in 20 mL of anhydrous tetrahydrofuran (THF) and cooled to -78°C and treated with a solution of potassium bid(trimethylsilyl)amide (2.44 mL. 1.2 equivalents, IM in THF via syringe. The solution was maintained at -78°C for 15 minutes and treated with a solution of 290 uL (2.44 mmol) of benzyl bromide. The solution was warmed to room temperature and poured into a saturated aqueous solution of ammonium chloride. The aqueous solution was extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give an oil that was purified by flash chromatography on silica gel eluting with 10% ethyl acetate/hexane to provide 396 mg-of the dialkylated product and 182 mg (19%) of ethyl 2- [4- (4- fluorophenyl) -5- [4-methylthio)phenyl]oxazol-2-yl] -1- benzyl-acetate that was used directly in the next step. A solution of 182 mg (0.344 mmol) of ethyl 2- [4- (4- fluorophenyl) -5- [4-methylthio)phenyl]oxazol-2-yl] -1- benzyl-acetate in 5 mL of dichloromethane was cooled to -78°C and treated with 272 mg (2 equivalents) of m- chloroperoxybenzoic acid for 2 hours. The reaction was poured into a solution of aqueous sodium metabisulfite. The aqueous solution was extracted using ethyl acetate and the organic layer was washed with saturated sodium metabisulfite, saturated sodium bicarbonate and brine. The resulting clear solution was dried over sodium sulfate and concentrated in vacuo to give a transparent oil which was purified by flash chromatography on a silica gel column using 30% ethyl acetate/hexane as the eluent. The purified material was an oil whose structure was assigned as ethyl 2- [4- (4-fluorophenyl) - 5- [4-methylsulfonyl)phenyl]oxazol-2-yl] -1-benzyl- acetate on the basis of its spectral characteristics: ^■H-NM (CDCI3, 300 MHz) 3 1.20 (t, J= 7.0Hz, 3H) , 3.07 (s, 3H) , 3.53 (m, 2H) , 4.19 (q, J= 7.0Hz, 2H) , 4.23 (m, IH) , 7.10 (d, J= 8.7Hz, 2H) , 7.25 (m, 5H) , 7.57 (m, 2H) , 7.70 (d, J= 8.7Hz, 2H) , 7.90 (d, J= 8.7Hz, 2H) .
19F-NMR (CDCI3, 280 MHz) 3 -112.15. LRMS m/z 493 (M)+. HRMS Calc'd. for C27H24NO5FS: 493.1359. Observed: 493.1371.
BIOLOGICAL EVALUATION
Rat Carrageenan Foot Pad Edema Test
The carrageenan foot edema test was performed with materials, reagents and procedures essentially as described by Winter, et al., (Proc. Soc. EXP. Biol. Med.. HI, 544 (1962)) . Male Sprague-Dawley rats were selected in each group so that the average body weight was as close as possible. Rats were fasted with free access to water for over sixteen hours prior to the test. The rats were dosed orally (1 mL) with compounds suspended in vehicle containing 0.5% methylcellulose and 0.025% surfactant, or with vehicle alone. One hour later a subplantar injection of 0.1 mL of 1% solution of carrageenan/sterile 0.9% saline was administered and the volume of the injected foot was measured with a displacement plethysmometer connected to a pressure transducer with a digital indicator. Three hours after the injection of the carrageenan, the volume of the foot was again measured. The average foot swelling in a group of drug-treated animals was compared with that of a group of placebo-treated animals and the percentage inhibition of edema was determined (Otterness and Bliven, Laboratory Models for Testing NSAIDs, in Non-steroidal Anti- Inflammatory Druαs, (J. Lombardino, ed. 1985) ) . The % inhibition shows the % decrease from control paw volume determined in this procedure and the data for selected compounds in this invention are summarized in Table 1.
Rat Carrageenan-induced Analgesia Test
The analgesia test using rat carrageenan was performed with materials, reagents and procedures essentially as described by Hargreaves, et al., (Pain, 32, 77 (1988)). Male Sprague-Dawley rats were treated as previously described for the Carrageenan Foot Pad Edema test. Three hours after the injection of the carrageenan, the rats were placed in a special plexiglass container with a transparent floor having a high intensity lamp as a radiant heat source, positionable under the floor. After an initial twenty minute period, thermal stimulation was begun on either the injected foot or on the contralateral uninjected foot. A photoelectric cell turned off the lamp and timer when light was interrupted by paw withdrawal. The time until the rat withdraws its foot was then measured. The withdrawal latency in seconds was determined for the control and drug-treated groups, and percent inhibition of the hyperalgesic foot withdrawal determined. Results are shown in Table I.
TABLE I.
RAT PAW EDEMA ANALGESIA
% Inhibition % Inhibition @ lOmg/kg body weight @20mg/kg body weight
Example
1 41* 44
3 30
7 24
8 12
10 18
11 42
16 26
28 2
30 4
31 5
* @ 20mg/kg body weight
Evaluation of COX I and COX II activity in vitro
The compounds of this invention exhibited inhibition in vitro of COX II. The COX II inhibition activity of the compounds of this invention illustrated in the Examples was determined by the following methods.
a. Preparation of recombinant COX baculoviruses A 2.0 kb fragment containing the coding region of either human or murine COX-I or human or murine COX-II was cloned into a BamHl site of the baculovirus transfer vector pVLl393 (Invitrogen) to generate the baculovirus transfer vectors for COX-I and COX-II in a manner similar to the method of D.R. O'Reilly et al [Baculovirus Expression Vectors : A Laboratory Manual (1992) ) . Recombinant baculoviruses were isolated by transfecting 4 μg of baculovirus transfer vector DNA into SF9 insect cells (2xl0e8) along with 200 ng of linearized baculovirus plasmid DNA by the calcium phosphate method. See M.D. Summers and G.E. Smith, A Manual of Methods for Baculovirus Vectors and Insect Cell Cul ture Procedures, Texas Agric. Exp. Station Bull. 1555 (1987). Recombinant viruses were purified by three rounds of plaque purification and high titer (10E7 - 10E8 pfu/ml) stocks of virus were prepared. For large scale production, SF9 insect cells were infected in 10 liter fermentors (0.5 x 10^/ml) with the recombinant baculovirus stock such that the multiplicity of infection was 0.1. After 72 hours the cells were centrifuged and the cell pellet homogenized in Tris/Sucrose (50 mM: 25%, pH 8.0) containing 1% 3- [ (3-cholamidopropyl) dimethylammonio] -1-propanesulfonate (CHAPS) . The homogenate was centrifuged at 10,000xG for 30 minutes, and the resultant supernatant was stored at -80°C before being assayed for COX activity.
b. Assay for COX I and COX II activity:
COX activity was assayed. as PGE2 formed/μg protein/time using an ELISA to detect the prostaglandin released. CHAPS-solubilized insect cell membranes containing the appropriate COX enzyme were incubated in a potassium phosphate buffer (50 mM, pH 8.0) containing epinephrine, phenol, and heme with the addition of arachidonic acid (10 μM) . Compounds were pre-incubated with the enzyme for 10-20 minutes prior to the addition of arachidonic acid. Any reaction between the arachidonic acid and the enzyme was stopped after ten minutes at 37°C/room temperature by transferring 40 μl of reaction mix into 160 μl ELISA buffer and 25 μM indomethacin. The PGE2 formed was measured by standard ELISA technology (Cayman Chemical) . Results are shown in Table II.
TABLE ! II.
COX I COX II
Figure imgf000104_0001
Example
1 6.9 .02
3 >10 .04
14 >30 >10
15 >30 .2
25 >10 .5
28 >100 .02
29 >100 100
30 >100 .02
31 >100 .025
32 15.9 .01
33 3.1 .05
Also embraced within this invention is a class of pharmaceutical compositions comprising one or more compounds of Formula I in association with one or more non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The compounds and composition may, for example, be administered intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically.
For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier.
The amount of therapeutically active compound that is administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound employed, and thus may vary widely. The pharmaceutical compositions may contain active ingredient in the range of about 0.1 to 1000 mg, preferably in the range of about 0.5 to 500 mg and most preferably between about 1 and 100 mg. A daily dose of about 0.01 to 100 mg/kg body weight, preferably between about 0.1 and about 50 mg/kg body weight and most preferably from about 1 to 20 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day.
For therapeutic purposes, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for con¬ venient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more immunomodulators, antiviral agents or other antiinfective agents. For example, the compounds of the invention can be administered in combination with antihistamines or with other such agents known heretofore to be effective in combination with antiinflammatory agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition. The examples herein can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be with in the scope and nature of the invention which are defined in the appended claims. Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.

Claims

What is claimed is:
1. A compound of Formula I
Figure imgf000108_0001
wherein R is selected from hydrido, alkyl, hydroxyalkyl, haloalkyl, alkenyl, hydroxyalkenyl, alkynyl, hydroxyalkynyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, heteroaryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, arylthioalkyl, aminocarbonylalkyl, N-alkylaminocarbonylalkyl and N,N-dialkylaminocarbonylalkyl; wherein R1 is selected from cycloalkyl, cycloalkenyl, aryl and heteroaryl, wherein R^- is optionally substituted at a substitutable position by alkyl, alkoxy and halo; and wherein R^ is selected from alkyl, haloalkyl and amino; or a pharmaceutically-acceptable salt thereof; provided R is not methyl when R2 is amino; and further provided that R1 is not phenyl when R2 is methyl and R is isopropyl or tert-butyl.
2. Compound of Claim 1 wherein R is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower alkenyl, lower hydroxyalkenyl, lower alkynyl, lower hydroxyalkynyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower aralkoxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonyl, lower alkoxycarbonylalkyl, carboxy, lower carboxyalkyl, lower arylthioalkyl, lower aminocarbonylalkyl, lower N- alkylaminocarbonylalkyl and lower N,N- dialkyla inocarbonylalkyl; wherein R^ is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl and heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2, 3-thianaphthalenyl, 2,3- dihydrothianaphthalenyl, 2, 3-benzofuryl, and 2,3- dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; and wherein R2 is selected from lower alkyl, lower haloalkyl and amino; or a pharmaceutically-acceptable salt or prodrug thereof .
3. Compound of Claim 2 wherein R is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, 1-propenyl, 2-propenyl, 1- butenyl, 2-butenyl, 3-butenyl, hydroxyetheny1, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2- butynyl, 3-butynyl, hydroxyethynyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethy1, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n- propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert- butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethy1 and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position on the phenyl radical with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position on the phenyl radical with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, carboxy, acetyl, propanoic, butanoic, pentanoic, hexanoic, phenylthiomethyl, aminocarbonylmethyl, N-methylaminocarbonylmethyl and N,N-dimethylaminocarbonylmethyl; wherein R1 is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl,
2-cyclohexenyl, 3-cyclohexenyl, cyclopentenyl, cycloheptenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2, 3-thianaphthalenyl, 2,3- dihydrothianaphthalenyl, 2, 3-benzofuryl, and 2,3- dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; and wherein R2 is selected from methyl, ethyl, trifluoromethyl, difluoromethyl, fluoromethyl and amino; or a pharmaceutically-acceptable salt or prodrug thereof .
4. Compound of Claim 3 selected from compounds, their prodrugs and their pharmaceutically- acceptable salts, of the group consisting of
4- [2-benzyl-5- (phenyl)oxazol-4-yl]benzenesulfonamide; 4- [2-benzyl-5- (4-fluorophenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3, 4-difluorophenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-chlorophenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3, 4-dichlorophenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3 , 4-dimethoxyphenyl) oxazol-4- y1]benzenesulfonamide;
4- [2-benzyl-5- (4-methylphenyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3, 4-dimethylphenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3-chloro-4-methylphenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-chloro-3-methylphenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3-chloro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-chloro-3-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3 , 5-dichloro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3-fluoro-4-methylphenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-fluoro-3-methylphenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3-fluoro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (2-thienyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (5-chloro-2-thienyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (cyclohexyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (1-cyclohexenyl) oxazol-4- yl]benzenesulfonamide; 2-benzyl-4- (4-methylsulfonylphenyl) -5-phenyloxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3,4- difluorophenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4- chlorophenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3, 4- dichlorophenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4- methoxyphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3,4- dimethoxyphenyl) oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (4- methylphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3,4- dimethylphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-chloro-4- methylphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-chloro-3- methylphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-chloro-4- methoxyphenyl) oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-chloro-3- methoxyphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3, 5-dichloro-4- ethoxyphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-fluoro-4- ethylphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-fluoro-3- methylphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-fluoro-4- methoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- [ 2 - thienyl) oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (5-chloro-2- thienyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5-
(cyclohexyl) oxazole-; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (1- cyclohexenyl) oxazole; 2- (ethyl) -4- (4-methylsulfonylphenyl) -5-phenyloxazole; 2- (trifluoromethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (difluoromethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (hydroxy ethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (carboxy) -4- (4-methylsulfonylphenyl) -5- phenyloxazole;
2- (methoxycarbonyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2 - (ethoxycarbonyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (propyl) -4- (4-methylsulfonylphenyl) -5-phenyloxazole; 2- (benzyl) -4- (4-methylsulfonylphenyl) -5-phenyloxazole; 2- (phenoxymethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- ( (4-chlorophenoxy) ethyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- ( (4-fluorophenoxy)methyl) -4- (4- ethylsulfonylphenyl) -5-phenyloxazole; 2- ( (4-carboxyphenoxy)methyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- (2-phenethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (3-phenpropyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (carboxymethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (ethoxycarbonylmethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole;
2- (methoxycarbonylmethyl) -4- (4-methylsulfonylphenyl) -
5-phenyloxazole; 2- (2-quinolyloxymethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 4- [2- (ethyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- [2- (trifluoromethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (difluoromethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (hydroxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (carboxy) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- [2- (methoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (ethoxycarbony1) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (propyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- [2- (benzyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- [2- (phenoxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- [2- ( (4-chlorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- ( (4-fluorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4-[2-( (4-carboxyphenoxy)methyl) -5-phenyloxazol-4- y1]benzenesulfonamide; 2- (2-phenethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- (3-phenpropyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (carboxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (ethoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (methoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (2-quinolyloxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2-benzy1-4-phenyloxazol-5-yl]benzenesulfonamide; 4- 2-benzyl-4- (4-fluorophenyl) oxazol-5- y1]benzenesulfonamide;
4- 2-benzyl-4- (3 , 4-difluorophenyl) oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (4-chlorophenyl) oxazol-5- y1]benzenesulfonamide; 4- 2-benzyl-4- (3 , 4-dichlorophenyl) oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (4-methoxyphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (3,4-dimethoxyphenyl) oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (4-methylphenyl) oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (3, 4-dimethylphenyl) oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (3-chloro-4-methylphenyl) oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (4-chloro-3-methylphenyl) oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (3-chloro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (4-chloro-3-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (3, 5-dichloro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (3-fluoro-4-methylphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (4-fluoro-3-methylphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (3-fluoro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (2-thienyl) oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (5-chloro-2-thienyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (cyclohexyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (1-cyclohexenyl) oxazol-5- yl]benzenesulfonamide; 2-benzyl-5- (4-methylsulfonylphenyl) -4-phenyloxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3 , 4- difluorophenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4- chlorophenyl) oxazol-4-yl]benzenesulfonamide; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3,4- dichlorophenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4- methoxyphenyl) oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (3,4- dimethoxyphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4- ethylphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3,4- dimethylphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-chloro-4- methylphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4-chloro-3- methylphenyl)oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-chloro-4- methoxyphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4-chloro-3- methoxyphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3, 5-dichloro-4- ethoxyphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-fluoro-4- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4-fluoro-3- methylphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-fluoro-4- methoxyphenyl) oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (2- thienyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (5-chloro-2- thienyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (cyclohexyl)oxazole-; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2- cyclohexenyl) oxazole; 2- (ethyl) -5- (4-methylsulfonylphenyl) -4-phenyloxazole; 2- (trifluoromethyl) -5- (4-methylsulfonylphenyl) -4- pheny1oxazo1e; 2- (difluoromethyl) -5- (4-methylsulfonylphenyl) -4- pheny1oxazo1e; 2- (hydroxymethy1) -5- (4-methylsulfonylphenyl) -4- phenyloxazole;
2- (carboxy) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2- (methoxycarbonyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2- (ethoxycarbonyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2- (propyl) -5- (4-methylsulfonylphenyl) -4-phenyloxazole; 2- (benzyl) -5- (4-methylsulfonylphenyl) -4-phenyloxazole; 2- (phenoxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole;
2- ( (4-chlorophenoxy) ethyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; ( (4-fluorophenoxy) ethyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; ( (4-carboxyphenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; (2-phenethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; (3-phenpropyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; (carboxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; (ethoxycarbonylmethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; (methoxycarbonylmethyl) -5- (4-methylsulfonylphenyl) -
4-phenyloxazole; (2-quinolyloxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; [2- (ethyl) -4-phenyloxazol-5-yl]benzenesulfonamide; [2- (trifluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; [2- (difluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; [2- (hydroxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; [2- (carboxy) -4-phenyloxazol-5-yl]benzenesulfonamide; [2- (methoxycarbonyl) -4-phenyloxazol-5- yl]benzenesulfonamide; [2- (ethoxycarbony1) -4-phenyloxazol-5- y1]benzenesulfonamide; [2- (propyl) -4-phenyloxazol-5-yl]benzenesulfonamide; [2- (benzyl) -4-phenyloxazol-5-y1]benzenesulfonamide; [2- (phenoxymethyl) -4-phenyloxazol-5- y1]benzenesulfonamide; [2- ( (4-chlorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; [2- ( (4-fluorophenoxy) ethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (4-carboxyphenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (2-phenethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (3-phenpropyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (carboxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (ethoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- [2- (methoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (2-quinolyloxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 5- (4-fluorophenyl) -2-methyl-4- [4-
(methylsulfonyl)phenyl]oxazole; 3- [5- (4-fluorophenyl) -4- [4- (methylsulfonyl)phenyl] oxazol-2-yl]propanoic acid; methyl 3- [5- (4-fluorophenyl) -4- [4- (methylsulfonyl) phenyl] oxazol-2-yl]propanate;
4- (4-fluorophenyl) -2- (2-phenyl) ethyl-5- (4-
(methylsulfonyl)phenyl) oxazole; 4- (4-fluorophenyl) -2-methyl-5- [4-
(methylsulfonylphenyl] oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenyloxazole; 2-benzyl-4- (4-fluorophenyl) -5- (4-
(methylsulfonyl)phenyl)oxazole; 4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2- (3- phenyl)propyloxazole;
4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2- propyloxazole; 2- (tert-butyl) -4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl]oxazole; 4- (4-fluorophenyl) -2- (4-methoxyphenyl)methyl-5- [4- methylsulfonylphenyl]oxazole 4- (4-fluorophenyl) -2- (3-methoxyphenyl) ethyl-5- [4- methylsulfonylphenyl] oxazole; 2-diphenylmethyl-4- (4-fluorophenyl) -5- [4- methylsulfon lphenyl] oxazole; 2-[4-(4-fluorophenyl)-5-[4- methylsulfonylphenyl] oxazol-2-yl]acetic acid; ethyl 2- [4- (4-fluorophenyl) -5- [4- methylsulfonyl)phenyl]oxazol-2-yl]acetate; 3- [4- (4-fluorophenyl) -5- [4- methylsulfonyl)phenyl] oxazol-2-yl] ropanoic acid; methyl 3- [4- (4-fluorophenyl) -5- [4- methylsulfonyl) henyl] oxazol-2-yl] ropanate; 4- [4- (4-fluorophenyl) -5- [4- methylsulfonyl)phenyl] oxazol-2-yl]butanoic acid; methyl 4- [4- (4-fluorophenyl) -5- [4-methylsulfonyl) phenyl] oxazol-2-yl]butanate; 3- [4- (4-fluorophenyl) -5- [4-methylsulfonyl) phenyl] oxazol-2-yl]propanamide; ethyl 2- [4- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl] oxazol-2-yl] -2-benzyl-acetate;
4- (4-fluorophenyl) -2- (cyclohexylethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (3-fluorophenoxymethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (3-chlorophenoxymethyl) -5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2- (pyridyloxymethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenoxymethyloxazole;
4- (4-fluorophenyl) -2- (2-hydroxyethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (hydroxymethyl) -5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (cyclohexyl) -2-phenyl-5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2-benzyloxymethyl-5- [4-
( ethylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2-cyclohexyl-5- [4-
(methylsulfonyl)phenyl] oxazole; and 5- (4-fluorophenyl) -2-phenyl-4- [4-
(methylsulfonyl)phenyl] oxazole.
5. Compound of Claim 1 wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R^ is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo, and wherein R2 is methyl; or a pharmaceutically-acceptable salt thereof; provided R^ is not phenyl when R is isopropyl or tert- butyl .
6. Compound of Claim 5 wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and wherein R1 is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2, 3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2, 3-dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically-acceptable salt or prodrug thereof.
7. Compound of Claim 6 wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethyl and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, pentanoic, hexanoic and aminocarbonylmethyl; and wherein R1 is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2 - cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2, 3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2, 3-dihydrobenzofuryl, wherein R1 is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert- butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; or a pharmaceutically-acceptable salt or prodrug thereof.
8. Compound of Claim 7 selected from compounds, their prodrugs and their pharmaceutically- acceptable salts, of the group consisting of 5- (4-fluorophenyl) -2-methyl-4- [4-
(methylsulfonyl)phenyl]oxazole; [5- (4-fluorophenyl) -4- [4- (methylsulfonyl)phenyl] -2 - oxazol-2-yl]propanoic acid; methyl 3- [5- (4-fluorophenyl) -4- [4- (methylsulfonyl) phenyl] -2-oxazol-2-yl]propanate; 4- (4-fluorophenyl) -2- (2-phenylethyl) -5- (4- ( ethylsulfonyl)phenyl) oxazole; 4- (4-fluorophenyl) -2-methyl-5- [4- methylsulfonylphenyl] oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenyloxazole; 2-benzyl-4- (4-fluorophenyl) -5- (4- (methylsulfonyl)phenyl)oxazole;
4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2- (3- phenyl)propyloxazole; 4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2 - propyloxazole; 2- (tert-butyl) -4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl] oxazole; 4- (4-fluorophenyl) -2- (4-methoxyphenyl)methyl-5- [4- methylsulfonylphenyl] oxazole 4- (4-fluorophenyl) -2- (3-methoxyphenyl)methyl-5- [4- methylsulfonylphenyl]oxazole;
2-diphenylmethy1-4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl] oxazole; 2- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] oxazol- 2-yl]acetic acid; ethyl 2- [4- (4-fluorophenyl) -5- [4-methylsulfonyl phenyl] oxazol-2-yl]acetate; 3- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl]oxazol-
2-yl]propanoic acid; methyl 3- [4- (4-fluorophenyl) -5- [4-methylsulfonyl phenyl] oxazol-2-yl]propanate;
4- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] oxazol- 2-yl]butanoic acid; methyl 4- [4- (4-fluorophenyl) -5- [4-methylsulfonyl phenyl]oxazol-2-yl]butanate; 3- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl]oxazol-
2-yl]propanamide; ethyl 2- [4-(4-fluorophenyl) -5-[4- (methylsulfonyl) phenyl]oxazol-2-yl] -2-benzyl acetate; 4- (4-fluorophenyl) -2-(cyclohexylethyl) -5-[4-
(methylsulfonyl)phenyl]oxazole; 4-(4-fluorophenyl) -2- (3-fluorophenoxymethyl) -5-[4- (methylsulfonyl)phenyl]oxazole;
4- (4-fluorophenyl) -2-(3-chlorophenoxymethyl) -5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2- (pyridyloxymethyl) -5-[4-
(methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenoxymethyl oxazole; 4- (4-fluorophenyl) -2- (2-hydroxy)ethyl) -5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2- (hydroxymethyl) -5-[4- (methylsulfonyl)phenyl]oxazole;
4- (cyclohexyl) -2-phenyl-5-[4-
(methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2-benzyloxymethyl-5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2-cyclohexyl-5-[4-
(methylsulfonyl)phenyl] oxazole; and 5- (4-fluorophenyl) -2-phenyl-4- [4-
(methylsulfonyl)phenyl] oxazole.
9. Compound of Claim 1 wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R1 is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo; and wherein R2 is amino; or a pharmaceutically-acceptable salt thereof; provided R is not methyl.
10. Compound of Claim 9 wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and wherein R^ is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2, 3-thianaphthalenyl, 2,3- dihydrothianaphthalenyl, 2, 3-benzofuryl, and 2,3- dihydrobenzofuryl, wherein Rl is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically- acceptable salt or prodrug thereof.
11. Compound of Claim 10 wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexyl ethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethy1 and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, pentanoic, hexanoic and aminocarbonylmethyl; and wherein R1 is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2- cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2, 3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2, 3-dihydrobenzofuryl, wherein R^- is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert- butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; or a pharmaceutically-acceptable salt or prodrug thereof.
12. Compound of Claim 11 selected from compounds, their prodrugs and their pharmaceutically- acceptable salts, of the group consisting of
4- [2-benzyl-5- (phenyl) oxazol-4-yl]benzenesulfonamide; 4- [2-benzyl-5- (4-fluorophenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3, 4-difluorophenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-chlorophenyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3 ,4-dichlorophenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3 , 4-dimethoxyphenyl) oxazol-4- yl]benzenesulfonamide; 4- 2-benzyl-5- (4-methylphenyl) oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5- (3, 4-dimethylphenyl)oxazol-4- yl]benzenesulfonamide;
2-benzyl-5- (3-chloro-4-methylphenyl) oxazol-4- yl]benzenesulfonamide;
4- benzyl-5- (4-chloro-3-methylphenyl) oxazol-4- yl]benzenesulfonamide; benzyl-5- (3-chloro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5- (4-chloro-3-methoxyphenyl)oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5- (3, 5-dichloro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; 4- 2-benzyl-5- (3-fluoro-4-methylphenyl)oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5- (4-fluoro-3-methylphenyl) oxazol-4- y1]benzenesulfonamide;
4- 2-benzyl-5- (3-fluoro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5- (2-thienyl) oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (5-chloro-2-thienyl) oxazol-4- yl]benzenesulfonamide; 4- 2-benzyl-5- (cyclohexyl) oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5- (1-cyclohexenyl) oxazol-4- yl]benzenesulfonamide;
4- 2- (ethyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- 2- (trifluoromethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (difluoromethyl) -5-phenyloxazol-4- y1]benzenesulfonamide;
4- 2- (hydroxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (carboxy) -5-phenyloxazol-4-yl]benzenesulfonamide; 2- (methoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- (ethoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide; - 2 - (n-propyl) -5-phenyloxazol-4-yl]benzenesulfonamide; - 2- (benzyl) -5-phenyloxazol-4-yl]benzenesulfonamide; - 2- (phenoxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- ( (4-chlorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; - 2- ( (4-fluorophenoxy) ethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- ( (4-carboxyphenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2 - (2-phenethyl) -5-phenyloxazol-4- y1]benzenesulfonamide;
4- 2- (3-phenpropyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (carboxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (ethoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- (methoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- (2-quinolyloxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2-benzy1-4-phenyloxazol-5-y1]benzenesulfonamide; 4- 2-benzyl-4- (3, 4-difluorophenyl) oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (4-chlorophenyl) oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (3, 4-dichlorophenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (4-methoxyphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (3, 4-dimethoxyphenyl) oxazol-5- yl]benzenesulfonamide; 4- 2-benzyl-4- (4-methylphenyl) oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (3, 4-dimethylphenyl) oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (3-chloro-4-methylphenyl) oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (4-chloro-3-methylphenyl) oxazol-5- yl]benzenesulfonamide; 4- 2-benzyl-4- (3-chloro-4-methoxyphenyl) oxazol-5- y1]benzenesulfonamide; 4- 2-benzyl-4- (4-chloro-3-methoxyphenyl) oxazol-5- yl]benzenesulfonamide;
2-benzyl-4- (3, 5-dichloro-4-methoxyphenyl) oxazol-5- y1]benzenesulfonamide;
2-benzyl-4- (3-fluoro-4-methylphenyl) oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (4-fluoro-3-methylphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (3-fluoro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (2-thienyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (5-chloro-2-thienyl) oxazol-5- y1]benzenesulfonamide; 2-benzyl-4- (cyclohexyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (1-cyclohexenyl) oxazol-5- yl]benzenesulfonamide;
4- 2- (ethyl) -4-phenyloxazol-5-yl]benzenesulfonamide; 4- 2- (trifluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 2- (difluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- 2- (hydroxymethyl) -4-phenyloxazol-5- y1]benzenesulfonamide; 2 - (carboxy) -4-phenyloxazol-5-yl]benzenesulfonamide; 4- [2- (methoxycarbonyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (ethoxycarbonyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (propyl) -4-phenyloxazol-5-yl]benzenesulfonamide; 4- [2- (benzyl) -4-phenyloxazol-5-yl]benzenesulfonamide; 4- [2- (phenoxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (4-chlorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- [2- ( (4-fluorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (4-carboxyphenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (2-phenethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (3-phenpropyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (carboxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- [2- (ethoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (methoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (2-quinolyloxymethyl) -4-phenyloxazol-5- y1]benzenesulfonamide; 4- [5- (4-fluorophenyl) -2-methyl-oxazol-4- yl]benzenesulfonamide; 3- [5- (4-fluorophenyl) -4- (4-aminosulfonylphenyl) oxazol- 2-yl]propanoic acid; methyl 3- [5- (4-fluorophenyl) -4- (4-aminosulfonylphenyl) oxazol-2-yl]propanate; 4- [4- (4-fluorophenyl) -2- (2-phenylethyl) -oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2-methyl-oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2-phenyloxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (4-fluorophenyl) oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (3-phenylpropyl) oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (n-propyl)oxazol-5- yl]benzenesulfonamide; 4- [2- (tert-butyl) -4- (4-fluorophenyl) oxazol-5- yl]benzenesulfonamide;
4- [4- (4-fluorophenyl) -2- (4-methoxyphenyl)methyloxazol-
5-yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (3-methoxyphenyl)methyloxazol-
5-y1]benzenesulfonamide; 4- [2-diphenylmethy1-4- (4-fluorophenyl) oxazol-5- yl]benzenesulfonamide; 2- [4- (4-fluorophenyl) -5- [4-aminosulfonylphenyl] oxazol-
2-yl] acetic acid; ethyl 2- [4- (4-fluorophenyl) -5- [4-aminosulfonylphenyl] oxazol-2-yl] acetate;
3- [4- (4-fluorophenyl) -5- [4-aminosulfonylphenyl] oxazol-
2-yl]propanoic acid; methyl 3- [4- (4-fluorophenyl) -5- [4- aminosulfonylphenyl] oxazol-2-yl]propanate; 4- [4- (4-fluorophenyl) -5- [4-aminosulfonylphenyl] oxazol-
2-yl]butanoic acid; methyl 4- [4- (4-fluorophenyl) -5- [4-aminosulfonyl phenyl] oxazol-2-yl]butanate; 3- [4- (4-fluorophenyl) -5- [4-aminosulfonyl phenyl] oxazol-2-yl]propanamide; ethyl 2- [4- (4-fluorophenyl) -5- [4-aminosulfonyl phenyl]oxazol-2-yl] -2-benzyl-acetate; 4- [4- (4-fluorophenyl) -2- (cyclohexylethyl) oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (3-fluorophenoxymethyl)oxazol-
5-yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (3-chlorophenoxymethyl) oxazol-
5-yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (pyridyloxymethyl)oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2-phenoxymethyloxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (2-hydroxyethyl) oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (hydroxymethyl)oxazol-5- yl]benzenesulfonamide;
4- [4- (cyclohexyl) -2-phenyloxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2-benzyloxymethyloxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2-cyclohexyloxazol-5- yl]benzenesulfonamide; and 4- [5- (4-fluorophenyl) -2-phenyloxazol-4- yl]benzenesulfonamide.
13. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from a family of compounds of Formula I
Figure imgf000135_0001
wherein R is selected from hydrido, alkyl, hydroxyalkyl, haloalkyl, alkenyl, hydroxyalkenyl, alkynyl, hydroxyalkynyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, heteroaryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, arylthioalkyl, aminocarbonylalkyl, N-alkylaminocarbonylalkyl and N,N-dialkylaminocarbonylalkyl; wherein R^ is selected from cycloalkyl, cycloalkenyl, aryl and heteroaryl, wherein R^ is optionally substituted at a substitutable position by alkyl, alkoxy and halo; and wherein R2 is selected from alkyl, haloalkyl and amino; or a pharmaceutically-acceptable salt thereof .
14. The composition of Claim 13 wherein R is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower alkenyl, lower hydroxyalkenyl, lower alkynyl, lower hydroxyalkynyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower aralkoxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonyl, lower alkoxycarbonylalkyl, carboxy, lower carboxyalkyl, lower arylthioalkyl, lower aminocarbonylalkyl, lower N- alkylaminocarbonylalkyl and lower N,N- dialkylaminocarbonylalkyl; wherein R^- is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl and heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2, 3-thianaphthalenyl, 2,3- dihydrothianaphthalenyl, 2, 3-benzofuryl, and 2,3- dihydrobenzofuryl, wherein R-L is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; and wherein R2 is selected from lower alkyl, lower haloalkyl and amino; or a pharmaceutically-acceptable salt or prodrug thereof.
15. The composition of Claim 14 wherein R is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, 1-propenyl, 2-propenyl, 1- butenyl, 2-butenyl, 3-butenyl, hydroxyethenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2- butynyl, 3-butynyl, hydroxyethynyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, eyelopentylmethy1, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n- propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert- butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethyl and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position on the phenyl radical with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position on the phenyl radical with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, carboxy, acetyl, propanoic, butanoic, pentanoic, hexanoic, phenylthiomethyl, aminocarbonylmethyl, N-methylaminocarbonylmethyl and N,N-dimethylaminocarbonylmethyl; wherein R^ is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, cyclopentenyl, cycloheptenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2, 3-thianaphthalenyl, 2,3- dihydrothianaphthalenyl, 2, 3-benzofuryl, and 2,3- dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; and wherein R2 is selected from methyl, ethyl, fluoromethyl, difluoromethyl, trifluoromethyl and amino; or a pharmaceutically-acceptable salt or prodrug thereof.
16. The composition of Claim 15 selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of
4- [2-benzyl-5- (phenyl)oxazol-4-yl]benzenesulfonamide; 4- [2-benzyl-5- (4-fluorophenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3, 4-difluorophenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-chlorophenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3 , 4-dichlorophenyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (3, 4-dimethoxyphenyl) oxazol-4- yl]benzenesulfonamide; - [2-benzyl-5- (4-methylphenyl) oxazol-4- yl]benzenesulfonamide; - [2-benzyl-5- (3, -dimethylphenyl) oxazol-4- yl]benzenesulfonamide; - [2-benzyl-5- (3-chloro-4-methylphenyl)oxazol-4- yl]benzenesulfonamide; - [2-benzyl-5- (4-chloro-3-methylphenyl) oxazol-4- yl]benzenesulfonamide; - [2-benzyl-5- (3-chloro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; - [2-benzyl-5- (4-chloro-3-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; - [2-benzyl-5- (3, 5-dichloro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (3-fluoro-4-methylphenyl) oxazol-4- yl]benzenesulfonamide; - [2-benzyl-5- (4-fluoro-3-methylphenyl) oxazol-4- yl]benzenesulfonamide; - [2-benzyl-5- (3-fluoro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (2-thienyl)oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (5-chloro-2-thienyl)oxazol-4- yl]benzenesulfonamide; - [2-benzyl-5- (cyclohexyl)oxazol-4- yl]benzenesulfonamide; - [2-benzyl-5- (1-cyclohexenyl)oxazol-4- yl]benzenesulfonamide; -benzyl-4- (4-methylsulfonylphenyl) -5-phenyloxazole; -benzyl-4- (4-methylsulfonylphenyl) -5- (3, 4- difluorophenyl)oxazole; -benzyl-4- (4-methylsulfonylphenyl) -5- (4- chlorophenyl)oxazole; -benzyl-4- (4-methylsulfonylphenyl) -5- (3, 4- dichlorophenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4- methoxyphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3,4- dimethoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4- methylphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3,4- dimethylphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-chloro-4- methylphenyl) oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-chloro-3- ethylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-chloro-4- methoxyphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-chloro-3- methoxyphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3, 5-dichloro-4- methoxyphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-fluoro-4- methylphenyl) oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-fluoro-3- methylphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-fluoro-4- methoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2- thienyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (5-chloro-2- thienyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (cyclohexyl) oxazole-;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (1- cyclohexenyl) oxazole; 2- (ethyl) -4- (4-methylsulfonylphenyl) -5-phenyloxazole; 2- (trifluoromethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole;
2- (difluoromethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- hydroxymethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; carboxy) -4- (4-methylsulfonylphenyl) -5- pheny1oxazo1e; methoxycarbonyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; ethoxycarbony1) -4- (4-methylsulfonylphenyl) -5- phenyloxazole;
2- propyl) -4- (4-methylsulfonylphenyl) -5-phenyloxazole; 2- benzyl) -4- (4-methylsulfonylphenyl) -5-phenyloxazole; 2- phenoxymethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole;
2- (4-chlorophenoxy)methyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- (4-fluorophenoxy)methyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; (4-carboxyphenoxy)methyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole;
2- 2-phenethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole;
2- 3-phenpropyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole;
2- carboxymethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole;
2- ethoxycarbonylmethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole;
2- methoxycarbonylmethyl) -4- (4-methylsulfonylphenyl) -
5-phenyloxazole;
2- 2-quinolyloxymethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole;
4- 2- (ethyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- 2- (trifluoromethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (difluoromethyl) -5-phenyloxazol-4- y1]benzenesulfonamide; 2- (hydroxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (carboxy) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- [2- (methoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (ethoxycarbony1) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- [2- (propyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- [2- (benzyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- [2- (phenoxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- ( (4-chlorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- ( (4-fluorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- ( (4-carboxyphenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- [2- (2-phenethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (3-phenpropyl) -5-phenyloxazol-4- y1]benzenesulfonamide; 4- [2- (carboxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (ethoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (methoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- [2- (2-quinolyloxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-4-phenyloxazol-5-y1]benzenesulfonamide; 4- [2-benzyl-4- (4-fluorophenyl) oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (3 , 4-difluorophenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (4-chlorophenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (3,4-dichlorophenyl)oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (3,4-dimethoxyphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (4-methylphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (3, -dimethylphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (3-chloro-4-methylphenyl) oxazol-5- yl]benzenesulfonamide;
4- [2-benzy1-4- (4-chloro-3-methylphenyl)oxazol-5- y1]benzenesulfonamide; 4- [2-benzyl-4- (3-chloro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (4-chloro-3-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (3, 5-dichloro-4-methoxyphenyl) oxazol-5- y1]benzenesulfonamide;
4- [2-benzyl-4- (3-fluoro-4-methylphenyl) oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (4-fluoro-3-methylphenyl) oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (3-fluoro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (2-thienyl) oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (5-chloro-2-thienyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (cyclohexyl) oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (1-cyclohexenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-5- (4-methylsulfonylphenyl) -4-phenyloxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3 , 4- difluorophenyl) oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (4- chlorophenyl) oxazol-4-yl]benzenesulfonamide; 2-benzyl-5- (4-methylsulfonylphenyl) -4- 3,4- dichlorophenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- 4- methoxyphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- 3,4- dimethoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- 3,4- dimethylphenyl) oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- 3-chloro-4- me hylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- 4-chloro-3- ethylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- 3-chloro-4- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- 4-chloro-3- methoxyphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- 3 , 5-dichloro-4- methoxyphenyl)oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- 3-fluoro-4- methylphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- 4-fluoro-3- methylphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- 3-fluoro-4- methoxyphenyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- 2- thienyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- 5-chloro-2- thienyl) oxazole;
2-benzyl-5- ( -methylsulfonylphenyl) -4-
(cyclohexyl) oxazole-; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (2- cyclohexenyl)oxazole; 2- (ethyl) -5- (4-methylsulfonylphenyl) -4-phenyloxazole; 2- (trifluoromethyl) -5- (4-methylsulfonylphenyl) -4- pheny1oxazole; (difluoromethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; (hydroxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; (carboxy) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; (methoxycarbonyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; (ethoxycarbonyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; (propyl) -5- (4-methylsulfonylphenyl) -4-phenyloxazole; (benzyl) -5- (4-methylsulfonylphenyl) -4-phenyloxazole,• (phenoxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; ( (4-chlorophenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; ( (4-fluorophenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; ( (4-carboxyphenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; (2-phenethyl) -5- ( -methylsulfonylphenyl) -4- phenyloxazole; (3-phenpropyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; (carboxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; (ethoxycarbonylmethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; (methoxycarbonylmethyl) -5- (4-methylsulfonylphenyl) -
4-phenyloxazole; (2-quinolyloxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; [2- (ethyl) -4-phenyloxazol-5-yl]benzenesulfonamide; [2- (trifluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; [2- (difluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (hydroxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (carboxy) -4-phenyloxazol-5-yl]benzenesulfonamide; 4- [2- (methoxycarbonyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- [2- (ethoxycarbony1) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (propyl) -4-phenyloxazol-5-yl]benzenesulfonamide; 4- [2- (benzyl) -4-phenyloxazol-5-yl]benzenesulfonamide; 4- [2- (phenoxymethyl) -4-phenyloxazol-5- y1]benzenesulfonamide; 4- [2- ( (4-chlorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (4-fluorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- [2- ( (4-carboxyphenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (2-phenethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (3-phenpropyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (carboxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (ethoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- [2- (methoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (2-quinolyloxymethyl) -4-phenyloxazol-5- y1]benzenesulfonamide; 5- (4-fluorophenyl) -2-methyl-4- [4-
(methylsulfonyl)phenyl] oxazole; 3- [5- (4-fluorophenyl) -4- [4- (methylsulfonyl)phenyl] oxazol-2-yl]propanoic acid; methyl 3- [5- (4-fluorophenyl) -4- [4- (methylsulfonyl) phenyl]oxazol-2-yl]propanate;
4- (4-fluorophenyl) -2- (2-phenyl) ethyl-5- (4- (methylsulfonyl)phenyl) oxazole; 4- (4-fluorophenyl) -2-methyl-5- [4-
(methylsulfonylphenyl]oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2 - pheny1oxazo1e; 2-benzyl-4- (4-fluorophenyl) -5- (4-
(methylsulfonyl)phenyl) oxazole; 4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2- (3- phenyl)propyloxazole; 4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2- propyloxazole;
2- (tert-butyl) -4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl] oxazole; 4- (4-fluorophenyl) -2- (4-methoxyphenyl)methyl-5- [4- methylsulfonylphenyl] oxazole 4- (4-fluorophenyl) -2 - (3-methoxyphenyl)methyl-5- [4- methylsulfonylphenyl] oxazole; 2-diphenylmethyl-4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl] oxazole; 2- [4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl] oxazol-2-yl] acetic acid; ethyl 2- [4- (4-fluorophenyl) -5- [4- methylsulfonyl)phenyl]oxazol-2-yl]acetate; 3- [4- (4-fluorophenyl) -5- [4- methylsulfonyl)phenyl]oxazol-2-yl]propanoic acid; methyl 3- [4- (4-fluorophenyl) -5- [4- methylsulfonyl)phenyl]oxazol-2-yl]propanate; 4- [4- (4-fluorophenyl) -5- [4- methylsulfonyl)phenyl]oxazol-2-yl]butanoic acid; methyl 4- [4- (4-fluorophenyl) -5- [4-methylsulfonyl) phenyl] oxazol-2-yl]butanate;
3- [4- (4-fluorophenyl) -5- [4-methylsulfonyl) phenyl] oxazol-2-yl]propanamide; ethyl 2- [4- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl]oxazol-2-yl] -2-benzyl-acetate; 4- (4-fluorophenyl) -2- (cyclohexylethyl) -5- [4-
( ethylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (3-fluorophenoxymethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (3-chlorophenoxymethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (pyridyloxymethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenoxymethyloxazole; 4- (4-fluorophenyl) -2- (2-hydroxyethyl) -5- [4- (methylsulfonyl)phenyl] oxazole;
4- (4-fluorophenyl) -2 - (hydroxymethyl) -5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (cyclohexyl) -2-phenyl-5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2-benzyloxymethyl-5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2-cyclohexyl-5- [4-
(methylsulfonyl)phenyl] oxazole; and 5- (4-fluorophenyl) -2-phenyl-4- [4- (methylsulfonyl)phenyl] oxazole.
17. The composition of Claim 13 wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R^ is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo, and wherein R2 is methyl; or a pharmaceutically-acceptable salt thereof.
18. The composition of Claim 17 wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and wherein R^ is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2, 3-dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically-acceptable salt or prodrug thereof.
19. The composition of Claim 18 wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethy1 and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, pentanoic, hexanoic and aminocarbonylmethyl; and wherein R1 is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2- cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2, 3-dihydrobenzofuryl, wherein R! is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert- butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; or a pharmaceutically-acceptable salt or prodrug thereof.
20. The composition of Claim 19 selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of
5- (4-fluorophenyl) -2-methyl-4- [4-
(methylsulfonyl)phenyl] oxazole; [5- (4-fluorophenyl) -4- [4- (methylsulfonyl)phenyl] -2- oxazol-2-yl]propanoic acid; methyl 3- [5- (4-fluorophenyl) -4- [4- (methylsulfonyl) phenyl] -2-oxazol-2-yl]propanate; 4- (4-fluorophenyl) -2- (2-phenylethyl) -5- (4-
( ethylsulfonyl)phenyl)oxazole; 4- (4-fluorophenyl) -2-methyl-5- [4- methylsulfonylphenyl] oxazole;
4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenyloxazole; 2-benzyl-4- (4-fluorophenyl) -5- (4-
(methylsulfonyl)phenyl) oxazole; 4- ( -fluorophenyl) -5- [4-methylsulfonylphenyl] -2- (3- phenyl)propyloxazole; 4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2 - propyloxazole; 2- (tert-butyl) -4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl]oxazole;
4- (4-fluorophenyl) -2 - (4-methoxyphenyl)methyl-5- [4- methylsulfonylphenyl]oxazole 4- (4-fluorophenyl) -2- (3-methoxyphenyl)methyl-5- [4- methylsulfonylphenyl]oxazole; 2-diphenylmethyl-4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl] oxazole; 2- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] oxazol-
2-yl] acetic acid; ethyl 2- [4- (4-fluorophenyl) -5- [4-methylsulfonyl phenyl] oxazol-2-yl]acetate; 3- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] oxazol- 2-yl]propanoic acid; methyl 3- [4- (4-fluorophenyl) -5- [4-methylsulfonyl phenyl] oxazol-2-yl]propanate; 4- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] oxazol-
2-yl]butanoic acid; methyl 4- [4- (4-fluorophenyl) -5- [4-methylsulfonyl phenyl]oxazol-2-yl]butanate; 3- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] oxazol-
2-yl]propanamide; ethyl 2- [4- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl] oxazol-2-yl] -2-benzyl acetate;
4- (4-fluorophenyl) -2- (cyclohexylethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (3-fluorophenoxymethyl) -5- [4-
( ethylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2- (3-chlorophenoxymethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (pyridyloxymethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenoxymethyl oxazole;
4- (4-fluorophenyl) -2- (2-hydroxy) ethyl) -5-[4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (hydroxymethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (cyclohexyl) -2-phenyl-5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2-benzyloxymethyl-5- [4- (methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2-cyclohexyl-5- [4-
(methylsulfonyl)phenyl] oxazole; and 5- (4-fluorophenyl) -2-phenyl-4- [4- (methylsulfonyl)phenyl] oxazole.
21. The composition of Claim 13 wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R^ is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo; and wherein R2 is amino; or a pharmaceutically-acceptable salt thereof.
22. The composition of Claim 21 wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and wherein R! is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2, 3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2, 3-dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically-acceptable salt or prodrug thereof.
23. The composition of Claim 22 wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethyl and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, pentanoic, hexanoic and aminocarbonylmethyl; and wherein R^ is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2- cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2,3-dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert- butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; or a pharmaceutically-acceptable salt or prodrug thereof.
24. The composition of Claim 23 selected from compounds, their prodrugs and their pharmaceutically-acceptable salts, of the group consisting of 4- 2-benzyl-5- (phenyl) oxazol-4-yl]benzenesulfonamide; 4- 2-benzyl-5- (4-fluorophenyl) oxazol-4- y1]benzenesulfonamide;
4- 2-benzyl-5- (3 , 4-difluorophenyl) oxazol-4- y1]benzenesulfonamide; 2-benzyl-5- (4-chlorophenyl) oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (3 , 4-dichlorophenyl) oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5- (3, 4-dimethoxyphenyl) oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5- (4-methylphenyl) oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (3, 4-dimethylphenyl) oxazol-4- y1]benzenesulfonamide; 2-benzyl-5- (3-chloro-4-methylphenyl) oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5- (4-chloro-3-methylphenyl) oxazol-4- y1]benzenesulfonamide;
4- 2-benzyl-5- (3-chloro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5- (4-chloro-3-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (3 , 5-dichloro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (3-fluoro-4-methylphenyl) oxazol-4- yl]benzenesulfonamide; 4- 2-benzyl-5- (4-fluoro-3-methylphenyl) oxazol-4- yl]benzenesulfonamide;
4- 2-benzyl-5- (3-fluoro-4-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (2-thienyl)oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (5-chloro-2-thienyl)oxazol-4- yl]benzenesulfonamide; 2-benzyl-5- (cyclohexyl) oxazol-4- yl]benzenesulfonamide;.
4- 2-benzyl-5- (1-cyclohexenyl) oxazol-4- yl]benzenesulfonamide; 4- 2- (ethyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- 2- (trifluoromethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (difluoromethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- (hydroxymethyl) -5-phenyloxazol-4- y1]benzenesulfonamide;
4- 2- (carboxy) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- 2- (methoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- (ethoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (n-propyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- 2- (benzyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- 2 - (phenoxymethyl) -5-phenyloxazol-4- y1]benzenesulfonamide;
4- 2- ( (4-chlorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- ( (4-fluorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- ( (4-carboxyphenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2- (2-phenethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (3-phenpropyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (carboxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (ethoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- (methoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; - [2- (2-quinolyloxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; - [2-benzyl-4-phenyloxazol-5-y1]benzenesulfonamide; - [2-benzyl-4- (3 , 4-difluorophenyl) oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (4-chlorophenyl) oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (3, 4-dichlorophenyl) oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (3, 4-dimethoxyphenyl) oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (4-methylphenyl)oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (3, 4-dimethylphenyl)oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (3-chloro-4-methylphenyl) oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (4-chloro-3-methylphenyl) oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (3-chloro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (4-chloro-3-methoxyphenyl)oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (3, 5-dichloro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (3-fluoro-4-methylphenyl) oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (4-fluoro-3-methylphenyl) oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (3-fluoro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (2-thienyl) oxazol-5- yl]benzenesulfonamide; - [2-benzyl-4- (5-chloro-2-thienyl) oxazol-5- yl]benzenesulfonamide; 4- 2-benzyl-4- (cyclohexyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (1-cyclohexenyl)oxazol-5- yl]benzenesulfonamide; 4- 2- (ethyl) -4-phenyloxazol-5-yl]benzenesulfonamide; 4- 2- (trifluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- 2- (difluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- 2 - (hydroxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- 2- (carboxy) -4-phenyloxazol-5-yl]benzenesulfonamide; 4- 2- (methoxycarbonyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- 2- (ethoxycarbonyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- 2- (propyl) -4-phenyloxazol-5-yl]benzenesulfonamide; 4- 2- (benzyl) -4-phenyloxazol-5-yl]benzenesulfonamide; 4- 2- (phenoxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- 2- ( (4-chlorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- 2- ( (4-fluorophenoxy)methyl) -4-phenyloxazol-5- y1]benzenesulfonamide; 4- 2- ( (4-carboxyphenoxy) ethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
4- 2- (2-phenethyl) -4-phenyloxazol-5- y1]benzenesulfonamide;
4- 2- (3-phenpropyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- 2- (carboxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- 2- (ethoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- 2- (methoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (2-quinolyloxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [5- (4-fluorophenyl) -2-methy1-oxazol-4- yl]benzenesulfonamide; 3- [5- (4-fluorophenyl) -4- (4-aminosulfonylphenyl) oxazol-
2-yl]propanoic acid; methyl 3- [5- (4-fluorophenyl) -4- (4-aminosulfonylphenyl) oxazol-2-yl]propanate; 4- [4- (4-fluorophenyl) -2- (2-phenylethyl) -oxazol-5- yl]benzenesulfonamide;
4- [4- (4-fluorophenyl) -2-methyl-oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2-phenyloxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (4-fluorophenyl)oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (3-phenylpropyl)oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (n-propyl)oxazol-5- yl]benzenesulfonamide;
4- [2- (tert-butyl) -4- (4-fluorophenyl)oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (4-methoxyphenyl)methyloxazol-
5-yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (3-methoxyphenyl)methyloxazol-
5-yl]benzenesulfonamide; 4- [2-diphenylmethyl-4- (4-fluorophenyl)oxazol-5- yl]benzenesulfonamide; 2 - [4- (4-fluorophenyl) -5- [4-aminosulfonylphenyl]oxazol- 2-yl] cetic acid; ethyl 2- [4- (4-fluorophenyl) -5- [4-aminosulfonylphenyl] oxazol-2-yl]acetate; 3- [4- (4-fluorophenyl) -5- [4-aminosulfonylphenyl]oxazol-
2-yl]propanoic acid; methyl 3- [4- (4-fluorophenyl) -5- [4- aminosulfonylphenyl]oxazol-2-yl]propanate; 4- [4- (4-fluorophenyl) -5- [4-aminosulfonylphenyl]oxazol- 2-yl]butanoic acid; methyl 4- [4- (4-fluorophenyl) -5- [4-aminosulfonyl phenyl]oxazol-2-yl]butanate; 3- [4- (4-fluorophenyl) -5- [4-aminosulfonyl phenyl] oxazol-2-yl]propanamide; ethyl 2- [4- (4-fluorophenyl) -5- [4-aminosulfonyl phenyl] oxazol-2-yl] -2-benzyl-acetate;
4- [4- (4-fluorophenyl) -2- (cyclohexylethyl) oxazol-5- yl]benzenesulfonamide;
4- [4- (4-fluorophenyl) -2- (3-fluorophenoxymethyl) oxazol-
5-yl]benzenesulfonamide; [4- (4-fluorophenyl) -2- (3-chlorophenoxymethyl) oxazol-
5-yl]benzenesulfonamide;
4- [4- (4-fluorophenyl) -2- (pyridyloxymethyl) oxazol-5- yl]benzenesulfonamide; [4- (4-fluorophenyl) -2-phenoxymethyloxazol-5- yl]benzenesulfonamide;
4- [4- (4-fluorophenyl) -2- (2-hydroxyethyl) oxazol-5- y1]benzenesulfonamide;
4- [4- (4-fluorophenyl) -2- (hydroxymethyl) oxazol-5- y1]benzenesulfonamide;
4- [4- (cyclohexyl) -2-phenyloxazol-5- yl]benzenesulfonamide; [4- (4-fluorophenyl) -2-benzyloxymethyloxazol-5- yl]benzenesulfonamide;
4- [4- (4-fluorophenyl) -2-cyclohexyloxazol-5- yl]benzenesulfonamide; and 4- [5- (4-fluorophenyl) -2-phenyloxazol-4- yl]benzenesulfonamide.
25. A method of treating inflammation or an inflammation-associated disorder in a subject, said method comprising administering to the subject having such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a compound of Formula I
Figure imgf000163_0001
wherein R is selected from hydrido, alkyl, hydroxyalkyl, haloalkyl, alkenyl, hydroxyalkenyl, alkynyl, hydroxyalkynyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, heteroaryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, carboxy, carboxyalkyl, arylthioalkyl, aminocarbonylalkyl, N-alkylaminocarbonylalkyl and N,N-dialkylaminocarbonylalkyl; wherein R^- is selected from cycloalkyl, cycloalkenyl, aryl and heteroaryl, wherein Rl is optionally substituted at a substitutable position by alkyl, alkoxy and halo; and wherein R2 is selected from alkyl, haloalkyl and amino; or a pharmaceutically-acceptable salt thereof. 26. The method of Claim 25 wherein R is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower alkenyl, lower hydroxyalkenyl, lower alkynyl, lower hydroxyalkynyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower aralkoxyalkyl optionally substituted at a substitutable position with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonyl, lower alkoxycarbonylalkyl, carboxy, lower carboxyalkyl, lower arylthioalkyl, lower aminocarbonylalkyl, lower N- alkylaminocarbonylalkyl and lower N,N- dialkylaminocarbonylalkyl; wherein R-L is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl and heteroaryl selected from pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3-thianaphthalenyl, 2,3- dihydrothianaphthalenyl, 2,3-benzofuryl, and 2,3- dihydrobenzofuryl, wherein R-1- is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; and wherein R2 is selected from lower alkyl, lower haloalkyl and amino; or a pharmaceutically-acceptable salt or prodrug thereof.
27. The method of Claim 26 wherein R is selected from hydrido, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, 1-propenyl, 2-propenyl, 1- butenyl, 2-butenyl, 3-butenyl, hydroxyethenyl, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2- butynyl, 3-butynyl, hydroxyethynyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n- propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl and quinolyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert- butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenyl ethyl and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position on the phenyl radical with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position on the phenyl radical with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, carboxy, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy and butoxy, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, carboxy, acetyl, propanoic, butanoic, pentanoic, hexanoic, phenylthiomethyl, aminocarbonylmethyl, N-methylaminocarbonylmethyl and N,N-dimethylaminocarbonylmethyl; wherein R! is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, eye1openteny1, cycloheptenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2, 3-thianaphthalenyl, 2,3- dihydrothianaphthalenyl, 2 , 3-benzofuryl, and 2,3- dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; and wherein R2 is selected from methyl, ethyl, fluoromethyl, difluoromethyl, trifluoromethyl and amino; or a pharmaceutically-acceptable salt or prodrug thereof . 28. The method of Claim 27 selected from compounds, their prodrugs and their pharmaceutically- acceptable salts, of the group consisting of
4- [2-benzyl-5- (phenyl) oxazol-4-yl]benzenesulfonamide; 4- [2-benzyl-5- (4-fluorophenyl)oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3,4-difluorophenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-chlorophenyl)oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3,4-dichlorophenyl)oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (4-methoxyphenyl)oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3, 4-dimethoxyphenyl) oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (4-methylphenyl) oxazol-4- y1]benzenesulfonamide;
4- [2-benzyl-5- (3 , 4-dimethylphenyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3-chloro-4-methylphenyl) oxazol-4- yl]benzenesulfonamide; [2-benzyl-5- (4-chloro-3-methylphenyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3-chloro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (4-chloro-3-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3 , 5-dichloro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3-fluoro-4-methylphenyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (4-fluoro-3-methylphenyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3-fluoro-4-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (2-thienyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (5-chloro-2-thienyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (cyclohexyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (1-cyclohexenyl) oxazol-4- yl]benzenesulfonamide; 2-benzyl-4- (4-methylsulfonylphenyl) -5-phenyloxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3,4- difluorophenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4- chlorophenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3,4- dichlorophenyl)oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (4- methoxyphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3,4- dimethoxyphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3, 4- dimethylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-chloro-4- methylphenyl)oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-chloro-3- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-chloro-4- methoxyphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-chloro-3- methoxyphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3, 5-dichloro-4- methoxyphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-fluoro-4- methylphenyl) oxazole;
2-benzyl-4- (4-methylsulfonylphenyl) -5- (4-fluoro-3- methylphenyl)oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (3-fluoro-4- methoxyphenyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (2- thienyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (5-chloro-2- thienyl) oxazole; 2-benzyl-4- (4-methylsulfonylphenyl) -5-
(cyclohexyl) oxazole-; 2-benzyl-4- (4-methylsulfonylphenyl) -5- (1- cyclohexenyl) oxazole;
2- (ethyl) -4- (4-methylsulfonylphenyl) -5-phenyloxazole; 2- (trifluoromethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (difluoromethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole;
2- (hydroxymethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (carboxy) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (methoxycarbonyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (ethoxycarbony1) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- (propyl) -4- (4-methylsulfonylphenyl) -5-phenyloxazole; 2- (benzyl) -4- (4-methylsulfonylphenyl) -5-phenyloxazole; 2- (phenoxymethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; 2- ( (4-chlorophenoxy)methyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- ( (4-fluorophenoxy)methyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- ( (4-carboxyphenoxy) ethyl) -4- (4- methylsulfonylphenyl) -5-phenyloxazole; 2- (2-phenethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole;
2- (3-phenpropyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; - (carboxymethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; - (ethoxycarbonylmethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; - (methoxycarbonylmethyl) -4- (4-methylsulfonylphenyl) -
5-phenyloxazole; - (2-quinolyloxymethyl) -4- (4-methylsulfonylphenyl) -5- phenyloxazole; - [2- (ethyl) -5-phenyloxazol-4-yl] enzenesulfonamide; - [2- (trifluoromethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; - [2- (difluoromethyl) -5-phenyloxazol-4- y1]benzenesulfonamide; [2- (hydroxymethyl) -5-phenyloxazol-4- y1]benzenesulfonamide; - [2- (carboxy) -5-phenyloxazol-4-yl]benzenesulfonamide; - [2- (methoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide; - [2- (ethoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide; - [2- (propyl) -5-phenyloxazol-4-yl]benzenesulfonamide; - [2- (benzyl) -5-phenyloxazol-4-yl]benzenesulfonamide; - [2- (phenoxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; [2- ( (4-chlorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; [2- ( (4-fluorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; - [2- ( (4-carboxyphenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; - [2- (2-phenethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; - [2- (3-phenpropyl) -5-phenyloxazol-4- y1]benzenesulfonamide; - [2- (carboxymethyl) -5-phenyloxazol-4- y1]benzenesulfonamide; 4- [2- (ethoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; [2- (methoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (2-quinolyloxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- [2-benzy1-4-phenyloxazol-5-yl]benzenesulfonamide; 4- [2-benzyl-4- (4-fluorophenyl)oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (3, 4-difluorophenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (4-chlorophenyl) oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (3, 4-dichlorophenyl) oxazol-5- y1]benzenesulfonamide;
4- [2-benzyl-4- (4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (3 , 4-dimethoxyphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (4-methylphenyl) oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (3 , 4-dimethylphenyl) oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (3-chloro-4-methylphenyl) oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (4-chloro-3-methylphenyl) oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (3-chloro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (4-chloro-3-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (3, 5-dichloro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (3-fluoro-4-methylphenyl)oxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (4-fluoro-3-methylphenyl) oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (3-fluoro-4-methoxyphenyl)oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (2-thienyl)oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (5-chloro-2-thienyl)oxazol-5- y1]benzenesulfonamide; 4- [2-benzyl-4-(cyclohexyl)oxazol-5- yl]benzenesulfonamide; 4- [2-benzyl-4- (1-cyclohexenyl)oxazol-5- yl]benzenesulfonamide;
2-benzyl-5- (4-methylsulfonylphenyl) -4-phenyloxazole; 2-benzyl-5-(4-methylsulfonylphenyl) -4- (3,4- difluorophenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4- chlorophenyl)oxazol-4-yl]benzenesulfonamide; 2-benzyl-5-(4-methylsulfonylphenyl) -4- (3,4- dichlorophenyl)oxazole; 2-benzyl-5-(4-methylsulfonylphenyl) -4-(4- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3,4- dimethoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4- methylphenyl)oxazole; 2-benzyl-5-(4-methylsulfonylphenyl) -4-(3,4- dimethylphenyl)oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-chloro-4- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4-(4-chloro-3- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-chloro-4- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4-chloro-3- methoxyphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4-(3,5-dichloro-4- methoxyphenyl)oxazole;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-fluoro-4- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (4-fluoro-3- methylphenyl)oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (3-fluoro-4- methoxyphenyl) oxazole; 2-benzyl-5- (4-me hylsulfonylphenyl) -4- (2- thienyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (5-chloro-2- thienyl) oxazole; 2-benzyl-5- (4-methylsulfonylphenyl) -4- (cyclohexyl) oxazole-;
2-benzyl-5- (4-methylsulfonylphenyl) -4- (2- cyclohexenyl)oxazole; 2- (ethyl) -5- (4-methylsulfonylphenyl) -4-phenyloxazole; 2- (trifluoromethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole;
2- (difluoromethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2- (hydroxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2 - (carboxy) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2- (methoxycarbonyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2- (ethoxycarbonyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole;
2- (propyl) -5- (4-methylsulfonylphenyl) -4-phenyloxazole; 2- (benzyl) -5- (4-methylsulfonylphenyl) -4-phenyloxazole; 2- (phenoxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; 2- ( (4-chlorophenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; 2- ( (4-fluorophenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole; 2- ( (4-carboxyphenoxy)methyl) -5- (4- methylsulfonylphenyl) -4-phenyloxazole;
2- (2-phenethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; - (3-phenpropyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; - (carboxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; - (ethoxycarbonylmethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; - (methoxycarbonylmethyl) -5- (4-methylsulfonylphenyl) -
4-phenyloxazole; - (2-quinolyloxymethyl) -5- (4-methylsulfonylphenyl) -4- phenyloxazole; - [2- (ethyl) -4-phenyloxazol-5-yl]benzenesulfonamide; - [2- (trifluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; - [2- (difluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; [2- (hydroxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; - [2- (carboxy) -4-phenyloxazol-5-yl]benzenesulfonamide; - [2- (methoxycarbonyl) -4-phenyloxazol-5- yl]benzenesulfonamide; [2- (ethoxycarbonyl) -4-phenyloxazol-5- yl]benzenesulfonamide; - [2- (propyl) -4-phenyloxazol-5-yl]benzenesulfonamide; - [2- (benzyl) -4-phenyloxazol-5-yl]benzenesulfonamide; - [2- (phenoxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; [2- ( (4-chlorophenoxy) ethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; - [2- ( (4-fluorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; - [2- ( (4-carboxyphenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; - [2- (2-phenethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; [2- (3-phenpropyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (carboxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (ethoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (methoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (2-quinolyloxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 5- (4-fluorophenyl) -2-methyl-4- [4- (methylsulfonyl)phenyl] oxazole;
3- [5- (4-fluorophenyl) -4- [4- (methylsulfonyl)phenyl] oxazol-2-yl] ropanoic acid; methyl 3- [5- (4-fluorophenyl) -4- [4- (methylsulfonyl) phenyl] oxazol-2-yl]propanate; 4-(4-fluorophenyl)-2-(2-phenyl)ethyl-5-(4-
(methylsulfonyl)phenyl)oxazole; 4- (4-fluorophenyl) -2-methyl-5- [4-
(methylsulfonylphenyl] oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl) henyl] -2- phenyloxazole;
2-benzyl-4- (4-fluorophenyl) -5- (4-
(methylsulfonyl)phenyl) oxazole; 4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2- (3- phenyl)propyloxazole; 4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2- propyloxazole; 2- (tert-butyl) -4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl] oxazole; 4- (4-fluorophenyl) -2 - (4-methoxyphenyl)methyl-5- [4- methylsulfonylphenyl] oxazole
4- (4-fluorophenyl) -2- (3-methoxyphenyl)methyl-5- [4- methylsulfonylphenyl] oxazole; 2-diphenylmethyl-4- (4-fluorophenyl) -5- [4- ethylsulfonylphenyl] oxazole; 2-[4-(4-fluorophenyl)-5-[4- methylsulfonylphenyl] oxazol-2-yl] acetic acid; ethyl 2- [4- (4-fluorophenyl) -5- [4- methylsulfonyl) henyl] oxazol-2-yl] acetate; 3- [4- (4-fluorophenyl) -5- [4- methylsulfonyl)phenyl] oxazol-2-yl]propanoic acid; methyl 3- [4- (4-fluorophenyl) -5- [4- methylsulfonyl)phenyl] oxazol-2-yl]propanate; 4- [4- (4-fluorophenyl) -5- [4- methylsulfonyl)phenyl] oxazol-2-yl]butanoic acid; methyl 4- [4- (4-fluorophenyl) -5- [4-methylsulfonyl) phenyl] oxazol-2-yl]butanate;
3- [4- (4-fluorophenyl) -5- [4-methylsulfonyl) phenyl] oxazol-2-yl]propanamide; ethyl 2- [4- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl] oxazol-2-yl] -2-benzyl-acetate; 4- (4-fluorophenyl) -2- (cyclohexylethyl) -5- [4- (methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2- (3-fluorophenoxymethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (3-chlorophenoxymethyl) -5- [4- (methylsulfonyl)phenyl]oxazole;
4- (4-fluorophenyl) -2- (pyridyloxymethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenoxymethyloxazole; 4- (4-fluorophenyl) -2- (2-hydroxyethyl) -5- [4- (methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (hydroxymethyl) -5- [4-
( ethylsulfonyl)phenyl]oxazole; 4- (cyclohexyl) -2-phenyl-5- [4- (methylsulfonyl)phenyl] oxazole;
4- (4-fluorophenyl) -2-benzyloxymethyl-5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2-cyclohexyl-5- [4-
(methylsulfonyl)phenyl] oxazole; and 5- (4-fluorophenyl) -2-phenyl-4- [4-
(methylsulfonyl)phenyl]oxazole. 29. The method of Claim 25 wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R^ is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo, and wherein R2 is methyl; or a pharmaceutically-acceptable salt thereof.
30. The method of Claim 29 wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and wherein R^ is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2,3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2, 3-dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically-acceptable salt or prodrug thereof.
31. The method of Claim 30 wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethyl and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, pentanoic, hexanoic and aminocarbonylmethyl; and wherein Rl is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2- cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2, 3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2, 3-dihydrobenzofuryl, wherein R-^- is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert- butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; or a pharmaceutically-acceptable salt or prodrug thereof.
32. The method of Claim 31 selected from compounds, their prodrugs and their pharmaceutically- acceptable salts, of the group consisting of
5- (4-fluorophenyl) -2-methyl-4- [4-
(methylsulfonyl)phenyl] oxazole; [5- (4-fluorophenyl) -4- [4- (methylsulfonyl)phenyl] -2- oxazol-2-yl]propanoic acid; methyl 3- [5- (4-fluorophenyl) -4- [4- (methylsulfonyl) phenyl] -2-oxazol-2-yl]propanate; 4- (4-fluorophenyl) -2 - (2-phenylethyl) -5- (4- (methylsulfonyl)phenyl) oxazole; 4- (4-fluorophenyl) -2-methyl-5- [4- methylsulfonylphenyl]oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenyloxazole;
2-benzyl-4- (4-fluorophenyl) -5- (4-
(methylsulfonyl)phenyl)oxazole; 4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2- (3- phenyl)propyloxazole; 4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] -2 - propyloxazole; 2- (tert-butyl) -4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl] oxazole; 4- (4-fluorophenyl) -2- (4-methoxyphenyl)methyl-5- [4- methylsulfonylphenyl]oxazole
4- (4-fluorophenyl) -2- (3-methoxyphenyl)methyl-5- [4- methylsulfonylphenyl] oxazole; 2-diphenylmethyl-4- (4-fluorophenyl) -5- [4- methylsulfonylphenyl] oxazole; 2- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] oxazol- 2-yl]acetic acid; ethyl 2- [4- (4-fluorophenyl) -5- [4-methylsulfonyl phenyl]oxazol-2-yl]acetate; 3- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] oxazol- 2-yl]propanoic acid; methyl 3- [4- (4-fluorophenyl) -5- [4-methylsulfonyl phenyl]oxazol-2-yl]propanate; 4- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl]oxazol- 2-yl]butanoic acid; methyl 4- [4- (4-fluorophenyl) -5- [4-methylsulfonyl phenyl]oxazol -2-yl]butanate; 3- [4- (4-fluorophenyl) -5- [4-methylsulfonylphenyl] oxazol-
2-yl]propanamide; ethyl 2- [4- (4-fluorophenyl) -5- [4- (methylsulfonyl) phenyl]oxazol-2-yl] -2-benzyl acetate;
4- (4-fluorophenyl) -2- (cyclohexylethyl) -5- [4- ( ethylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2- (3-fluorophenoxymethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (3-chlorophenoxymethyl) -5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2- (pyridyloxymethyl) -5- [4-
( ethylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -5- [4- (methylsulfonyl)phenyl] -2- phenoxymethyl oxazole; 4- (4-fluorophenyl) -2- (2-hydroxy) ethyl) -5- [4- (methylsulfonyl)phenyl] oxazole;
4- (4-fluorophenyl) -2- (hydroxymethyl) -5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (cyclohexyl) -2-phenyl-5- [4-
(methylsulfonyl)phenyl] oxazole; 4- (4-fluorophenyl) -2-benzyloxymethyl-5- [4-
(methylsulfonyl)phenyl]oxazole; 4- (4-fluorophenyl) -2-cyclohexyl-5- [4-
(methylsulfonyl)phenyl] oxazole; and 5- (4-fluorophenyl) -2-phenyl-4- [4- (methylsulfonyl)phenyl] oxazole.
33. The method of Claim 25 wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R- is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo; and wherein R2 is amino; or a pharmaceutically-acceptable salt thereof; provided R is not methyl.
34. The method of Claim 33 wherein R is selected from lower alkyl, lower hydroxyalkyl, lower haloalkyl, lower cycloalkyl, lower cycloalkylalkyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower aralkyl optionally substituted at a substitutable position on the aryl radical by halo, carboxy, lower alkyl and lower alkoxy, lower aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, lower alkyl and lower alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by halo, carboxy, lower alkyl and lower alkoxy, lower heteroaryloxyalkyl optionally substituted at a substitutable position on the heteroaryl radical with halo, carboxy, lower alkyl and lower alkoxy, lower alkoxycarbonylalkyl, lower carboxyalkyl and lower aminocarbonylalkyl; and wherein R^ is selected from lower cycloalkyl, lower cycloalkenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2, 3-thianaphthalenyl, 2,3- dihydrothianaphthalenyl, 2, 3-benzofuryl, and 2,3- dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by lower alkyl, lower alkoxy and halo; or a pharmaceutically- acceptable salt or prodrug thereof.
35. The method of Claim 34 wherein R is selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cycloheptylmethyl, aryl selected from phenyl and naphthyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyl, phenethyl, diphenylmethy1 and phenpropyl, optionally substituted at a substitutable position on the phenyl radical by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, phenoxymethyl optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, benzyloxymethyl optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, pyridyloxymethyl and quinolyloxymethyl, optionally substituted at a substitutable position by fluoro, chloro, bromo, iodo, methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, isobutyl, carboxy, methoxy, ethoxy, propoxy and butoxy, methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, acetyl, propanoic, butanoic, pentanoic, hexanoic and aminocarbonylmethyl; and wherein R1 is selected from cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 1-cyclohexenyl, 2- cyclohexenyl, 3-cyclohexenyl, phenyl, naphthyl, pyridyl, thienyl, thiazolyl, oxazolyl, imidazolyl, furyl, quinolyl, benzothiazolyl, 2,3- thianaphthalenyl, 2, 3-dihydrothianaphthalenyl, 2,3- benzofuryl, and 2, 3-dihydrobenzofuryl, wherein R^ is optionally substituted at a substitutable position by methyl, ethyl, n-propyl, isopropyl, butyl, tert- butyl, isobutyl, methoxy, ethoxy, propoxy, butoxy, fluoro, chloro, bromo and iodo; or a pharmaceutically-acceptable salt or prodrug thereof.
36. Compound of Claim 35 selected from compounds, their prodrugs and their pharmaceutically- acceptable salts, of the group consisting of
4- [2-benzyl-5- (phenyl) oxazol-4-yl]benzenesulfonamide; 4- [2-benzyl-5- (4-fluorophenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3,4-difluorophenyl)oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (4-chlorophenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3,4-dichlorophenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3,4-dimethoxyphenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-methylphenyl)oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3,4-dimethylphenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3-chloro-4-methylphenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-chloro-3-methylphenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3-chloro-4-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-chloro-3-methoxyphenyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3, 5-dichloro-4-methoxyphenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (3-fluoro-4-methylphenyl)oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (4-fluoro-3-methylphenyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (3-fluoro-4-methoxyphenyl)oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (2-thienyl) oxazol-4- yl]benzenesulfonamide; 4- [2-benzyl-5- (5-chloro-2-thienyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (cyclohexyl) oxazol-4- yl]benzenesulfonamide;
4- [2-benzyl-5- (1-cyclohexenyl) oxazol-4- yl]benzenesulfonamide;
4- [2- (ethyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- [2- (trifluoromethyl) -5-phenyloxazol-4- y1]benzenesulfonamide; 4- [2- (difluoromethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- [2- (hydroxymethyl) -5-phenyloxazol-4- y1]benzenesulfonamide; 4- [2- (carboxy) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- [2- (methoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- [2- (ethoxycarbonyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- [2- (n-propyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- [2- (benzyl) -5-phenyloxazol-4-yl]benzenesulfonamide; 4- [2- (phenoxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- ( (4-chlorophenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 2-( (4-fluorophenoxy) ethyl) -5-phenyloxazol-4- yl] enzenesulfonamide;
4- 2- ( (4-carboxyphenoxy)methyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- (2-phenethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2- (3-phenpropyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2-(carboxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2-(ethoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide; 4- 2-(methoxycarbonylmethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2- (2-quinolyloxymethyl) -5-phenyloxazol-4- yl]benzenesulfonamide;
4- 2-benzy1-4-phenyloxazol-5-yl]benzenesulfonamide; 4- 2-benzyl-4- (3,4-difluorophenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (4-chlorophenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (3,4-dichlorophenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (4-methoxyphenyl)oxazol-5- yl]benzenesulfonamide;
4- 2-benzyl-4- (3,4-dimethoxyphenyl)oxazol-5- yl]benzenesulfonamide; 4- 2-benzyl-4-(4-methylphenyl)oxazol-5- yl]benzenesulfonamide; 4- 2-benzyl-4- (3,4-dimethylphenyl)oxazol-5- yl]benzenesulfonamide; 4- 2-benzyl-4- (3-chloro-4-methylphenyl)oxazol-5- yl]benzenesulfonamide; 2-benzyl-4- (4-chloro-3-methylphenyl)oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (3-chloro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (4-chloro-3-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (3, 5-dichloro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (3-fluoro-4-methylphenyl)oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (4-fluoro-3-methylphenyl) oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (3-fluoro-4-methoxyphenyl) oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (2-thienyl) oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (5-chloro-2-thienyl) oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (cyclohexyl) oxazol-5- yl]benzenesulfonamide; [2-benzyl-4- (1-cyclohexenyl) oxazol-5- yl]benzenesulfonamide; [2- (ethyl) -4-phenyloxazol-5-yl]benzenesulfonamide; [2- (trifluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; [2- (difluoromethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
■ [2- (hydroxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
■ [2- (carboxy) -4-phenyloxazol-5-yl]benzenesulfonamide; • [2- (methoxycarbonyl) -4-phenyloxazol-5- yl]benzenesulfonamide;
■ [2- (ethoxycarbonyl) -4-phenyloxazol-5- yl]benzenesulfonamide; [2- (propyl) -4-phenyloxazol-5-yl]benzenesulfonamide; [2- (benzyl) -4-phenyloxazol-5-yl]benzenesulfonamide; [2- (phenoxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (4-chlorophenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- ( (4-fluorophenoxy)methyl) -4-phenyloxazol-5- y1]benzenesulfonamide; 4-[2-( (4-carboxyphenoxy)methyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (2-phenethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (3-phenpropyl) -4-phenyloxazol-5- yl] enzenesulfonamide;
4- [2- (carboxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (ethoxycarbonylmethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [2- (methoxycarbonylmethyl) -4-phenyloxazol-5- y1]benzenesulfonamide; 4- [2- (2-quinolyloxymethyl) -4-phenyloxazol-5- yl]benzenesulfonamide; 4- [5- (4-fluorophenyl) -2-methyl-oxazol-4- yl]benzenesulfonamide;
3- [5- (4-fluorophenyl) -4- (4-aminosulfonylphenyl) oxazol-
2-yl]propanoic acid; methyl 3- [5- (4-fluorophenyl) -4- (4-aminosulfonylphenyl) oxazol-2-yl]propanate; 4- [4- (4-fluorophenyl) -2- (2-phenylethyl) -oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2-methyl-oxazol-5- yl] enzenesulfonamide; 4- [4- (4-fluorophenyl) -2-phenyloxazol-5- yl]benzenesulfonamide;
4- [2-benzyl-4- (4-fluorophenyl) oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (3-phenylpropyl)oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (n-propyl) oxazol-5- y1]benzenesulfonamide; 4- [2- (tert-butyl) -4- (4-fluorophenyl) oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (4-methoxyphenyl)methyloxazol-
5-yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (3-methoxyphenyl)methyloxazol-
5-yl]benzenesulfonamide; 4- [2-diphenylmethyl-4- (4-fluorophenyl) oxazol-5- yl]benzenesulfonamide; 2- [4- (4-fluorophenyl) -5- [4-aminosulfonylphenyl] oxazol- 2-yl]acetic acid; ethyl 2- [4- (4-fluorophenyl) -5- [4-aminosulfonylphenyl] oxazol-2-yl]acetate; 3- [4- (4-fluorophenyl) -5- [4-aminosulfonylphenyl] oxazol-
2-yl]propanoic acid; methyl 3- [4- (4-fluorophenyl) -5- [4- aminosulfonylphenyl]oxazol-2-yl]propanate; 4- [4- (4-fluorophenyl) -5- [4-aminosulfonylphenyl] oxazol-
2-yl]butanoic acid; methyl 4- [4- (4-fluorophenyl) -5- [4-aminosulfonyl phenyl] oxazol-2-yl]butanate;
3- [4- (4-fluorophenyl) -5- [4-aminosulfonyl phenyl]oxazol-2-yl]propanamide; ethyl 2- [4- (4-fluorophenyl) -5- [4-aminosulfonyl phenyl] oxazol-2-yl] -2-benzyl-acetate; 4- [4- (4-fluorophenyl) -2- (cyclohexylethyl)oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (3-fluorophenoxymethyl) oxazol-
5-yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (3-chlorophenoxymethyl) oxazol- 5-yl]benzenesulfonamide;
4- [4- (4-fluorophenyl) -2- (pyridyloxymethyl) oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2-phenoxymethyloxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (2-hydroxyethyl) oxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2- (hydroxymethyl) oxazol-5- yl]benzenesulfonamide; 4- [4- (cyclohexyl) -2-phenyloxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2-benzyloxymethyloxazol-5- yl]benzenesulfonamide; 4- [4- (4-fluorophenyl) -2-cyclohexyloxazol-5- yl]benzenesulfonamide; and 4- [5- (4-fluorophenyl) -2-phenyloxazol-4- yl]benzenesulfonamide.
37. The method of Claim 25 for use in treatment of inflammation.
38. The method of Claim 25 for use in treatment of an inflammation-associated disorder.
39. The method of Claim 38 wherein the inflammation-associated disorder is arthritis.
41. The method of Claim 38 wherein the inflammation-associated disorder is pain.
42. The method of Claim 38 wherein the inflammation-associated disorder is fever.
RECTIFIED SHEET (RULE 91) ISA/EP
PCT/US1994/005395 1993-05-21 1994-05-19 Substituted oxazolyl compounds for the treatment of inflammation WO1994027980A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AT94917983T ATE221054T1 (en) 1993-05-21 1994-05-19 SUBSTITUTED OXAZOLYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATION
DE69431056T DE69431056T2 (en) 1993-05-21 1994-05-19 SUBSTITUTED OXAZOLYL DERIVATIVES FOR TREATING INFLAMMATION
EP94917983A EP0699192B1 (en) 1993-05-21 1994-05-19 Substituted oxazolyl compounds for the treatment of inflammation
DK94917983T DK0699192T3 (en) 1993-05-21 1994-05-19 Substituted oxazolyl compounds for the treatment of inflammation
CA002161769A CA2161769A1 (en) 1993-05-21 1994-05-19 Substituted oxazolyl compounds for the treatment of inflammation
JP7500726A JPH08510736A (en) 1993-05-21 1994-05-19 Substituted oxazolyl compounds for treating inflammation
US08/535,227 US5719163A (en) 1993-05-21 1994-05-19 Substituted oxazolyl compounds for the treatment of inflammation
AU69495/94A AU6949594A (en) 1993-05-21 1994-05-19 Substituted oxazolyl compounds for the treatment of inflammation
US09/203,451 US6090834A (en) 1993-05-21 1998-12-01 Substituted oxazoles for the treatment of inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/065,730 1993-05-21
US08/065,730 US5380738A (en) 1993-05-21 1993-05-21 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/065,730 Continuation-In-Part US5380738A (en) 1993-05-21 1993-05-21 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US44531295A Continuation-In-Part 1993-05-21 1995-05-19

Publications (1)

Publication Number Publication Date
WO1994027980A1 true WO1994027980A1 (en) 1994-12-08

Family

ID=22064709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/005395 WO1994027980A1 (en) 1993-05-21 1994-05-19 Substituted oxazolyl compounds for the treatment of inflammation

Country Status (11)

Country Link
US (2) US5380738A (en)
EP (1) EP0699192B1 (en)
JP (1) JPH08510736A (en)
AT (1) ATE221054T1 (en)
AU (1) AU6949594A (en)
CA (1) CA2161769A1 (en)
DE (1) DE69431056T2 (en)
DK (1) DK0699192T3 (en)
ES (1) ES2180580T3 (en)
PT (1) PT699192E (en)
WO (1) WO1994027980A1 (en)

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019462A1 (en) * 1994-12-20 1996-06-27 Japan Tobacco Inc. Oxazole derivatives and use thereof
WO1996019463A1 (en) * 1994-12-20 1996-06-27 Japan Tobacco Inc. Heteroaromatic oxazole compounds and use thereof
WO1996036617A1 (en) * 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
WO1996038418A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
WO1996038442A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
WO1996041645A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
WO1997034882A1 (en) * 1996-03-21 1997-09-25 Almirall Prodesfarma, S.A. 2-(3h)-oxazolone derivatives and their use as cox-2 inhibitors
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US5719163A (en) * 1993-05-21 1998-02-17 G.D. Searle & Co. Substituted oxazolyl compounds for the treatment of inflammation
WO1998011080A1 (en) * 1996-09-13 1998-03-19 Laboratoires Upsa Novel 3,4-diaryloxazolone derivatives, methods of preparation and therapeutic uses thereof
WO1998047509A1 (en) * 1997-04-18 1998-10-29 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
WO1999014205A1 (en) * 1997-09-12 1999-03-25 Almirall Prodesfarma S.A. New 2-(3h)-oxazolone derivatives
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
US5968974A (en) * 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6045773A (en) * 1995-10-17 2000-04-04 G.D. Searle & Co. Method of detecting cyclooxygenase-2
US6090834A (en) * 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US6172096B1 (en) 1996-02-13 2001-01-09 G. D. Searle & Co. Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist
US6376528B1 (en) 1996-02-13 2002-04-23 G. D. Searle & Co. Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6407140B1 (en) 1996-02-13 2002-06-18 G.D. Searle & Co. Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6573252B1 (en) 1998-07-28 2003-06-03 Nicox, S.A. Medicine nitrate salts
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
US6613789B2 (en) 1994-07-28 2003-09-02 G. D. Searle & Co. Heterocyclo-substituted imidazoles for the treatment of inflammation
US6613790B2 (en) 2001-04-17 2003-09-02 Pharmacia Corporation Prodrugs of COX-2 inhibitors
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US6649629B2 (en) 1999-12-23 2003-11-18 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US6936632B2 (en) 2000-01-13 2005-08-30 Merckle Gmbh Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof
WO2005080357A2 (en) * 2004-02-13 2005-09-01 Sanofi-Aventis Oxazole derivatives, preparation and therapeutic use therof
US6998415B2 (en) 1996-05-31 2006-02-14 Pharmacia Corporation Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US7067159B2 (en) 2003-12-05 2006-06-27 New Chapter, Inc. Methods for treating prostate cancer with herbal compositions
US7070816B2 (en) 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
US7211598B2 (en) 2002-06-28 2007-05-01 Nitromed, Inc. Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
US7320996B2 (en) 2001-08-15 2008-01-22 Sugen, Inc Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer
US7329401B2 (en) 2002-04-15 2008-02-12 The Regents Of The University Of California Cyclooxygenase-2 selective agents useful as imaging probes and related methods
WO2008077599A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS
EP1977749A1 (en) 1996-10-15 2008-10-08 G.D. Searle LLC Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7622142B2 (en) 2004-09-14 2009-11-24 New Chapter Inc. Methods for treating glioblastoma with herbal compositions
EP2196201A2 (en) 2002-12-13 2010-06-16 Warner-Lambert Company LLC Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms
US7790738B2 (en) 2000-07-20 2010-09-07 Lauras As Methods of treating and preventing AIDS using of COX-2 inhibitors
US7838023B2 (en) 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
US8067414B2 (en) 2006-03-29 2011-11-29 Nicox S.A. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8367038B2 (en) 2004-05-23 2013-02-05 HMI Medical Innovations, LLC Therameutin modulators
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
US8541471B2 (en) 2003-05-07 2013-09-24 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
WO2016177776A1 (en) 2015-05-04 2016-11-10 Academisch Medisch Centrum Biomarkers for the detection of aspirin insensitivity
US10562916B2 (en) 2010-05-26 2020-02-18 Sunovion Pharmaceuticals, Inc. Substituted quinoxalines as PDE-10 inhibitors

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69625709D1 (en) 1995-09-29 2003-02-13 Shionogi & Co ALPHA-SUBSTITUTED HETEROCYCLIC BENZYL DERIVATIVES, INTERMEDIATE COMPOUNDS TO THEIR PRODUCTION AND PESTICIDES THAT CONTAIN THEM AS AN ACTIVE COMPONENT
US5945538A (en) * 1996-06-28 1999-08-31 American Cyanamid Company Ammonium oxazole and amino oxazolium intermediates, methods for the preparation thereof and the use therefor in the manufacture of insecticidal arylpyrroles
US5925773A (en) * 1996-06-28 1999-07-20 American Cyanamid Company Ammonium oxazole and amino oxazolium intermediates, methods for the preparation thereof and the use thereof in the manufacture of insecticidal arylpyrroles
US5777132A (en) * 1996-06-28 1998-07-07 American Cyanamid Company Process for the manufacture of 2-aryl-5 perfluoroalkylpyrrole derivatives
US5750726A (en) * 1996-06-28 1998-05-12 American Cyanamid Company Process for the manufacture of 2-aryl-5-perfluoroalkylpyrrole derivatives and intermediates useful therefor
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US20010024664A1 (en) * 1999-03-19 2001-09-27 Obukowicz Mark G. Selective COX-2 inhibition from edible plant extracts
FR2800373B1 (en) * 1999-10-27 2001-12-07 Oreal PROCESS FOR THE PREPARATION OF TRISUBSTITUTED OXAZOLES
ES2236007T3 (en) * 1999-12-08 2005-07-16 Pharmacia Corporation CYCLLOXYGENASA-2 EU INHIBITOR COMPOSITIONS HAS A FAST THERAPEUTIC EFFECT.
AU2001255600A1 (en) * 2000-04-25 2001-11-07 Pharmacia Corporation Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
AU5754701A (en) * 2000-07-13 2002-01-30 Pharmacia Corp Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
PE20020146A1 (en) * 2000-07-13 2002-03-31 Upjohn Co OPHTHALMIC FORMULATION INCLUDING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR
AU2001285334A1 (en) * 2000-08-29 2002-03-13 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
US20020122836A1 (en) * 2000-12-15 2002-09-05 Pharmacia Corporation Selective COX-2 inhibition from non-edible plant extracts
AU2002229074A1 (en) * 2000-12-15 2002-06-24 Pharmacia Corporation Selective cox-2 inhibition from plant extracts
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2435350A1 (en) * 2001-02-02 2002-08-15 Pharmacia Corporation Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
MY137736A (en) 2001-04-03 2009-03-31 Pharmacia Corp Reconstitutable parenteral composition
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
US20030153801A1 (en) * 2001-05-29 2003-08-14 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
DE60234057D1 (en) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc COMPOSITIONS AND METHODS FOR MODULATING TRANSPORT BY THE BLOOD-BRAIN BARRIER
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US20030236308A1 (en) * 2001-09-18 2003-12-25 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
US20030114483A1 (en) * 2001-09-18 2003-06-19 Pharmacia Corporation Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
WO2003049678A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
US20040126438A1 (en) * 2001-12-13 2004-07-01 Obukowicz Mark G. Selective cox-2 inhibition from plant extracts
US20040062823A1 (en) * 2001-12-13 2004-04-01 Obukowicz Mark G. Selective cox-2 inhibition from non-edible plant extracts
TW562937B (en) * 2002-03-26 2003-11-21 Nanya Technology Corp Method for fast determining defect type of word line
MXPA04010397A (en) * 2002-04-22 2005-02-17 Pfizer Prod Inc Indol-2-ones as selective inhibitors of cyclooxygenase-2.
WO2003095623A2 (en) * 2002-05-10 2003-11-20 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
US20030225054A1 (en) * 2002-06-03 2003-12-04 Jingwu Duan Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
EP1534683A4 (en) * 2002-06-27 2005-08-24 Nitromed Inc Cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP1536863A1 (en) * 2002-07-02 2005-06-08 Pharmacia Corporation Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event
AU2003297397A1 (en) * 2002-12-19 2004-07-14 Pharmacia Corp Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
WO2004058354A1 (en) * 2002-12-20 2004-07-15 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
TW200505446A (en) * 2003-01-17 2005-02-16 Fuj Isawa Pharmaceutical Co Ltd Inhibitor of cox
US20050026902A1 (en) * 2003-01-31 2005-02-03 Timothy Maziasz Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
EP2266584B1 (en) * 2003-05-07 2012-09-05 Osteologix A/S Composition with strontium and vitamin D for the prophylaxis and/or treatment of cartilage and/or bone conditions
JP2007522084A (en) * 2003-06-24 2007-08-09 ファルマシア・コーポレーション Treatment of migraine with nausea
AU2004266705A1 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2005023183A2 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
US20090131342A1 (en) * 2004-01-22 2009-05-21 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
JP2007518788A (en) 2004-01-22 2007-07-12 ファイザー・インク Triazole derivatives that inhibit the antagonist activity of vasopressin
PE20060362A1 (en) * 2004-05-24 2006-05-15 Irm Llc OXAZOLE COMPOUNDS AS PPAR MODULATORS
CA2571807A1 (en) 2004-07-01 2006-01-19 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2005304770A1 (en) * 2004-11-08 2006-05-18 Nicox S.A. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
JP2008520578A (en) * 2004-11-15 2008-06-19 ニトロメッド インコーポレーティッド Diuretic compounds containing heterocyclic nitric oxide donor groups, compositions and methods of use
WO2006078995A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
AU2006336387A1 (en) * 2005-02-16 2007-08-02 Nicox S.A. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
US7521435B2 (en) * 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
JP2008531697A (en) * 2005-02-28 2008-08-14 ニトロメッド インコーポレーティッド Cardiovascular compounds containing nitric oxide enhancing groups, compositions and methods of use
WO2006099058A2 (en) * 2005-03-09 2006-09-21 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
US20060222671A1 (en) * 2005-03-30 2006-10-05 Astion Development A/S Dermatological compositions and salts for the treatment of dermatological diseases
AU2006228869A1 (en) * 2005-03-30 2006-10-05 Astion Pharma A/S Oxaprozin or a closely related compound for the treatment of eczema
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
ES2382814T3 (en) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Cis-4 - [(4-chlorophenyl) sulfonyl] -4- (2,5-difluorophenyl) cyclohexanopropanoic acid for cancer treatment
US20090048219A1 (en) * 2005-05-23 2009-02-19 Nitromed Inc. Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
WO2007041681A2 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. Methods for treating respiratory disorders
CN103789389B (en) * 2005-11-23 2017-01-04 杰勒德·M·豪斯 Identify, synthesize, optimize and the Compounds and methods for of profiling protein modulators
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
WO2007087246A2 (en) 2006-01-24 2007-08-02 Merck & Co., Inc. Jak2 tyrosine kinase inhibition
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
TW200813039A (en) 2006-04-19 2008-03-16 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
CA2663377A1 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20080208179A1 (en) * 2006-10-26 2008-08-28 Reliant Technologies, Inc. Methods of increasing skin permeability by treatment with electromagnetic radiation
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
GEP20115337B (en) 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
JP2010516679A (en) * 2007-01-19 2010-05-20 マリンクロット インコーポレイテッド Diagnostic and therapeutic cyclooxygenase-2 binding ligands
MX2009009304A (en) 2007-03-01 2009-11-18 Novartis Ag Pim kinase inhibitors and methods of their use.
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
US20090017140A1 (en) * 2007-07-09 2009-01-15 Peter Koepke Maytenus abenfolia extract and methods of extracting and using such extract
MX2010000465A (en) 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders.
US20090035395A1 (en) * 2007-08-01 2009-02-05 Peter Koepke Spondias mombin l. extract and methods of extracting and using such extract
US8263641B2 (en) 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
US7879369B2 (en) * 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
WO2010027875A2 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
EP2398500B1 (en) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system
SG10201402069PA (en) 2009-05-06 2014-07-30 Lab Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
UA109417C2 (en) 2009-10-14 2015-08-25 Мерк Шарп Енд Доме Корп. Substituted piperidines, which improve activity of p53, and use thereof
JP2013525448A (en) 2010-04-27 2013-06-20 カルシメディカ，インク． Compounds that regulate intracellular calcium
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
RU2745848C2 (en) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. RNA INTERFERENCE-MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION WITH THE USE OF A SMALL INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
AU2011293201B2 (en) 2010-08-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
CA2831730A1 (en) 2011-04-21 2012-10-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013066729A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (en) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Novel compounds that are ERK inhibitors
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR102161331B1 (en) 2012-11-28 2020-09-29 머크 샤프 앤드 돔 코포레이션 Compositions and methods for treating cancer
ES2707305T3 (en) 2012-12-20 2019-04-03 Merck Sharp & Dohme Imidazopyridines substituted as HDM2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3019171B1 (en) 2013-07-11 2018-09-05 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
US10329294B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of IRAK4 activity
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
US10040802B2 (en) 2015-03-12 2018-08-07 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of IRAK4 activity
CN104892495B (en) * 2015-06-08 2017-04-26 青岛农业大学 Novel method for synthesizing pyridine-containing compounds
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210309688A1 (en) 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
AU2020408148A1 (en) 2019-12-17 2022-06-16 Merck Sharp & Dohme Llc PRMT5 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles
US3901908A (en) * 1970-12-28 1975-08-26 Ciba Geigy Corp 2-alkyl- and 2-cycloalkyl-4,5-bis-phenyl-imidazoles
US4632930A (en) * 1984-11-30 1986-12-30 E. I. Du Pont De Nemours And Company Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1271082A (en) * 1968-05-07 1972-04-19 Wyeth John & Brother Ltd Furan, pyrrole and thiophene derivatives
US3743656A (en) * 1969-05-01 1973-07-03 Wyeth John & Brother Ltd Thiophene and furan lower alkanoic acids and derivatives
US4020082A (en) * 1970-02-21 1977-04-26 Enzo Marchetti 2-Aminomethyl- and 2-(2-aminoethyl)-substituted 4,5-diphenyloxazoles
DE2129012A1 (en) * 1971-06-11 1973-01-04 Merck Patent Gmbh AZOLE DERIVATIVES
CH585212A5 (en) * 1973-07-09 1977-02-28 Serna Ag
GB1507032A (en) * 1974-08-06 1978-04-12 Serono Lab 2-thiol-4,5-diphenyloxazole s-derivatives
US4143047A (en) * 1975-06-07 1979-03-06 Lilly Industries Limited 2-sulfinyl and 2-sulfonyl oxazoles
IE52909B1 (en) * 1981-04-28 1988-04-13 Wyeth John & Brother Ltd Oxazole derivatives
ES8403890A1 (en) * 1982-02-27 1984-04-01 Beecham Group Plc Antibacterial 1-normon-2-yl-heterocyclic compounds.
US4820827A (en) * 1982-03-03 1989-04-11 E. I. Du Pont De Nemours And Company 2,3-diaryl-5-bromothiophene compounds of use for the treatment of inflammaton and dysmenorrhea
US4590205A (en) * 1982-03-03 1986-05-20 E. I. Du Pont De Nemours And Company Antiinflammatory and/or analgesic 2,3-diaryl-5-halo thiophenes
US4489084A (en) * 1983-06-30 1984-12-18 Abbott Laboratories [1-(2-Oxazolyl) or -(2-thiazolyl) hydrazino]alkyl nitriles
JPH06779B2 (en) * 1985-06-10 1994-01-05 武田薬品工業株式会社 Thiazolidione derivative and pharmaceutical composition comprising the same
ZW19786A1 (en) * 1985-10-17 1988-05-18 Hoffmann La Roche Heterocyclic compounds
US4791124A (en) * 1986-04-30 1988-12-13 Fmc Corporation Photoactive azole pesticides
DE3816120A1 (en) * 1988-05-11 1989-11-23 Bayer Ag METHOD FOR PRODUCING UNBALANCED BIARYL COMPOUNDS
DE3903993A1 (en) * 1989-02-10 1990-08-16 Basf Ag DIARYL SUBSTITUTED HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND MEDICINAL PRODUCTS THEREOF
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
JPH03173874A (en) * 1989-09-29 1991-07-29 Mitsubishi Kasei Corp New heterocyclic compound
US5262540A (en) * 1989-12-20 1993-11-16 Bristol-Myers Squibb Company [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (en) * 1990-06-14 1994-05-06 Bellon Laboratoires NEW OXAZOLE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5137357A (en) * 1990-06-27 1992-08-11 Honeywell Inc. Interferometric signal analysis with modulation switching
FR2677477B1 (en) * 1991-06-06 1993-08-20 Bellon Labor Sa Roger NEW OXAZOLE DERIVATIVES, THEIR PREPARATION, THEIR USE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP0764644A1 (en) * 1993-01-15 1997-03-26 G.D. Searle & Co. Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a gastrointestinal condition
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles
US3901908A (en) * 1970-12-28 1975-08-26 Ciba Geigy Corp 2-alkyl- and 2-cycloalkyl-4,5-bis-phenyl-imidazoles
US4632930A (en) * 1984-11-30 1986-12-30 E. I. Du Pont De Nemours And Company Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RICHARD J. CREMLYN ET AL: "Some heterocyclic sulfonyl derivatives", JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 22, no. 5, September 1985 (1985-09-01), PROVO US, pages 1211 - 1214 *
T. VAN ES ET AL: "Substitution of 4,5-diphenyl-oxazoles and -imidazoles,and some related compounds", JOURNAL OF THE CHEMICAL SOCIETY, 1963, LETCHWORTH GB, pages 1363 - 1370 *

Cited By (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090834A (en) * 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US5719163A (en) * 1993-05-21 1998-02-17 G.D. Searle & Co. Substituted oxazolyl compounds for the treatment of inflammation
US6613789B2 (en) 1994-07-28 2003-09-02 G. D. Searle & Co. Heterocyclo-substituted imidazoles for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US7220770B2 (en) 1994-07-28 2007-05-22 Khanna Ish K Heterocyclo-substituted imidazoles for the treatment of inflammation
US5994381A (en) * 1994-12-20 1999-11-30 Japan Tobacco, Inc. Heterocyclic aromatic oxazole compounds and use thereof
US6002014A (en) * 1994-12-20 1999-12-14 Japan Tobacco, Inc. Oxazole derivatives and use thereof
US5945539A (en) * 1994-12-20 1999-08-31 Japan Tobacco, Inc. Oxazole derivatives and use thereof
WO1996019462A1 (en) * 1994-12-20 1996-06-27 Japan Tobacco Inc. Oxazole derivatives and use thereof
US6362209B1 (en) 1994-12-20 2002-03-26 Japan Tobacco Inc. Heterocyclic aromatic oxazole compounds and use thereof
WO1996019463A1 (en) * 1994-12-20 1996-06-27 Japan Tobacco Inc. Heteroaromatic oxazole compounds and use thereof
EP0825989A1 (en) 1995-05-19 1998-03-04 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
WO1996036617A1 (en) * 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6432999B2 (en) 1995-06-02 2002-08-13 Pharmacia Corporation Pyrazole substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
EP0995747A1 (en) * 1995-06-02 2000-04-26 G.D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6875785B2 (en) 1995-06-02 2005-04-05 Pharmacia Corporation Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
WO1996038442A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
WO1996038418A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6753344B2 (en) 1995-06-02 2004-06-22 Pharmacia Corporation Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6696477B2 (en) 1995-06-02 2004-02-24 Pharmacia Corporation Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6136839A (en) * 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US5990148A (en) * 1995-06-12 1999-11-23 G.D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
WO1996041645A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
US6342510B1 (en) 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
US5968974A (en) * 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
US6649649B1 (en) 1995-07-19 2003-11-18 Merck & Co., Inc. Method of treating colonic adenomas
US6045773A (en) * 1995-10-17 2000-04-04 G.D. Searle & Co. Method of detecting cyclooxygenase-2
US6376528B1 (en) 1996-02-13 2002-04-23 G. D. Searle & Co. Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6172096B1 (en) 1996-02-13 2001-01-09 G. D. Searle & Co. Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist
US6617345B1 (en) 1996-02-13 2003-09-09 G.D. Searle & Co. Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin
US7141599B2 (en) 1996-02-13 2006-11-28 Pharmacia Corporation Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin
US6407140B1 (en) 1996-02-13 2002-06-18 G.D. Searle & Co. Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
CN1110488C (en) * 1996-03-21 2003-06-04 阿尔米雷尔-普罗迪斯制药有限公司 2-(3H)-oxazolene derivatives and their use as cox-2 inhibitors
ES2125161A1 (en) * 1996-03-21 1999-02-16 Grupo Farmaceutico Almirall S 2-(3h)-oxazolone derivatives and their use as cox-2 inhibitors
WO1997034882A1 (en) * 1996-03-21 1997-09-25 Almirall Prodesfarma, S.A. 2-(3h)-oxazolone derivatives and their use as cox-2 inhibitors
US6869968B1 (en) 1996-03-21 2005-03-22 Allmirall Prodesfarma S.A. 2-(3H)-oxazolone derivatives and their use as COX-2 inhibitors
AU713811B2 (en) * 1996-03-21 1999-12-09 Almirall Prodesfarma S.A. 2-(3H)-oxazolone derivatives and their use as COX-2 inhibitors
USRE39420E1 (en) * 1996-04-05 2006-12-05 Sankyo Company, Limited 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
LT4586B (en) 1996-04-12 1999-12-27 G. D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
US5932598A (en) * 1996-04-12 1999-08-03 G. D. Searle & Co. Prodrugs of benzenesulfonamide-containing COX-2 inhibitors
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
EP1288206A1 (en) * 1996-04-12 2003-03-05 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
US6815460B2 (en) 1996-04-12 2004-11-09 Pharmacia Corporation Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors
US6436967B1 (en) 1996-04-12 2002-08-20 Pharmacia Corporation Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors
US7420061B2 (en) 1996-04-12 2008-09-02 Pharmacia Corporation Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors
AP1009A (en) * 1996-04-12 2001-09-21 Searle & Co Substituted benzenesulfonamide derivatives as products of COX-2 inhibitors.
EA003319B1 (en) * 1996-04-12 2003-04-24 Джи. Ди. Сирл Энд Ко. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
US6998415B2 (en) 1996-05-31 2006-02-14 Pharmacia Corporation Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
FR2753449A1 (en) * 1996-09-13 1998-03-20 Union Pharma Scient Appl NOVEL 3,4-DIARYLOXAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR USES IN THERAPEUTICS
WO1998011080A1 (en) * 1996-09-13 1998-03-19 Laboratoires Upsa Novel 3,4-diaryloxazolone derivatives, methods of preparation and therapeutic uses thereof
EP1977749A1 (en) 1996-10-15 2008-10-08 G.D. Searle LLC Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
WO1998047509A1 (en) * 1997-04-18 1998-10-29 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
ES2131015A1 (en) * 1997-09-12 1999-07-01 Almirall Prodesfarma Sa New 2-(3h)-oxazolone derivatives
WO1999014205A1 (en) * 1997-09-12 1999-03-25 Almirall Prodesfarma S.A. New 2-(3h)-oxazolone derivatives
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US7745481B2 (en) 1997-12-24 2010-06-29 Daiichi Sankyo Company, Limited Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US6573252B1 (en) 1998-07-28 2003-06-03 Nicox, S.A. Medicine nitrate salts
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6649629B2 (en) 1999-12-23 2003-11-18 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US7166618B2 (en) 1999-12-23 2007-01-23 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US7432285B2 (en) 1999-12-23 2008-10-07 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US6936632B2 (en) 2000-01-13 2005-08-30 Merckle Gmbh Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof
US7790738B2 (en) 2000-07-20 2010-09-07 Lauras As Methods of treating and preventing AIDS using of COX-2 inhibitors
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
US6613790B2 (en) 2001-04-17 2003-09-02 Pharmacia Corporation Prodrugs of COX-2 inhibitors
US7320996B2 (en) 2001-08-15 2008-01-22 Sugen, Inc Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer
US7329401B2 (en) 2002-04-15 2008-02-12 The Regents Of The University Of California Cyclooxygenase-2 selective agents useful as imaging probes and related methods
US7211598B2 (en) 2002-06-28 2007-05-01 Nitromed, Inc. Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP2196201A2 (en) 2002-12-13 2010-06-16 Warner-Lambert Company LLC Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms
US8541471B2 (en) 2003-05-07 2013-09-24 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US7070816B2 (en) 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
US7067159B2 (en) 2003-12-05 2006-06-27 New Chapter, Inc. Methods for treating prostate cancer with herbal compositions
JP2007522191A (en) * 2004-02-13 2007-08-09 サノフイ−アベンテイス Oxazole derivatives, their preparation and their therapeutic use
WO2005080357A3 (en) * 2004-02-13 2005-12-15 Sanofi Aventis Oxazole derivatives, preparation and therapeutic use therof
WO2005080357A2 (en) * 2004-02-13 2005-09-01 Sanofi-Aventis Oxazole derivatives, preparation and therapeutic use therof
US7320978B2 (en) 2004-02-13 2008-01-22 Sanofi-Aventis Oxazole derivatives, preparation and therapeutic use thereof
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US11839617B2 (en) 2004-05-23 2023-12-12 HMI Medical Innovations, LLC Theramutein modulators
US11925647B2 (en) 2004-05-23 2024-03-12 HMI Medical Innovations, LLC Theramutein modulators
US9579326B2 (en) 2004-05-23 2017-02-28 HMI Medical Innovations, LLC Theramutein modulators
US11504377B2 (en) 2004-05-23 2022-11-22 HMI Medical Innovations, LLC Theramutein modulators
US10806738B2 (en) 2004-05-23 2020-10-20 HMI Medical Innovations, LLC Theramutein modulators
US8367038B2 (en) 2004-05-23 2013-02-05 HMI Medical Innovations, LLC Therameutin modulators
US10471065B2 (en) 2004-05-23 2019-11-12 HMI Medical Innovations, LLC Theramutein modulators
US9795610B2 (en) 2004-05-23 2017-10-24 Gerard M. Housey Theramutein modulators
US7622142B2 (en) 2004-09-14 2009-11-24 New Chapter Inc. Methods for treating glioblastoma with herbal compositions
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
US11714080B2 (en) 2005-05-23 2023-08-01 HMI Medical Innovations, LLC Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
US9222933B2 (en) 2005-05-23 2015-12-29 HMI Medical Innovations, LLC Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
US10018619B2 (en) 2005-05-23 2018-07-10 HMI Medical Innovations, LLC Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
US10473643B2 (en) 2005-05-23 2019-11-12 HMI Medical Innovations, LLC Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
US10955408B2 (en) 2005-05-23 2021-03-23 HMI Medical Innovations, LLC Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
US11692998B2 (en) 2005-05-23 2023-07-04 HMI Medical Innovations, LLC Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
US7838023B2 (en) 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
US8846674B2 (en) 2006-03-29 2014-09-30 Nicox, S.A. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8067414B2 (en) 2006-03-29 2011-11-29 Nicox S.A. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
WO2008077599A1 (en) 2006-12-22 2008-07-03 Recordati Ireland Limited COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS
US10562916B2 (en) 2010-05-26 2020-02-18 Sunovion Pharmaceuticals, Inc. Substituted quinoxalines as PDE-10 inhibitors
EP3318561B1 (en) * 2010-05-26 2021-12-22 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2016177776A1 (en) 2015-05-04 2016-11-10 Academisch Medisch Centrum Biomarkers for the detection of aspirin insensitivity

Also Published As

Publication number Publication date
JPH08510736A (en) 1996-11-12
DE69431056T2 (en) 2003-01-16
EP0699192A1 (en) 1996-03-06
ES2180580T3 (en) 2003-02-16
ATE221054T1 (en) 2002-08-15
AU6949594A (en) 1994-12-20
US5380738A (en) 1995-01-10
DE69431056D1 (en) 2002-08-29
EP0699192B1 (en) 2002-07-24
DK0699192T3 (en) 2002-11-04
PT699192E (en) 2002-12-31
CA2161769A1 (en) 1994-12-08
US5719163A (en) 1998-02-17

Similar Documents

Publication Publication Date Title
US5719163A (en) Substituted oxazolyl compounds for the treatment of inflammation
US5668161A (en) Substituted thiazoles for the treatment of inflammation
WO1996036617A1 (en) Substituted oxazoles for the treatment of inflammation
US5475018A (en) 1,5-diphenyl pyrazole compounds for treatment of inflammation
JP6853619B2 (en) Pharmaceutical use of cyanotriazole compounds
US5736579A (en) Substituted spiro compounds for the treatment of inflammation
EP0809636B1 (en) Substituted isoxazoles for the treatment of inflammation
JP5305914B2 (en) Oxazole compounds and pharmaceutical compositions
AU734275B2 (en) Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
US5633272A (en) Substituted isoxazoles for the treatment of inflammation
EP0731796B1 (en) 1,3,5-trisubstituted pyrazole compounds for treatment of inflammation
RO115354B1 (en) Phenyl-heterocyclic compounds, processes for preparing said compounds and preparation intermediate, pharmaceutical composition and method for treating an inflamatory disease
US5418254A (en) Substituted cyclopentadienyl compounds for the treatment of inflammation
JP2006516254A (en) Fused heterocyclic derivatives as PPAR modulators
KR20010034586A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
JP2007515484A (en) PPAR modifiers of triazole, oxadiazole, and thiadiazole derivatives
EA012704B1 (en) Novel pharmaceutical compounds
WO1991017160A1 (en) Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof
MX2007012392A (en) Substituted oxazole derivatives and their use as tyrosine kinase inhibitors.
US6090834A (en) Substituted oxazoles for the treatment of inflammation
AU2007265965B2 (en) Pyridylisoxazole derivative
KR100635315B1 (en) Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient
KR20040084905A (en) 2-oxazolamines and their use as 5-ht2b receptor antagonists
US20040077659A1 (en) Method for treating ppar gamma mediated diseases or conditions
WO2002067912A2 (en) Method for treating ppar gamma mediated diseases or conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT.BUL.27/94 UNDER INID (60)"PARENT APPLICATION OR GRANT",REPLACE "940521" BY "930521"

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 08535227

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2161769

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994917983

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994917983

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1994917983

Country of ref document: EP